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1General introduction

1IntroductIon
Streptocococcus pneumoniae, referred to as the pneumococcus, is a Gram-positive, alpha-
hemolytic bacterium belonging to the family Streptococcaceae. Other species belonging 
to the genus Streptococcus include a.o. S. agalactiae, S. mutans, S. oralis, S. pyogenes, S. 
suis and S. viridans. Pneumococci have a diameter of 0.5-1.25 μm and are usually 
seen as pairs of cocci (diplococci), but they may also occur singly or in short chains 
(Figure 1). Pneumococcal growth in the laboratory requires a source of catalase (e.g. blood) 
to neutralize the large amount of hydrogen peroxide produced by the bacteria, and the 
bacteria grow best in 5% carbon dioxide. 
Pneumococcal carriaGe and disease
Since the pneumococcus is a frequent inhabitant of the upper respiratory tract in healthy 
individuals, it can be said that all humans are colonized at least once in their life with this 
bacterium. Nasopharyngeal colonization by pneumococci is readily detectable in about 10% 
of healthy adults and over 40% in children (22,123). The nasopharynx is the major source 
of transmission as person-to-person spread is thought to occur through aerosols or direct 
contact with colonized individuals. In addition, it can also be transmitted through surfaces 
indirectly such as toys or door handles. Once colonized, an individual strain can be carried 
asymptomatically for weeks or months until its clearance from the host. In susceptible 
individuals, the bacterium can spread from the nasopharynx to other sites of the body 
such as the middle ears, lungs, lower respiratory tract, and blood (Figure 2). S. pneumoniae 
is common cause of non-invasive diseases such as otitis media (OM) and sinusitis, but 
also of severe and often fatal invasive pneumococcal diseases (IPD) such as pneumonia, 
bacteremia, and meningitis. It is usually the pre-existing nasopharyngeal pneumococci 
of the host that serve as the source of the disease-causing strain. Among pneumococcal 
invasive infections, about 90% is represented by pneumonia, 5% by meningitis, and the 
remaining 5% is from a mixture of other infections (1).
IPD and other infections caused by S. pneumoniae represent a health problem of 
primary importance worldwide. The World Health Organization (WHO) estimates that 
~1.6 million people, including up to 1 million children less than 5 years of age, die of IPD 
Fig. 1. Adherence of Streptococcus 
pneumoniae to the human epithelial cell 
line HEp-2 3 h after infection as visualized 
by high-resolution field emission 
scanning electron microscopy. Courtesy 
of Dr. Manfred Rohde, Helmholtz Centre 
for Infection Research, Braunschweig, and 
Dr. Sven Hammerschmidt, Universität 
Greifswald, Germany. Cover Illustration 
of Infect Immun (2005) 73(9), reprinted 
with permission from the American 
Society of Microbiology.
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Figure 1. Adherence of Streptococcus pneumoniae to the human epithelial cell line HEp-2 3 h after infection as 
visualized by high-resolution field emission scanning electron microscopy. Courtesy of Dr. Manfred Rohde, 
Helmholtz Centre for Infection Research, Braunschweig, and Dr. Sven Hammerschmidt, Universität Greifswald, 
Germany. Cover Illustration of Infect Immun (2005) 73(9), reprinted with permission from the American Society
of Microbiology.
Pneumococcal carriage and disease
Since the pneumococcus is a frequent inhabitant of the upper respiratory tract in healthy 
individuals, it can be said that all humans are colonized at least once in their life with this 
bacterium. Nasopharyngeal colonization by pneumococci is readily detectable in about 10% 
of healthy adults and over 40% in children (22,123). The nasopharynx is the major source of 
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every year (2), with developing countries bearing the greatest burden (109). The incidence 
of invasive disease varies due to several factors: age (especially children <2 and elderly 
>65 years), ethnicity, socioeconomic status, immune status, and geographic location. The 
versatile nature of S. pneumoniae in causing disease makes this pathogen a major cause of 
morbidity and mortality worldwide. 
animal infection models used to study S. pneumoniae
Several in vitro methods are available to study certain aspects of pneumococcal 
pathogenesis, such as adherence to and invasion of epithelial and endothelial cells 
(23,58,61) and phagocytosis (66), but they are a limited reflection of the overall picture in 
vivo. Experimental infection models using a variety of animals have served as valuable tools 
in the research of pneumococcal colonization and/or disease. While experimental animals 
differ from humans, data collected from in vivo studies provide a unique perspective that 
in vitro studies alone cannot. Information gathered from both may be complementary, thus 
helping to better understand the complex relationship between host and pathogen. The use 
of a physiological setting allows researchers to investigate pneumococcal virulence factor(s) 
Fig. 2. Infections caused by S. pneumoniae. Infections in the human host are depicted on the left. The use 
of animal infection models, such as the mouse (right) help define the bacterial factors that contribute to 
pneumococcal colonization and disease. Pneumococcal disease is usually preceded by nasopharyngeal 
carriage after which pneumococci can spread to the middle ear causing otitis media or disseminate to the 
lungs causing pneumonia. During infection of the lungs, bacteria may penetrate into the blood circulation, 
causing bacteremia. Infection of the meningi may also be caused through otitis media. Arrows indicate 
the progression of infection in the human and the mouse. Intranasal (i.n.) and intravenous (i.v.) routes of 
infection used in experiments are shown for the mouse; 10 μl volume i.n. used for colonization and otitis 
media model; 50 μl volume i.n. used for pneumonia model; and 100 μl volume (i.v.) used  for bacteremia 
model. Illustration by Nicolien Pul.
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Figure 2. Infections caused by S. pneumoniae. Infections in the human host are depicted on the left. The use of 
animal infection models, such as the mouse (right) help define the bacterial factors that contribute to 
pneumococcal colonization and disease. Pneumococcal disease is usually preceded by nasopharyngeal carriage 
after which pneumococci can spread to the middle ear causing otitis media or disseminate to the lungs causing 
pneumonia. During infection of the lungs, bacteria may penetrate into the blood circulation, causing bacteremia. 
Infection of the meningi may also be caused through otitis media. Arrows indicate the progression of infection in 
the human and the mouse. Intranasal (i.n.) and intravenous (i.v.) routes of infection used in experiments are 
shown for the mouse; 10 μl volume i.n. used for colonization and otitis media model; 50 μl volume i.n. used for 
pneumonia model; and 100 μl volume (i.v.) used  for bacteremia model. Illustration by Nicolien Pul. 
Animal infection models used to study S. pneumoniae
Several in vitro methods are available to study certain aspects of pneumococcal pathogenesis, 
such as adherence to and invasion of epithelial and endothelial cells (23,58,61) and 
phagocytosis (66), but they are a limited reflection of the overall picture in vivo. Experimental 
infection models using a variety of animals have served as valuable tools in the research of 
pneumococcal colonization and/or disease. While experimental animals differ from humans, 
data collected from in vivo studies provide a unique perspective that in vitro studies alone 
cannot. Information gathered from both may be complementary, thus helping to better 
understand the complex relationship between host and pathogen. The use of a physiological 
setting allows researchers to investigate pneumococcal virulence factor(s) and immune 
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and immune response(s) to the pneumococcus, and to evaluate the potential of (novel) 
vaccine candidates to protect against pneumococcal infection. 
The mouse is the most frequently used animal to study pneumococcal infection, as they 
are small, inexpensive, easy to house, and the ability to manipulate them transgenically 
is readily available. In addition, rats and rabbits are used predominantly for studying 
pneumococcal disease such as pneumonia, bacteremia, and meningitis, while chinchillas, 
gerbils, and guinea pigs are used for otitis media (OM) studies. In the work described in 
this thesis, we used four different mouse infection models as shown in Figure 2, briefly 
discussed here. 
In the colonization model, long-term nasopharyngeal carriage is accomplished with 
a low-volume inoculum (10 µl), with no significant pulmonary infection or bacteremia 
occurring. This model is a frequently used to study mechanisms of colonization of the 
nasopharynx, the major reservoir of pneumococci. 
In the non-invasive OM model recently developed by Stol et al. (113), a pressure cabin 
is used to translocate pneumococci from the nasopharyngeal cavity into both mouse 
middle ears. This model, adapted from a previously developed rat OM model (118), results 
in reproducible infection of the middle ear without the need for invasive inoculation 
procedures. 
The pneumonia model is used to study infection of the lungs as well as dissemination of 
pneumococci to the bloodstream. This model allows for the analysis of various parameters, 
such as survival of mice after infection, presence of bacteria in lungs and blood, levels of 
inflammation, and histology of lung tissue. Infection of the lungs is established intranasally 
using a larger volume (50 µl), mimicking the natural route of infection. Alternatively, 
pneumonia can be initiated by intratracheal administration of pneumococci. 
In the bacteremia model, infection is accomplished by intravenous injection of a 100-µl 
inoculum into the lateral tail vein. This model is useful for direct examination of growth 
and survival of pneumococci in the bloodstream. Systemic infection can also be induced 
intraperitoneally, but this infection route may cause tissue damage or pain to the animal, 
and may not allow the study of bacterial clearance by the reticuloendothelial system (27). 
While all these models are used to study pneumococcal infections, it is well-known that 
the experimental outcome is dependent on the strains of bacteria and mice used (21,55,68). 
Inbred strains provide a more uniform response to experimental treatments due to their 
tightly controlled immune system, while outbred strains maintain maximum heterogeneity 
in an experiment (37). Furthermore, BALB/c mice are resistant to pneumococcal intranasal 
infection and can be used for clearance studies whereas CBA mice are very susceptible (55). 
Genetic background of the pneumococcal strain is also important for disease development 
in the mouse. Depending on the strain used, a greater impact on humans than mice and 
vice versa can be observed (27). In particular, strains of capsular serotypes 2-6 are virulent 
in mice, whereas serotypes 14, 19, and 23 are relatively avirulent (10).
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structural asPects of the Pneumococcus
The surface of the pneumococcus comprises a capsule, a cell wall, and a cell membrane 
(Figure 3). The polysaccharide capsule is highly heterogeneous and it covers the entire 
pneumococcal surface. Beneath this capsule is the cell wall, a peptidoglycan-backbone 
composed of three layers that serves as an anchor for polysaccharides, teichoic acids, 
and the capsular polysaccharides. Anchoring lipoteichoic acid is the cell membrane, the 
innermost structure surrounding the cytoplasm. 
Virulence factors
The word virulent comes from the Latin word virulentus, meaning “poisonous” or “full of 
poison.” Virulence can be defined as the degree of pathogenicity indicated by case fatality 
rates and/or the ability of the organism to invade the tissues of the host. Virulence is 
multifactorial, involving a complex interplay between the invading organism and host. One 
factor imperative for S. pneumoniae growth and, consequently, virulence is the acquisition 
of essential minerals and nutritional substrates; however, little is known yet about 
pneumococcal metabolism in vivo during pathogenesis. Other components determining 
the pathogenic capacity of S. pneumoniae are its virulence factors. An array of putative 
virulence factors have been identified to be important for pneumococcal pathogenesis in 
studies using signature-tagged mutagenesis (STM) (59,78,100), differential fluorescence 
induction (83), transcriptome analysis (93), and genomic array footprinting (GAF) (20,88). 
Many of these virulence factors are proteins such as enzymes, adhesions and toxins, that are 
secreted or deposited on the bacterial outer surface and facilitate adherence and invasion 
of specific host cells as well as immune evasion (Figure 3). The innate immune system 
is the first line of defense against S. pneumoniae with host complement proteins being 
considered a crucial part, linking together the innate and adaptive immune systems. There 
are three complement pathways: the classical pathway, the alternative pathway and the 
lectin pathway. While all three of these pathways are diverse, they are similar in respect to 
the generation of a specific C3 convertase that activates complement. Once complement is 
activated, opsonization of pneumococci followed by phagocytosis and intracellular killing 
of the bacteria by neutrophils and macrophages can occur. It is believed that activation of 
complement is the major immune mechanism protecting the host against infections with 
pneumococci.
caPsule
The most important virulence factor of the pneumococcus is its polysaccharide capsule as 
the entire pneumococcal surface is enveloped by this protective layer. The polysaccharide 
capsule contributes to protection against phagocytosis, enabling the pneumococcus to 
evade the immune system of the host (50,53). Over 90 serotypes distinct in biochemical 
structure have been identified (60). The capsule is approximately 200 to 400 nm thick (110) 
and, with the exception of the type 3, is considered to be covalently attached to the outer 
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surface of the cell wall (112). Encapsulated (“smooth”) strains are highly more virulent than 
nonencapsulated (“rough”) strains, at least 105 times more (125). However, it is not solely 
the thickness of the capsule that determines the virulence of the serotype (74), but more 
importantly, the biological properties of the capsular polysaccharide itself (81). The capsule 
is thought to be the first point of contact with host cells. Reduced capsule expression is 
believed to benefit the initial adherence and colonization of pneumococci. In line with this, 
Hammerschmidt et al. demonstrated that the thickness of the capsule was reduced upon 
adherence of pneumococci to epithelial cells, which substantially enhanced their ability to 
invade host cells (Figure 1) (58). Interestingly, despite its inhibitory effect on adherence, 
capsule expression was shown to be a prerequisite for colonization, as only encapsulated 
strains were able to transit efficiently from the luminal mucus to the epithelial surface (90). 
In addition, it has been shown that some pneumococci possess pili protruding the capsular 
polysaccharide, which contribute to the initial adhesion to host cells (9).
Pneumolysin
Next to the capsule, pneumolysin (Ply) is the most important virulence factor and probably 
the most extensively studied of all virulence factors found in almost all S. pneumoniae 
clinical isolates (72,75,95). Unlike most pneumococcal virulence factors which are surface 
exposed, Ply (53 kDa) is an intracellular toxin found in the cytoplasm. Ply belongs to 
Fig. 3. Virulence factors of S. pneumoniae. Illustrated here are the capsule and the cell wall where the majority 
of the virulence factors are found. Furthermore, the major cell-surface protein families (choline-binding 
proteins, lipoproteins, LPxTG proteins, the non-classical surface proteins, and the pneumococcal histidine 
triad (Pht) family proteins) are depicted, with some examples of each class. Further details are discussed in 
the text. Adapted from Kadioglu et al. (71) by Nicolien Pul.
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Figure 3. Virulence factors of S. pneumoniae. Illustrated here are the capsule and the cell wall where the 
majority of the virulence factors are found. Furthermore, the major cell-surface protein families (choline-binding 
proteins, lipoproteins, LPxTG proteins, the non-classical surface proteins, and the pneumococcal histidine triad 
(Pht) family proteins) are depicted, with some examples of each class. Further details are discussed in the text. 
Adapted from Kadioglu et al. (71) by Nicolien Pul. 
Capsule
The most important virulence factor of the pneumococcus is its polysaccharide capsule as the 
entire pneumococcal surface is enveloped by this protective layer. The polysaccharide capsule 
contributes to protection against phagocytosis, enabling the pneumococcus to evade the 
immune system of the host (50,53). Over 90 s rotypes distinct in biochemical structure have 
been identified (60). The capsule is approximately 200 to 400 nm thick (110) and, with the 
exception of the type 3, is considered to be covalently attached to the outer surface of the cell 
wall (112). Encapsulated (“smooth”) strains are highly more virulent than nonencapsulated 
(“rough”) strains, at least 105 times more (125). However, it is not solely the thickness of the 
capsule that determines the virulence of the serotype (74), but more importantly, the 
biological properties of the capsular polysaccharide itself (81). The capsule is thought to be 
the first point of contact with host cells. Reduced capsule expression is believed to benefit the 
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the family of pore-forming cholesterol-dependent cytolysins (CDC) which are produced 
by more than 20 species of Gram-positive bacteria (121). Acting as a CDC, Ply binds to 
cholesterol in the host cell plasma membrane and forms pores via oligomerization that 
are 350-450 Å in diameter, causing cell lysis (4,54). In addition, Ply is a signal peptide-
lacking protein that can activate complement via the classical pathway, stimulate host cell 
apoptosis, slow human ciliary beating and damage respiratory epithelium (24,49,96,99). It 
was once believed that this toxin is only released when pneumococci undergo spontaneous 
lysis (95); however, there is evidence that Ply can be released independently of autolysin (7). 
While the role of Ply in colonization is debatable (70,107), there is substantial evidence that 
Ply plays a crucial role in invasive disease (16,18,19,33,63,70,92). 
Pneumococcal cell-surface Proteins
Pneumococcal cell-surface proteins can be classified into different groups based on their 
mode of attachment to the cell. They include: choline-binding proteins, lipoproteins, 
LPxTG proteins, the pneumococcal histidine triad (Pht) family proteins, and the non-
classical surface proteins (Figure 3).
choline-binding proteins (cBPs)
One of the features on the cell surface is phosphorylcholine (ChoP), which is a constituent 
of both cell-wall-associated acids and lipoteichoic acids (41). CBPs bind non-covalently 
to ChoP through choline binding domains located on the C-terminus of the proteins. 
S. pneumoniae encodes 10-15 choline-binding proteins depending on the pneumococcal 
strain. 
Pneumococcal surface protein A (PspA)
PspA is probably one of the best well-studied pneumococcal surface proteins to date. PspA 
is a serologically highly variable protein found on all serotypes that ranges in size from 
67-99 kDa (40,64). This protein has a signal peptide and the mature protein is composed 
of four domains: (i) an a-helical domain, (ii) a proline rich region, (iii) a choline binding 
domain, and (iv) a C-terminal tail (64,86,129). The variable amino acid sequence located 
before the proline-rich region is designated as the clade-defining region, where a total of 6 
clades are divided into 3 families (64). PspA binds to human lactoferrin, a protein exhibiting 
high affinity for iron thereby preventing utilization by bacteria on mucosal surfaces, 
such as adherence and colonization (56); however, pneumococci are not able to utilize 
lactoferrin as an iron source. In addition, PspA has the ability to interfere with the fixation 
of complement component C3 on the pneumococcal cell surface, reducing complement-
mediated opsonization (28,120). Compared to wild type, PspA-deficient mutants were 
more rapidly cleared from the blood of mice (85). An additive attenuation was observed for 
a double mutant deficient for both Ply and PspA, suggesting that each have an independent 
function in the pathogenesis of systemic pneumococcal disease (18).
16
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Pneumococcal surface protein c (Pspc)
PspC, also referred to as S. pneumoniae secretory immunoglobulin A-binding protein 
(SpsA) and choline-binding protein A (CbpA) is a multi-functional CBP highly homologous 
to PspA (29,57). The molecular weight of PspC ranges from 59-105 kDa. PspC contains a 
highly conserved signal peptide in addition to a mature N-terminal domain, a proline-rich 
domain, and the choline binding repeats. One of the roles attributed to PspC is its ability 
to bind to epithelial cells by binding to the secretory component, part of the secretory 
IgA or polymeric Ig receptor (pIgR), promoting pneumococcal adherence (57,105). 
Other functions of PspC include its ability to interfere with complement such as binding 
complement component C3 (35) and factor H (42,47). In vivo, loss of PspC has been shown 
to reduce colonization of infant rats (105) and pIgR knock-out mice (130). PspC was also 
found to be of importance for full virulence in a pneumonia model, but not in a bacteremia 
model. However, deletion of both PspC and PspA did impair the ability of pneumococci to 
cause bacteremia (6), supporting the idea that proteins with similar backgrounds (such as 
similar motifs or roles in virulence) are able to complement each other.
Autolysin (LytA)
LytA is a 36 kDa protein anchored to the choline residues in the cell wall. This cell-wall 
degrading enzyme is normally inactive, but when cell wall biosynthesis ceases, either 
because of nutrient starvation or penicillin treatment, the enzyme is activated causing 
cellular autolysis (26). LytA is composed of two distinct domains: a C-terminal part 
composed of six 20-21 amino acid repeats responsible for the attachment to teichoic or 
lipoteichoic acids on the pneumococcal surface, and a N-terminus containing the lytic 
activity against pneumococcal peptidoglycan structures. Reduced virulence in murine 
models of pneumonia and bacteremia has been described for LytA-negative S. pneumoniae 
mutants (18,33).
liPoProteins
Lipoproteins are synthesized as precursors with N-terminal signal peptides containing 
a characteristic recognition sequence for lipid modification at the C-terminal end. This 
so-called lipobox motif directs the covalent attachment to a lipid component of the 
bacterial cell membrane to the N-terminal Cys residue of the mature protein, anchoring 
the protein in the plasma membrane beneath the capsule and cell wall. Pneumococcal 
lipoproteins have been reported to have diverse functions such as substrate transport 
and bacterial fitness. Depending upon the strain, there are 42-47 lipoproteins found in 
S. pneumoniae (11). 
Pneumococcal surface adhesin A (PsaA)
PsaA is a 37 kDa lipoprotein, and the substrate-binding protein of an ATP binding cassette 
(ABC)-type manganese transport system with specificity for Mn2+ and Zn2+  (44). PsaA binds 
to the human cellular receptor E-cadherin (5). Loss of PsaA causes decreased adhesion to 
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host cells (17) and increased sensitivity to oxidative stress (119). Furthermore, attenuation 
of a psaA mutant was observed in the nasopharynx, lungs, and blood of mice and middle 
ears of gerbils (84).
Iron transporters- pneumococcal iron uptake protein A (PiuA) and 
pneumococcal iron acquisition protein A (PiaA)
PiuA and PiaA are components of two separate iron uptake ABC transporters, Piu and Pia, 
respectively. Both transporter operons contain one gene encoding an ATPase, one gene 
encoding an iron receptor, and two genes encoding transmembrane permease proteins 
(30). PiuA and PiaA are produced by all pneumococci and their genes are highly conserved 
(67). Mutagenesis studies using both lung and intraperitoneal models of infection have 
shown that both proteins contribute to virulence in mice (30).
Peptidyl-prolyl isomerases: streptococcal lipoprotein rotamase A (SlrA) and 
putative proteinase maturation protein A (PpmA)
SlrA and PpmA are two conserved, abundantly produced lipoproteins belonging to a family 
of chaperones, the peptidly-prolyl isomerases (PPIase). PPIases are thought to be involved 
in secretion and activation of cell surface molecules. SlrA (29 kDa) shares homology with 
members of the cyclophilin family while PpmA (34 kDa) is homologous to the parvulin 
family (61,94). A deficiency in SlrA substantially reduced pneumococcal adherence to and 
internalization by epithelial and endothelial cells (61). In addition, SlrA was shown to be 
a functional PPIase involved in pneumococcal colonization as mutants lacking slrA were 
rapidly eliminated from the upper airways in a mouse pneumonia model (61). Similarly, 
ppmA-deficient mutants display reduced virulence in a mouse pneumonia model (94), 
but to date no detectable PPIase activity has been found for PpmA (61). Recently, Stol 
et al. showed that deletion of slrA, but not of ppmA, significantly reduced pneumococcal 
virulence in a mouse otitis media model. 
lPxtG-anchored Proteins 
This group of proteins is covalently linked to the to the peptidoglycan backbone of the 
bacterial cell wall by a sortase transpeptidase that recognizes the carboxy (C)-terminal 
amino-acid sequence LPxTG,  where x denotes any amino acid. It is estimated that up to 20 
S. pneumoniae proteins are anchored by an LPxTG motif (11), several of which have been 
shown to be important for colonization and immune evasion. 
Hyaluronate lyase
Hyaluronate lyase (Hyl) is part of a broad group of enzymes called hyaluronidases that 
depolymerize hyaluronic acid, an important component of the extracellular matrixes and 
connective tissues, and is produced by virtually all pneumococcal strains (97). The full 
length of Hyl is 107 kDa and the enzyme is anchored to the cell surface as well as released by 
S. pneumoniae to surrounding host tissues during infection to facilitate bacterial invasion. 
No significant impact on virulence in a mouse intraperitoneal infection model was found 
18
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using a single hyl mutant; however, when a double mutant including ply was tested, virulence 
was significantly decreased (18). The exact role of Hyl in pneumococcal pathogenesis has 
yet to be clarified.
neuraminidase
Neuraminidases are exoglycosidases that cleave terminal sialic acid residues from 
glycoproteins, glycolipids and oligosaccharides on host cell surfaces and in host body 
fluids (108). Two neuraminidases, encoded by nanA and nanB, have been described for 
S. pneumoniae (17,32). Virtually all clinical isolates examined to date produce an enzyme 
with neuraminidase activity. A nanB homolog, nanC, has also been identified in the 
pneumococcal genome (116), but its expression and activity have not been described to 
date. Of the three neuraminidases, NanA (~108 kDA) is the only one with a C-terminus 
containing the LPxTG anchoring motif. Loss of NanA plays no role in meningitis-associated 
deafness (127) and no attenuation was observed in an intraperitoneal model (18). However, 
it has been shown that loss of NanA impairs pneumococcal persistence in the nasopharynx 
and middle ear in a chinchilla infection model (117). Furthermore, a nanA deletion mutant 
was cleared from the nasopharynx, trachea, and lungs within 12 h post-infection, while the 
nanB mutant persisted but never increased in either the nasopharynx, trachea, or lungs (82). 
Immunoglobulin A1 (IgA1) protease
IgA1 protease cleaves human IgA1 (73) including secretory IgA1 in the hinge region, thus 
interfering with the functions of IgA antibodies by eliminating the Fc-mediating effector 
function. IgA1 protease has a molecular mass of ~215 kDa and contains a signal peptide, 
a LPxTG motif for anchoring and a zinc-binding motif (101,124). Due to the specificity 
of this zinc-metalloprotease for human IgA1, there is currently no appropriate animal 
model available to investigate the role of this protease in pneumococcal pathogenesis. 
However, Weiser et al. showed that human IgA1 antibodies enhanced bacterial attachment 
to respiratory epithelial cells in culture, but only when cleaved by IgA1 protease (126).
Pneumococcal histidine triad family proteins
The recently recognized pneumococcal hisitidine triad (Pht) family consists of four 
members, PhtA (91.5 kDa), PhtB (92.1 kDa), PhtD (93.5 kDa), and PhtE (114.6 kDa) (3). 
All members share extensive peptide sequence identity and contain 5 (PhtA, PhtB, PhtD) or 
6 (PhtE) characteristic histidine-triad motifs (HxxHxH), in addition to α-helical coiled-coil 
regions, a proline-rich regions, and two repeats of 61-amino-acids (3). PhtD, PhtE, PhtB 
and PhtA are present in 100%, 97%, 81% and 62% of the strains, respectively, and, analysis 
of 107 pneumococcal strains showed little variability in the sequence conservation for PhtD 
(104). Ogunniyi et al. showed that Pht proteins are required for inhibiting complement 
deposition on the pneumococcal surface by recruiting complement regulator factor H (91). 
In a sepsis and pneumonia model of infection, avirulence was observed when mutagenesis of 
all 4 genes was used relative to the wild-type, suggesting significant functional redundancy 
among the Pht proteins (91).
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non-classical surface Proteins
There are several proteins that do not possess the classical features of bacterial surface 
proteins, i.e. signal peptides and anchor motifs. These proteins, also named “moonlighting 
proteins” (11), constitute a new class of virulence factors (36). 
Pneumococcal adherence and virulence factor a (PavA)
PavA was identified as a pneumococcal adhesin for fibronectin (65), an adhesive glycoprotein 
present in the extracellular matrix and basement membrane. Pneumococci bind to the 
immobilized form of fibronectin (122) and it is suggested that the C-terminal part of PavA 
mediates the binding to fibronectin (102). PavA has been shown to modulate adherence of 
S. pneumoniae to epithelial and endothelial cells (102). In addition, mutants lacking pavA 
were significantly attenuated in a mouse sepsis model and a mouse experimental meningitis 
model (65,69,102). Recently, PavA-deficient pneumococci were rapidly cleared from 
nasopharyngeal tissue in a long-term carriage model. However, in a pneumonia model pavA 
mutants were not cleared from the lungs of infected mice and persisted to cause chronic 
infection, and were able to only survive in blood when administered intravenously (69).
Enolase (Eno)
Eno, an anchorless surface protein, is a plasmin(ogen)-binding protein (12) facilitating 
transmigration of pneumococci through the basement membrane. It was also found that 
this 47 kDa protein exhibits α-enolase activity and is necessary for viability as it may be 
an essential enzyme of the glycolytic pathway (12). By use of immunoelectron microscopy, 
Eno was detected not only in the cytoplasm, but also on the surface of encapsulated and 
unencapsulated pneumococci (15). In particular, it is the α-enolase located on the surface 
that is responsible for the recruitment of proteolytic activity (14). Enolase mutants were 
attenuated in a mouse model of intranasal infection (15).
Glyceraldehyde-3-phosphate dehydrogenase (GAPdH)
As with enolase, GAPDH is also a plasmin(ogen)-binding protein located in the cytoplasm 
as well as on the surface (13). However, GAPDH exhibits a significantly lower affinity for 
plasminogen, but has a high affinity for plasmin (13). GAPDH catalyzes the phosphorylation 
of glyceraldehyde-3-phosphate into 1,3-biphosphoglycerate (25). 
Vaccination strateGies - Polysaccharides and Proteins
Over the past three decades, vaccines formulated against the polysaccharide capsule of 
the pneumococcus have been the mode of prevention. The first vaccine developed against 
pneumococcal disease in adults was a 14-valent pneumococcal polysaccharide vaccine 
(PPV) in 1977 which was then reformulated to a 23-valent PPV (PNEUMOVAX®, Merck, 
USA) in 1983. A heptavalent, immunogenic protein carrier-containing pneumococcal 
conjugate vaccine (PCV) for children became available in 2000 (Prevnar®, Pfizer, USA), only 
to be replaced by a 13-valent PCV in early 2010 (Prevnar-13®, Pfizer, USA). 
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Both of these vaccines, PPV and PCV, target the polysaccharide antigens of the 
pneumococcal capsule and their ability to induce an antibody response by producing 
specific protective immunoglobulins (51). The 23-valent vaccine includes 25 μg of each 
of the selected 23 capsular polysaccharides isolated from their respective pneumococcal 
strains, purified and treated with phenol. The 23 serotypes included in this vaccine are 
serotypes 1-5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 
and 33F. The antibody response resulting from a PPV is T-cell independent and lacks any 
immunological memory which is unsuitable for use in children less than 2 years. Since 
children under the age of 2 have an immature immune system, they are recommended 
to take the PCV instead. The PCV formulation includes the purified polysaccharides 
conjugated with a protein component of the diphteric toxoid which induces a T-cell 
dependent response, providing greater immunogenicity and allowing the establishment of 
immunologic memory. Serotypes 1, 3-5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F are 
included in Prevnar-13®. The serotypes included in each of the vaccines represent the most 
frequently antibiotic-resistance serotypes and the most virulent serotypes responsible for 
invasive infections. A major drawback of these types of vaccines is the cost of production 
and manufacturing, making it impossible for developing countries to afford them.
Vaccines are a good choice in keeping pneumococcal disease low in both the vaccinated 
population and their contacts through herd immunity. This effect provides a measure of 
protection for individuals who have not been vaccinated or have not developed immunity. 
While PPV and PCV do provide good immune protection, protection is restricted to 
the serotypes included in the vaccine, allowing replacement by non-vaccine serotypes to 
occur. Indeed, after introduction of Prevnar-7, incidence of IPD due to vaccine serotypes 
decreased dramatically, while IPD by non-vaccine serotypes, namely, 3, 6A, 15, 19A, 22F, 
and 33F increased (48,62,77,103). It will be of interest to see the protective effect of adding 
serotypes 1, 3, 5, 6A, 7F, and 19A to the Prevnar-13 vaccine and if any new non-vaccine 
serotypes causing IPD will emerge once again. As long as cases of IPD caused by serotype 
replacement occur, a greater emphasis for development of a serotype-independent vaccine 
will exist (31,79).
Consequently, current research focuses on developing vaccines based on protein antigens 
common to all pneumococcal types, either to be added to the conjugate formulation or 
to be used separately as protein vaccines (for a review see references (8,87,114). Highly 
conserved surface or cell-wall associated proteins are excellent targets for protein vaccines. 
The potential advantages of protein vaccines are that they 1) have epitopes common to 
all serotypes, instead of the limitations accompanied with PPV and PCV, i.e. restricted 
number of capsular-specific polysaccharides included, and 2) would not be age-restricted 
as the antibody response would induce a T-cell dependent response (89). Promising data 
for efficient vaccination in a mouse model have so far been obtained for pneumolysin (98), 
the choline binding proteins PspA (128) and PspC (6), and the lipoprotein PsaA (115). 
Recently, the protective efficacy of PhtD and dPly (a detoxified form of pneumolysin) was 
evaluated in a rhesus macaque model of pneumonia where survival was significantly higher 
in the protein-vaccinated group (43). A potential drawback that could be associated with 
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the use of proteins in a vaccine is the thickness of the pneumococcal capsule during invasive 
disease, blocking protein exposure and thus, potentially, accessibility of antibodies.
It is not likely that any future protein vaccine will consist of one protein, but rather it will 
contain a combination of several recombinant proteins that display the highest protective 
immunity and are common to all pneumococcal strains leaving serotype replacement to be 
a non-issue. Moreover, the costs of a protein vaccine are expected to be considerably lower, 
making it much more affordable for the developing countries that need it most.
laboratory diaGnosis of Pneumococcal infection
The current reference standard for diagnosis of pneumococcal infections is the isolation 
of the bacterium from normally sterile bodily fluids. Four phenotypic characteristics 
are traditionally used in the diagnostic microbiological laboratory for the identification 
of S. pneumoniae: colony morphology (colonies with a depression in the center showing 
alpha-hemolysis on sheep blood agar), optochin sensitivity, deoxycholate (DOC) solubility 
(commonly referred to as bile solubility), and a positive reaction (agglutination) with 
antipneumococcal polysaccharide capsule antibodies, also known as the quellung reaction. 
While these techniques have been the “go-to” methods for years, they are quite labor 
intensive, requiring skillful knowledge and laboratory reagents and equipment that may 
not be present in a non-laboratory setting or in poor resource settings. Furthermore, these 
conventional tests are not always sufficient to distinguish S. pneumoniae from other closely 
related upper respiratory streptococci.
Pneumococcal pneumonia is the most common manifestation of IPD and is particularly 
difficult to diagnose due to various reasons. In addition to the issues mentioned above, the 
main problem is the difficulty in obtaining appropriate samples for testing, i.e. amount of 
sample collected and the time of sampling in relation to progression of the disease. Prior 
antibiotic use can also make it difficult to isolate S. pneumoniae from clinical samples. 
Blood culture is fairly insensitive, mostly since insufficient number of bacteria may yield 
false-negative results. Thereby, an infected individual exists in either a state of transiently 
bacteremic or completely bacteremic. 
Within the last decade, several new ways to obtain and/or confirm a diagnosis of IPD 
without the use of culture-based methods have emerged. Recent developments of diagnostic 
tests have significantly shortened the diagnosis time, but optimization is still needed as 
many pitfalls still exist, such as lack of sensitivity and specificity or cross-reactions with 
other streptococcal species. In 1999, a pneumolysin-based agglutination test allowing easy, 
rapid (within an hour), cost-effective identification with good sensitivity and specificity was 
developed (39), but this still requires culturing of pneumococci from clinical specimens. 
More recent developments exploit detection of pneumococcal antigens in urine of patients, 
such as an ELISA assay for pneumolysin (52). However, both Ply-based tests can give false 
results (38). The BinaxNOW® antigen test is a non-invasive, rapid (within 15 minutes) 
immunochromatographic test (ICT), targeting C-polysaccharide antigen in the urine of 
adults suffering from pneumonia and in the cerebrospinal fluid of patients with meningitis 
(80,106). This assay also has limitations, such as low specificity in young children because 
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of correlation with pneumococcal carriage (45,46) and possible cross-reaction with some 
α-hemolytic oral streptococci (S. mitis and S. oralis). 
In addition to the antigen-detection tests, molecular approaches based on PCR 
amplification of ubiquitous pneumococcal genes such as ply or lytA are used to identify 
S. pneumoniae infections (34,111), but homologues of these genes have been detected in 
strains of closely related streptococcal species. Finally, it has been suggested that quantitative 
PCR may help distinguish colonization from infection, as a higher bacterial burden in 
IPD than in carriage is observed (76). Despite these developments, there is still a need 
for improved diagnostics, with tests that are sensitive, specific, rapid, easy, and preferably 
cheap, as the burden of disease is highest in developing countries. 
aims and outline of this thesis    
A better understanding of the molecular pathogenesis of S. pneumoniae, such as the 
identification of (novel) factors contributing to virulence, will facilitate the development 
of improved vaccines and diagnostics. The studies described in this thesis focused on 
the characterization of several pneumococcal proteins with respect to various aspects of 
pneumococcal pathogenesis, ranging from colonization to invasive disease. In addition, we 
examined the protective potential of two newly identified virulence factors, and investigated 
the use of a surface protein for laboratory diagnosis of pneumococcal infection. 
In addition to surface components directly involved in adhesion and immune invasion, 
factors influencing proper protein folding, such as peptidyl-prolyl isomerases (PPIases) 
are also essential for bacterial virulence. The pneumococcal genome contains four putative 
PPIases, among which is the surface-associated lipoprotein PpmA (putative proteinase 
maturation protein A). Using knockout mutants in three strains, Chapter 2 describes the 
role of PpmA in adherence to epithelial cells, nasopharyngeal colonization, and immune 
evasion.  
Maintaining a proper nutritional balance is essential for pneumococcal virulence, 
and in Chapter 3 the contribution of branched-chain amino acid (BCAA) metabolism 
to colonization was evaluated by determining phenotypes of mutants of the BCAA ABC 
transporter Liv, the BCAA carrier protein BrnQ, the BCAA aminotransferase IlvE, and the 
putative transcriptional regulator SP0743/SPD0647 (located upstream of the liv locus) in 
the mouse colonization model.  
In addition to nutrient levels, CO2 levels are considered to vary between the different 
niches S. pneumoniae occupies inside and outside the host. Carbonic anhydrases catalyze 
the reversible hydration of CO2 to bicarbonate, an essential step to prevent the cellular 
release of CO2. Chapter 4 reports the characterization of pneumococcal carbonic anhydrase 
(PCA), and its relevance to pneumococcal growth and virulence. 
Chapter 5 describes the identification of two conserved pneumococcal proteins of an 
as yet unknown function, SP1298 and SP2205, classified as DHH subfamily 1 proteins. 
A thorough analysis of their contribution to different phases of pneumococcal carriage and 
disease, namely adherence, colonization, otitis media, pneumonia, and bacteremia, was 
performed using single and double knockout mutants in three different strains. Finally, 
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the protective potential of SP1298 and SP2205 against pneumococcal pneumonia was 
examined by a vaccination study. 
Diagnosis of pneumococcal infections was addressed in Chapter 6 by development of 
a western blot assay for direct detection of PpmA in the urine samples of children.
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abstract
Streptococcus pneumoniae produces two surface-associated lipoproteins that share 
homology with two distinct families of peptidyl-prolyl isomerases (PPIases), the 
streptococcal lipoprotein rotamase A (SlrA) and the putative proteinase maturation protein 
A (PpmA). Previously, we have demonstrated that SlrA has PPIase activity, and that the 
enzyme plays a role in pneumococcal virulence. Here, we investigated the contribution of 
PpmA to pneumococcal pathogenesis. Pneumococcal mutants of D39 and TIGR4 lacking 
the gene encoding PpmA were less capable of persisting in the nasopharynx of mice, 
demonstrating the contribution of PpmA to pneumococcal colonization. This observation 
was partially confirmed in vitro, as the pneumococcal mutants NCTC10319ΔppmA and 
TIGR4ΔcpsΔppmA but not D39ΔcpsΔppmA, were impaired in adherence to Detroit 562 
pharyngeal cells. This suggests that the contribution of PpmA to pneumococcal colonization 
is not solely the result of its role in adherence to epithelial cells. Deficiency in PpmA did 
not result in reduced binding to various extracellular matrix and serum proteins. Similar to 
SlrA, we observed that PpmA was involved in immune evasion. Uptake of PpmA-deficient 
D39Δcps and NCTC10319 by human polymorphonuclear leukocytes was significantly 
enhanced compared to the isogenic wild-types. In addition, ingestion of D39ΔppmA, but 
not that of neither NCTC10319ΔppmA or TIGR4ΔppmA, by murine macrophage cell line 
J774 was also enhanced, whereas intracellular killing remained unaffected. We conclude 
that PpmA contributes to the early stages of infection, i.e. colonization. The contribution 
of PpmA to virulence can be explained by its strain-specific role in adherence to epithelial 
cells and contribution to the evasion of phagocytosis.
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introduction
Streptococcus pneumoniae resides in the nasopharyngeal cavity of the human host. 
Pneumococcal carriage is regarded as the key linking transmission of this Gram-positive 
bacterium to other susceptible individuals, but is also considered to be a prerequisite for 
disease. Although colonization is usually asymptomatic, it can progress to disease when 
colonizing S. pneumoniae infiltrate the middle ear, lungs, brain, or blood. Consequently, 
this pathogen is a major cause of morbidity and mortality worldwide, especially in young 
children, elderly, and immunocompromised individuals (7).  
Multiple bacterial factors are required for colonization and infection of the host to occur. 
For instance, the expression of capsule reduces entrapment in the luminal mucus, allowing 
the pneumococci access to epithelial surfaces (39). Inside the host, this polysaccharide 
capsule serves as a biochemical barrier, protecting the pneumococcus from phagocytosis 
and killing by inhibiting complement deposition and consequently complement activation 
(24). Several bacterial adhesins are involved in adherence to the epithelial surface, including 
phosphorylcholine (ChoP), which interacts with the receptor for platelet-activating factor 
(rPAF) (14,48). In addition, ChoP serves as a non-covalent anchor for a group of surface 
proteins known as the choline-binding proteins. Of these, PspC (also referred to as CbpA or 
SpsA), binds to human secretory component (SC) of the polymeric Ig receptor during the 
first stage of translocation across the epithelium (19,21,54). 
In addition to the surface components directly involved in adhesion and immune 
invasion, factors influencing proper protein folding and surface composition are also 
essential for bacterial virulence. Peptidyl-prolyl isomerases (PPIases) are ubiquitous 
foldases, which accelerate the cis-trans conformational changes at the Xaa-Pro bonds 
during protein folding (28,42). They are classified into three separate families, i.e., the 
parvulins, the FK506-binding proteins (FKBP), and the cyclophilins. The parvulins are 
the smallest known proteins with PPIase activity, and have a lower relative activity against 
biological substrates than the cyclophilins and the FK506-binding proteins. PPIases have 
been identified in both eukaryotes and prokaryotes. For example, SurA is a parvulin located 
in the periplasm of Escherichia coli which has a role in the assembly of outer membrane 
proteins of Gram-negative bacteria (35,45). Another parvulin is PrsA, which is a membrane-
bound lipoprotein known to be involved in the protein export and maturation machinery of 
Gram-positive bacteria (52). The product of a prsA-like gene from Lactococcus lactis, PmpA, 
is thought to possess foldase activity facilitating protein secretion (18). Several studies have 
also indicated a role for PPIases in virulence. For instance, the trigger factor of Streptococcus 
pyogenes is considered to be responsible for the secretion of many virulence factors (37). 
The macrophage infectivity potentiator (Mip) protein of Legionella pneumophila belongs 
to the FKBPs and is required for entry of human alveolar macrophages and intracellular 
replication of this Gram-negative micro-organism (12,13).
The pneumococcal genome contains four putative PPIases, two of which are produced 
as surface-associated lipoproteins: the streptococcal lipoprotein rotamase A (SlrA) and the 
putative proteinase maturation protein A (PpmA). In a previous study, we demonstrated 
that SlrA is a functional cyclophilin-type PPIase involved in pneumococcal colonization, as 
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slrA mutants are rapidly eliminated from the upper airways in a mouse pneumonia model. 
In addition, we provided evidence that a deficiency in SlrA substantially reduces adherence 
to and internalization by epithelial and endothelial cells (28).
PpmA is the second surface-associated PPIase, and is abundantly produced and 
conserved among pneumococci. It has homology to the parvulin family of proteins, but 
no detectable PPIase activity has been found to date (28,40). It was previously shown that 
ppmA-deficient mutants display reduced virulence in a mouse pneumonia model (40). In 
the current study, we investigated the role of PpmA in pneumococcal virulence in more 
detail. We showed here that PpmA contributes to pneumococcal colonization of the murine 
nasopharynx. Furthermore, we demonstrated that PpmA is involved in in vitro adherence 
to epithelial cells and that expression of PpmA interferes with uptake by professional 
phagocytes.
materials & methods
Pneumococcal strains and growth conditions. Pneumococcal strains used in this 
study are shown in Table 1. S. pneumoniae was routinely grown in Todd-Hewitt broth 
supplemented with 5 g yeast extract l-1 (THY) or on Columbia blood agar (BA) plates 
(Oxoid) at 37 °C and 5% CO2. The number of c.f.u. per milliliter in a particular sample 
was quantified by plating serial 10-fold dilutions on BA plates. When indicated, antibiotics 
were used at the following concentrations: kanamycin, 250 µg ml-1, trimethoprim, 25 µg 
ml-1, and streptomycin, 100 µg ml-1.
Construction of pneumococcal mutants. The D39DppmA and NCTC10319DppmA 
mutants were constructed by in-frame insertion deletion mutagenesis using the 
Table 1. Bacterial strains and mutants used in this study.
Strain Serotype Antibiotic Resistance Reference
D39 wild-type 2 NCTC 7466
D39::rpsL 2 Streptomycin This study
D39DppmA 2 Trimethoprim (28)
D39Dcps - Kanamycin This study
D39DppmADcps - Trimethoprim, Kanamycin This study
NCTC10319 wild-type 35A (28)
NCTC10319::rpsL 35A Streptomycin This study
NCTC10319DppmA 35A Trimethoprim (28)
TIGR4 wild-type 4 (50)
TIGR4::rpsL 4 Streptomycin This study
TIGR4DppmA 4 Trimethoprim This study
TIGR4Dcps - Kanamycin This study
TIGR4DppmADcps - Trimethoprim, Kanamycin This study
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trimethoprim resistance cassette, dfr13, as described previously (28). To obtain the 
TIGR4DppmA strain, a DppmA-PCR product was amplified from D39DppmA with 
primer pair HBppmAF1 (5'-CTCTTGATGGCTGAACATGC-3') and HBppmAR1 
(5'-GCAGCCTACAGCTAGCTTCC-3'). This PCR product was introduced into TIGR4 by 
transformation, and trimethoprim-resistant colonies were checked for the ppmA mutation 
by PCR.    
The isogenic capsule locus (cps) deletion mutants were constructed by allelic replacement 
of the entire capsule gene cluster with the kanamycin resistance cassette of plasmid 
pR410 (11) as follows. Primers HBdexBF3 (5’-TATCAGGAAGGTCAGCCTAA-3') and 
HBdexBR2_F4 (5’-TAAGCTTGATATCGAATTCCTGCACTAAGGACACGCTTCT-3'), 
and HBaliAF_R (5’-GGATGAATTGTTTTAGTACCTGACGCGCTTACGATATTCA-3') 
and HBaliAR (5’-TTTCGCAAATTCAACAGAGG-3') were used to generate PCR 
products of the left (dexB) and right (aliA) flanking regions of the cps locus (approx. 
900 bp each). These PCR products were fused to the kanamycin resistance gene 
amplified with primers HBkanF4 (5’-GGAATTCGATATCAAGCTTA-3') and HBkanR 
(5’-AGGTACTAAAACAATTCATCC-3') by means of overlap extension PCR. The resulting 
PCR product was transformed into S. pneumoniae, and kanamycin-resistant transformants 
were checked for the presence of the cps-deletion by PCR. The DppmADcps double mutants 
were constructed by transformation of the Dcps-PCR product (amplified with primer 
pair HBdexBF3 and HBaliAR) to each DppmA mutant and selecting for trimethoprim 
and kanamycin resistance. Resulting transformants were checked for the ppmA and cps 
deletions by PCR.
To obtain the streptomycin-resistant D39::rpsL, NCTC10319::rpsL, and 
TIGR4::rpsL strains, the rpsL gene encoding a streptomycin-resistant mutant of the 
ribosomal protein S12 was amplified from D39::rpsL (28) with primer pair HBrpsLF 
(5’-GTACAGGGACGTGCTGACAA-3') and HBrpsLR (5’-CCCTTTCCTTATGCTTT-
TGG-3'). This PCR product was introduced into D39, NCTC10319, and TIGR4 by 
transformation, and streptomycin-resistant transformants were checked for the rpsL 
mutation by sequence analysis. 
Mouse colonization model: single infection. Prior to mouse infection experiments, 
bacteria were passaged in mice to maintain virulence as described previously (31). Cultures 
of mouse-passaged S. pneumoniae strains were grown to an OD620 of 0.25 and stored in 
aliquots at -80 °C in 15% glycerol. Prior to infection, aliquots of bacteria were spun down 
and were resuspended in sterile PBS. In the colonization model, female 8 week old CD-1 
mice were lightly anesthetized with 2.5% (v/v) isoflurane over oxygen (1.5 l min-1). Ten 
microlitres containing 5×106 c.f.u. of bacteria was distributed over both nostrils while the 
mice were held vertically by the scruff of the neck. Because such a low volume is given, only 
the nasopharynx of the mice becomes infected. Groups of five or six mice were sacrificed at 
0.5, 24, 48, 96, and 192 h post-infection. Bacteria were recovered from the nasopharynx by 
flushing each nare with 1 ml of sterile PBS (26) and plated for c.f.u. count. In addition, the 
lungs from each mouse were removed from the body, homogenized in 2 ml sterile PBS using 
a hand-held homogenizer (Polytron PT 1200, Kinematica AG), and plated. The 30 min time 
point is considered to be the start of the infection, and is therefore referred to as t=0. 
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Mouse colonization model: co-infection. For the co-infection, a 10 ml inoculum containing 
a 1:1 ratio of streptomycin-resistant wild-type and trimethoprim-resistant ppmA mutants 
(5×106 c.f.u. total) was used to infect female 8-week-old CD-1 mice intranasally as described 
above. This model reduces variation between individual mice, inoculation preparation 
and distribution, and sample collection. Groups of five or six mice were sacrificed at 0.5, 
24, 48, 96, 192 h post-infection. Samples from nasopharynx and lungs were collected as 
described above. Again, the 30 min time point is considered to be the start of the infection, 
and is therefore referred to as t=0. Bacteria recovered from the nasopharynx were plated 
onto BA plates and Columbia agar plates supplemented with 5% (v/v) defribrinated sheep 
blood (Biotrading) containing either streptomycin or trimethoprim to determine c.f.u. 
counts. Competitive index (CI) scores were calculated for the co-infection experiments as 
previously described (25). In short, a CI score was obtained by dividing the output ratio of 
the c.f.u. counts of mutant to wild-type by the input ratio of mutant to wild-type bacteria. 
For experiments in which no mutant bacteria were recovered from a particular mouse, the 
lower limit of detection (i.e. 20 c.f.u. ml-1) was substituted as the numerator. A CI score 
of 1 indicates no change in the ratio of wild-type and mutant before and after infection. 
Values lower than 1 indicate that the mutant is out-competed by the wild-type strain. All 
experiments were performed with approval of the Animal Experimentation Committee 
(DEC) of the Radboud University Nijmegen Medical Centre. 
Cell lines and cell culture. The human pharyngeal epithelial cell line Detroit 562 (ATCC 
number CCL-138) was routinely grown in RPMI 1640 medium without phenol red 
(Invitrogen) supplemented with 1 mM sodium pyruvate and 10% (v/v) fetal calf serum 
(FCS). The murine macrophage-like cell line J774 (ATCC TIB 67) was cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, PAA Laboratories) supplemented with 10% 
FCS, 2 mM glutamine, penicillin G (100 IU ml-1), and streptomycin (100 mg ml-1). All cells 
were cultured at 37 °C in a 5% CO2 environment.
Adherence assay. For adherence assays, bacteria were grown to mid-exponential phase in 
THY and stored in 1 ml aliquots at -80 °C in THY containing 15% glycerol. Before each 
assay, bacteria were resuspended in RPMI 1640 medium without phenol red supplemented 
with 1% FCS. Adherence of pneumococci to epithelial cells was performed as described 
previously (8,28). Briefly, Detroit 562 cells were seeded into 24-well plates and incubated for 
48 h. Confluent monolayers were washed twice with PBS and infected with 1×107 c.f.u. ml-1 
(m.o.i. of 10 bacteria per cell) and pneumococci were allowed to adhere to the cells for 2 h at 
37 °C in a 5% CO2 environment. Non-adherent bacteria were removed by three 1 ml washes 
with PBS, after which 200 µl of 25% trypsin and 1 mM EDTA was added to detach the cells, 
followed by 800 ml of ice-cold 0.025% Triton X-100 in PBS to lyse the cells. Samples were 
plated for c.f.u. count, and corrected to account for small differences in the initial inoculum 
count. All experiments were performed in triplicate and repeated at least three times. The 
adherence of the mutants is given as the percentage relative to the wild-type. Wild-type and 
mutant strains grew comparably in RPMI medium (without phenol red supplemented with 
1% FCS) alone.   
Binding of pneumococci to immobilized host proteins and extracellular matrix. Human 
factors such as laminin, fibronectin, fibrinogen, lactoferrin, type IV collagen, plasminogen, 
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serum IgA, human secretory component, and reconstituted basement membrane (Matrigel®; 
BD Biosciences) were used to coat 96-well plates and kept overnight at 4 °C. The proteins 
were purchased from commercial suppliers (Calbiochem, Sigma, and Roche). The surface 
of the wells was then blocked with 1% BSA for at least 3 h at room temperature. Labelling of 
the bacteria with FITC was performed as described Bergmann et al. (5). Extensively washed 
FITC-labeled wild-type or ppmA-deficient pneumococci (2.5 × 107) were added to the wells 
and incubated for 1 h at 37 °C to allow binding. Fluorescence was measured at 485/538 
nm (excitation/emission) using a Fluoroskan Ascent (ThermoLabsystems). Binding is 
expressed as the percentage of the total applied FITC-labeled pneumococci bound to the 
immobilized proteins. Values are from a representative experiment and are the mean of 
triplicates. Each experiment was performed at least three times with similar results.
Phagocytosis of bacteria by granulocytes. Human polymorphonuclear leukocytes 
(PMNs) were isolated from peripheral blood of four healthy volunteers. Equal volumes 
of blood and PBS were mixed, layered on a Ficoll-Histopaque gradient, and centrifuged 
for 20 min at 800 g. The isolated phase containing PMN cells was depleted of erythrocytes 
by two consecutive hypotonic shocks (30). Finally, the PMNs were resuspended in RPMI 
1640 (PAA Laboratories) and immediately used for the phagocytosis assay. PMNs were 
incubated at a density of 6 x 105 ml-1 for 30 min in 50 µl RPMI 1640/1% FCS with FITC-
labeled S. pneumoniae at an m.o.i. of 50 at 37 °C. The attachment to PMNs and the uptake of 
pneumococci by phagocytosis was stopped by centrifugation. The PMNs were fixed with 200 
µl PBS/1% FBS/1% paraformaldehyde. Binding and uptake of FITC-labelled bacteria were 
assessed by flow cytometry using a FACSCanto (Becton Dickinson). The mean fluorescence 
intensity (MFI) of the entire PMN population was recorded as a measure for bacterial 
binding and/or uptake. All experiments were performed independently three times. 
J774 internalization assay. The number of viable intracellular pneumococci after 
phagocytosis by murine J744 macrophages was quantified by the antibiotic protection assay 
as described previously (28). Briefly, the J774 cells were seeded in a 96-well format at a 
density of 1×105 per well. All bacterial suspensions were washed with PBS and diluted in 
a defined concentration in RPMI 1640, 1% FCS medium. The confluent monolayers were 
then inoculated at an m.o.i. of 50. To synchronize the assay, the plates were centrifuged at 
100 g for 4 min. The number of c.f.u. inoculated per well was quantified by plating on BA 
plates. After 30 minutes of infection, the wells were washed four times with PBS to remove 
unbound pneumococci. To kill any extracellular bacteria, an incubation step with 1 ml 
per well of DMEM (4.5 g glucose l-1) and 1% FCS (no Hepes) containing gentamicin (100 
mg ml-1) and penicillin G (100 IU ml-1) was carried out for 1 h. Intracellular pneumococci 
were recovered after three washes with DMEM by a saponin-mediated lysis (1% w/v) for 10 
min at 37 °C in 5% CO2, and samples were plated for c.f.u. count. To differentiate between 
uptake and intracellular survival, time kinetic experiments were carried out as follows. 
Monolayers were infected for 30 minutes and then treated with gentamicin and penicillin G 
as described above. After removal of the antibiotics by washing, fresh medium was added, 
and the plate was incubated for 1, 2, and 3 h. Intracellular pneumococci were recovered by 
a saponin-mediated lysis, and samples were plated for c.f.u. count. All experiments were 
performed at least in triplicate. 
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Statistical analysis. Comparisons of bacterial loads between wild-type and mutant bacterial 
strains were performed using Student’s t-test (unpaired) for all in vitro assays and with the 
single infection of the colonization model. For the co-infection, a one sample t-test (with 
an arbitrary mean of 1) was used to calculate statistical significance for the CI scores. All 
statistical analyses were performed using GraphPad Prism version 4.0. 
results
Contribution of PpmA to pneumococcal colonization in vivo. To assess the contribution of 
PpmA to pneumococcal virulence, we inactivated the ppmA gene in the D39, NCTC10319, 
and TIGR4 strains using insertion deletion mutagenesis. Immunoblot analysis of wild-type 
and ppmA mutant cell lysates using anti-PpmA rabbit serum showed that PpmA was expressed 
in all wild-type strains, but not in generated mutants (data not shown). To examine the role 
of PpmA in colonization, both single and co-infections of wild-type and DppmA mutant 
pneumococci were carried out using the murine colonization model. In this model, extended 
colonization of the nasopharynx is achieved by using a low volume (10 µl) of inoculum. Some 
infection in the lungs was seen at the earlier time points, but, importantly, mice did not show 
any signs of invasive disease, and no mice died during the course of the experiment. After 
192 h, the D39 and TIGR4 wild-type strains colonized the nasopharynx at higher levels (400-
1000 times, respectively) than the NCTC10319 strain. A significant decrease in bacterial load 
of the nasopharynx was seen at 24 hours post-infection and onwards with the D39ΔppmA 
mutant compared to its wild-type (Fig. 1a). By 192 h, all six mice infected with D39ΔppmA 
had cleared the infection. Similar to D39ΔppmA, TIGR4ΔppmA-infected mice had significant 
decreases in bacterial load after 48 h post-infection (Fig. 1b). Decrease in colonization with 
the NCTC10319ΔppmA mutant compared to its wild-type was seen as well, albeit only 
statistically significant in two out of six time points (Fig. 1c).    
To validate the previous findings, we performed co-infections with each wild-type 
and its respective mutant over a period of 8 days. Again, overall colonization levels of 
the NCTC10319 wild-type were significantly lower those that of D39 and TIGR4 wild-
type strains. In fact, the mice had cleared the infection caused by NCTC10319 wild-type 
and ppmA mutant at 192 h post-infection in four out of six mice. Results of co-infection 
experiments confirmed the decreased ability of D39ΔppmA to colonize the nasopharynx, 
up to 60% less by the 192 h time point (Fig. 2a). Likewise, the TIGR4ΔppmA showed 
also a reduced colonization efficiency, at 192 h post-infection (35%; Fig. 2b), while the 
NCTC10319 wild-type was unable to out-compete its isogenic ppmA mutant (Fig. 2c).
Contribution of PpmA to pneumococcal adherence in vitro. To assess the role of PpmA 
in pneumococcal adherence, we examined adherence of all three S. pneumoniae wild-type 
strains and their isogenic ppmA-deficient mutants to human nasopharyngeal epithelial 
Detroit 562 cells. Since previous studies have shown a negative effect of capsule expression 
on the adherence ability of S. pneumoniae (8,24,38,46,49), we used non-encapsulated 
derivatives of all strains except NCTCC10319, which has a very low intrinsic level of 
capsule expression. In this way, all PpmA-expressing strains showed comparable levels of 
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adherence (approx. 105 c.f.u., data not shown). For the NCTC10319 and TIGR4 strains, a 
significant decrease in adherence of the ΔppmA mutants relative to wild-type was observed, 
namely 41% and 47% reduction, respectively (Fig. 3). Interestingly, no effect of the ppmA 
deletion was observed in the D39 background, suggesting that the contribution of PpmA to 
adherence is strain-specific. 
Effects of PpmA on pneumococcal host protein binding. Various host proteins derived 
from the extracellular matrix or serum are potential binding targets for S. pneumoniae, such as 
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Fig. 1. Single infection: mouse colonization model. Bacterial loads in the nasopharyngeal lavage fluid of mice 
intranasally infected with (a) D39 wild-type or D39∆ppmA, (b) TIGR4 wild-type or TIGR4∆ppmA, and (c) 
NCTC10319 wild-type or NCTC10319∆ppmA. Five or six animals per group were used, with the following 
exceptions: NCTC10319 wild-type at t=48 h (n=4) and for NCTC10319∆ppmA at t=96 h (n=4). The dashed lines 
represent the lower limit of detection. *, P < 0.05. 
(b)
(a) 
(c)
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Fig. 1. Single infection: mouse 
colonization model. Bacterial loads 
in the nasopharyngeal lavage fluid of 
mice intranasally infected with (a) 
D39 wild-type or D39DppmA, (b) 
TIGR4 wild-type or TIGR4DppmA, 
and (c) NCTC10319 wild-type or 
NCTC10319DppmA. Five or six animals 
per group were used, with the following 
exceptions: NCTC10319 wild-type at 
t=48 h (n=4) and for NCTC10319DppmA 
at t=96 h (n=4). The dashed lines 
represent the lower limit of detection. *, 
P < 0.05.
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Fig. 2. Co-infection: mouse colonization model. Female CD-1 mice were infected intranasally with a 1:1 mix of 
(a) D39 streptomycin-resistant wild-type and D39∆ppmA, (b) TIGR4 streptomycin-resistant wild-type and 
TIGR4∆ppmA or (c) NCTC10319 streptomycin-resistant wild-type and NCTC10319∆ppmA. Data from only two 
mice are given for NCTC10319 at t=192 h since no bacteria were found for either wild-type or ppmA mutant in 
the other four mice. Each dot represents one mouse. *, P < 0.05.
(b)
(a) 
(c)
Fig. 2. Co-infection: mouse colonization 
model. Female CD-1 mice were infected 
intranasally with a 1:1 mix of (a) D39 
streptomycin-resistant wild-type and 
D39DppmA, (b) TIGR4 streptomycin-
resistant wild-type and TIGR4DppmA or 
(c) NCTC10319 streptomycin-resistant 
wild-type and NCTC10319DppmA. 
Data from only two mice are given for 
NCTC10319 at t=192 h since no bacteria 
were found for either wild-type or ppmA 
mutant in the other four mice. Each dot 
represents one mouse. *, P < 0.05.
factor H and the secretory component (SC) of the human polymeric immunoglobin receptor 
(hpIgR). To assess whether deficiency in ppmA affects the interaction of pneumococcal 
surface proteins with these cellular receptors or host proteins, we investigated the binding 
of S. pneumoniae NCTC10319 and its isogenic ppmA mutant to various immobilized 
extracellular matrix proteins. The pneumococcal mutant lacking ppmA bound equally well 
to laminin, fibronectin, fibrinogen, lactoferrin, type IV collagen, plasminogen, serum IgA, 
human secretory component, and reconstituted basement membrane (Fig. 4).
Contribution of PpmA to pneumococcal uptake by host cells in vitro. Phagocytosis 
by neutrophils and macrophages is an important process to eliminate bacteria. To 
investigate the role of PpmA in this process, we first explored the interactions between the 
pneumococcus and human PMNs by flow cytometry using FITC-labelled D39∆cpsΔppmA 
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Fig. 2. Co-infection: mouse colonization model. Female CD-1 mice were infected intranasally with a 1:1 mix of 
(a) D39 strepto ycin-resistant wild-type and D39∆ppmA, (b) TIGR4 streptomycin-resistant wild-type and 
TIGR4∆pp A or (c) NCTC10319 streptomycin-resistant wild-type and NCTC10319∆ppmA. Data from only two 
mice are given for N TC10319 at t=192 h since o bacteria were found for either wild-type or ppmA mutant in 
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and NCTC10319ΔppmA and their respective wild-types. The ppmA mutants of both D39∆cps 
and NCTC10319 demonstrated a significantly increased association with human PMNs 
compared to their isogenic wild-types (Fig. 5a; P-values of 0.001 and 0.043, respectively). 
Next, we examined the effect of PpmA on pneumococcal uptake by murine J774 professional 
phagocytes. A significant increase in the amount of internalized D39∆cpsDppmA compared 
to D39∆cps was measured (Fig. 5b; P-value of 0.0004). However, no significant difference 
in uptake between the NCTC10319 wild-type or TIGR4∆cps and their respective DppmA 
mutants by J774 cells was observed. To determine whether the observed difference is indeed 
due to increased uptake of the ppmA mutant, and not the result of enhanced killing of 
intracellular wild-type, we examined intracellular survival using longer incubation periods 
of the bacteria and macrophages. This showed that the observed difference is indeed caused 
by enhanced uptake of D39ΔppmA, as the rate of intracellular killing of wild-type and 
mutant was the same over time, with a mean of 5.3-fold per hour (Fig. 5c).
Fig. 3. In vitro adherence of 
pneumococcal strains to the human 
pharyngeal epithelial cell line Detroit 
562. The adherence of the mutants is 
given as a percentage relative to the 
wild-type. *, P < 0.001.
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Contribution of PpmA to pneumococcal adherence in vitro. To assess the role of 
PpmA in pneumococcal adherence, we examined adherence of all three S. pneumoniae wild-
type strains and their isogenic ppmA-deficient mutants to human nasopharyngeal epithelial 
Detroit 562 cells. Since previous studies have shown a negative effect of capsule expression 
on the adherence ability of S. pneumoniae (8,24,38,46,49), we used non-encapsulated 
derivatives of all strains except NCTCC10319, which has a very low intrinsic level of capsule 
expression. In this way, all PpmA-expressing strains showed comparable levels of adherence 
(approx. 105 c.f.u., data not shown). For the NCTC10319 and TIGR4 strains, a significant 
decrease in adherence of the ΔppmA mutants relative to wild-type was observed, namely 41% 
and 47% reduction, respectively (Fig. 3). Interestingly, no effect of the ppmA deletion was 
observed in the D39 background, suggesting that the contribution of PpmA to adherence is 
strain-specific.  
Fig. 3. In vitro adherence of pneumococcal strains to the human pharyngeal epithelial cell line Detroit 562. The 
adherence of the mutants is given as a percentage relative to the wild-type. *, P < 0.001. 
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Effects of PpmA on pneumococcal host protein binding. Various host proteins 
derived from the extracellular matrix or serum are pot ntial binding targets for S. pneumoniae,
such as factor H and the secretory component (SC) of the human polymeric immunoglobin
receptor (hpIgR). To assess whether deficiency in ppmA affects the interaction of 
pneumococcal surface proteins with these cellular receptors or host protei s, we investigated 
the binding of S. pneumoniae NCTC10319 and its isogenic ppmA mutant to various 
immobilized extracellular matrix proteins. The pneumococcal mutant lacking ppmA bound 
equally well to laminin, fibronectin, fibrinogen, lactoferrin, type IV collagen, plasminogen, 
serum IgA, human secretory component, and reconstituted basement membrane (Fig. 4). 
Fig. 4. Effect of ppmA deletion on host-protein binding by pneumococci. Binding of FITC-labeled S. 
pneumoniae NCTC10319 and its isogenic ppmA mutant was assayed to immobilized host factors (Lm, laminin; 
Fn, fibronectin; Fbg, fibrinogen; Lf, lactoferrin; Col, type IV collagen; Plg, plasminogen; IgA, serum IgA; SC, 
human secretory component; BM, Matrigel; and BSA, bovine serum albumin). 
Fig. 4. Effect of ppmA deletion on host-protein binding by pneumococci. Binding of FITC-labeled S. 
pneumoniae NCTC10319 and its isogenic ppmA mutant was assayed to immobilized host factors (Lm, 
laminin; Fn, fibronectin; Fbg, fibrinogen; Lf, lactoferrin; Col, type IV collagen; Plg, plasminogen; IgA, serum 
IgA; SC, human secretory compo ent; BM, Matrigel; and BSA, bovi e serum albumin). 
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Fig. 5. Internalization and killing of ppmA-deficient pneumococci by PMNs and J774 macrophages. (a) Uptake 
of FITC-labeled pneumococci by PMNs. (b) Internalization of pneumococci by J774 macrophages. (c) Killing of 
pneumococci by J774 macrophages. *, P < 0.005. 
(b)
(a)
(c)
Fig. 5. Internalization and killing of ppmA-
deficient pneumococci by PMNs and J774 
macrophages. (a) Uptake of FITC-labeled 
pneumococci by PMNs. (b) Internalization 
of pneumococci by J774 macrophages. 
(c) Killing of pneumococci by J774 
macrophages. *, P < 0.005.
discussion
Nasopharyngeal colonization is a prerequisite for the development of pneumococcal 
disease. Colonization and subsequent invasive infection of S. pneumoniae is dependent on 
the presence of various proteins targeting host components, such as pneumococcal surface 
adhesin A (PsaA) (16,43), pneumococcal adherence and virulence factor A (PavA) (29,34), 
and PspC  (19,23,44,54). Proper and efficient folding of such translocated or secreted 
proteins is crucial for their biochemical function and contribution to pneumococcal 
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pathogenesis. PPIases are ubiquitous protein foldases, which have been shown to be 
required for virulence in various microorganisms, such as L. pneumophila and S. pyogenes 
(12,13,37). S. pneumoniae produces two surface-associated PPIases, the lipoproteins SlrA 
and PpmA. Previously, we showed SlrA to be a functional cyclophilin contributing to the 
early stages of pneumococcal infection (28). In this study, we examined the role of PpmA 
in pneumococcal virulence. 
Our results clearly demonstrate that PpmA is involved in the early stages of the 
infection process in a strain-specific manner. The colonization ability of D39ΔppmA 
and TIGR4ΔppmA was found to be severely reduced compared to the wild-type strains 
in both single and co-infection models. However, even though deletion of ppmA in the 
NCTC10319 strain resulted in lower levels of colonization compared to its wild-type, the 
difference was not statistically significant. The NCTC10319 strain was a poor colonizer 
of the mouse nasopharynx, which interferes with appropriate colonization read-out over 
time. Contributing to the poor colonization ability of NCTC10319 could be the fact that it 
produces very low amounts of capsule compared to the other two strains (24). By testing 
defined mutants of the capsule locus, Magee and Yother (38) demonstrated that expression 
of a certain amount of capsule is required for efficient in vivo colonization. In line with 
this, pneumococci are known to undergo spontaneous phase variation, resulting in opaque 
and transparent colony variants which are characterized by high or low levels of capsule, 
respectively. Enhanced colonization and adherence are typically seen with the transparent 
phase variants, possibly by allowing better exposure to surface proteins that are important 
for adherence (32,53). Furthermore, Briles et al. (9) showed that mucosal tissues of mice 
support both the transparent and opaque populations of pneumococci. They hypothesized 
that local nasal mucosa may be required for maintenance of long-term carriage and by way 
of spontaneous phase shift, pneumococci create a reservoir in the mucosa giving sufficient 
opportunity to repopulate the nasal surface over time (9). Interestingly, PpmA was shown to 
be more prevalent in the transparent phenotype that is selected for during nasopharyngeal 
colonization {Overweg, 2000 55 /id}.   
Since adherence of S. pneumoniae is a prerequisite for successful colonization, it is likely 
that the observed role of PpmA in colonization is at least partially due to its contribution to 
adherence. The significant reduction in adherence observed with ppmA-deficient mutants 
of NCTC10319 and TIGR4 compared to their respective wild-type strains supports 
this hypothesis. However, no difference with the ppmA mutant was seen with the D39 
background. This apparent discrepancy could, at least partly, be related to host-specific 
characteristics, i.e. differences between murine (in vivo colonization) and human (in vitro 
adherence) epithelial cells. S. pneumoniae binds via surface-located adhesins to various 
extracellular matrix and serum proteins, for example lactoferrin (22), plasmin(ogen) (3-5), 
and immobilized fibronectin (29,51). These adhesins and interactions have shown to be 
involved in pneumococcal pathogenesis (5,29,47). However, our results indicate that PpmA 
does not contribute to the interactions of the pneumococcus with any of the aforementioned 
factors of the extracellular matrix and serum. Nonetheless, the effect of PpmA on adherence 
could still be mediated through host receptor/protein(s) not tested in this study.
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Once colonization has been established, pneumococci can replicate and evade the 
defence mechanisms of the host’s immune system. Macrophages and PMNs are essential 
players in eliminating bacterial infections. Significantly increased uptake by mouse J774 
macrophages and human PMNs was seen with the D39ΔppmA mutant compared to the 
wild-type, whereas the deletion of ppmA did not affect uptake in the TIGR4 background. No 
difference between intracellular killing of the D39 wild-type and ppmA mutant was observed. 
Our data suggest that in addition to colonization, PpmA contributes to immune evasion by 
preventing recognition and uptake by the macrophages at least in a D39 background.
PPIases are known to catalyze the cis-trans isomerization of peptidyl-prolyl bonds in 
vitro, but the physiological function of many of them is still unknown. The effects resulting 
from PPIase mutational inactivation can range from severe defects (15,36) to none (17). 
Our data indicate that PpmA has a role in adherence, possibly by altering the surface 
composition of other bacterial surface proteins and adhesins that are involved in this 
process. In addition, the presence of PpmA appears to protect the pneumococcus against 
phagocytosis. So far, presumed pneumococcal protein target(s) of PpmA remain unknown 
and are the subject of current investigation. Because no PPIase activity has been detected 
for PpmA (28), it is plausible that PpmA has evolved from a parvulin-like ancestor to 
perform functions other than peptidyl-prolyl isomerization. 
The amino acid sequence of PpmA is conserved among strains, suggesting that not 
PpmA itself but the presumed target(s) of PpmA act in a strain-specific manner. Strain 
specificity of pneumococcal virulence factors has been described before. More than a 
decade ago it was demonstrated that the degree of protection of mice immunized with 
a pneumolysin toxoid derivative and subsequently challenged with various serotypes 
differs between strains (1). Furthermore, in a study examining pneumococcal invasion 
of epithelial cells, where several hpIgR expressing cell lines were used along with various 
non-encapsulated and encapsulated S. pneumoniae strains, the hpIgR-dependent invasion 
of epithelial cells by S. pneumoniae was both strain-specific and host cell type-specific 
(10). Finally, strain specificity is also present at the level of regulation of gene expression. 
For instance, the contribution to virulence of response regulator 09 (RR09) was found to 
vary between strains and routes of infection (6). In line with this, Hendriksen et al. (27) 
demonstrated strain-specific regulation of gene expression by RR09 when comparing D39 
and TIGR4.  
Alternatively, the targets of PpmA could differ between strains. The genomes of D39 
and TIGR4 differ by approximately 10 % of their genes {Hakenbeck, 2001 199 /id}. Several 
of these loci are surface-exposed and/or related to pathogenesis, and these differences 
may contribute to the diversity in virulence seen in animal infection models (33,50). A 
prominent example is the rlrA pathogenicity islet, which is found in TIGR4 but not D39. 
The pilus encoded by this islet has been shown to contribute to colonization and invasive 
disease in vivo as well as adherence in vitro when using encapsulated strains (2). Whether 
any of these strain-specific loci actually are targets of PpmA and as such contribute to the 
differences observed in our study remains to be investigated.
In summary, we have demonstrated that PpmA has a role in pneumococcal pathogenesis 
in a murine colonization infection model. Altogether, the data suggest that the contribution 
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of PpmA to colonization is not exclusively attributable to its role in adherence, but also to 
its role in preventing phagocytosis.  
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abstract
The pneumococcal ATP-binding cassette (ABC) transporter for branched-chain amino 
acids (BCAAs) is encoded by the livJHMGF operon. Recently, it was shown that a livHMGF 
mutant had reduced virulence in mouse models of pneumonia and septicemia, but 
only when in competition with its wild-type. Since colonization is the first step toward 
pneumococcal disease, we investigated the contribution of the Liv ABC transporter, the 
acetoin utilization protein AcuB (encoded by the gene immediately downstream of the 
liv locus), the BCAA carrier protein BrnQ, the BCAA aminotransferase IlvE, and the 
putative transcriptional regulator SP0743/SPD0647 (located upstream of the liv locus), to 
pneumococcal colonization of two pneumococcal strains, D39 and TIGR4. The livJHMGF 
and acuB genes were found to be transcribed as one single polycistronic messenger in 
both strains. Mutants were generated in both strains and tested individually in a mouse 
nasopharyngeal colonization model. Attenuated phenotypes were observed mainly in the 
D39 background, where deletion mutants of livJ (encoding the BCAA binding protein), 
livJHMGF, acuB, and ilvE displayed reduced colonization only at a late stage of colonization, 
i.e. 192 h. In addition, the brnQ mutant was significantly attenuated from 48 h onwards. 
Deletion of the putative transcriptional regulator SP0743/SPD0647, located upstream of 
the liv locus, resulted in significant reductions in bacterial load throughout the course of 
infection in both strains. Real-time PCR analysis showed that SP0743/SPD0647 does not 
control expression of any of the BCAA-related genes examined. Although the mechanism 
by which the livJHMGF operon contributes to full pneumococcal colonization remains to 
be determined, our data indicate that the Liv and BrnQ BCAA transporters contribute to 
pneumococcal colonization in a strain-specific manner.
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introduction
Streptococcus pneumoniae is an important human pathogen and a leading cause of 
pneumonia, septicemia, meningitis, and otitis media. Infections caused by pneumococci 
are invariably preceded by asymptomatic nasopharyngeal colonization, where pneumococci 
adhere to the epithelial layer in the nasopharynx.
In addition to the expression of capsule, adhesins and toxins, nutritional balance is 
essential for pneumococcal colonization and virulence. ATP-binding cassette (ABC) 
transporters play a central role in this process by import and export of a variety of substrates, 
such as amino acids, sugars, peptides, sterols, ions, and drugs. Typically, ABC transporters 
are composed of four domains, i.e. two membrane-associated ATP-binding proteins and 
two membrane-spanning permeases located at the intracellular face of the membrane. In 
addition, some ABC transporters contain a surface-exposed substrate-binding protein (13). 
The pneumococcal genome encodes over 70 ABC transporters. The importance of these 
transporters for pneumococcal virulence is underscored by their identification in various 
genome-wide screening studies using signature-tagged mutagenesis (STM) and genomic 
array footprinting (GAF) technologies (7,10,15,18,19). Moreover, specific ABC transporters 
have been shown to play a role in virulence, such as PsaA that is part of an ABC-type 
manganese-transport system (9), and the two separate iron uptake ABC transporters PiuA 
and PiaA (4). Complete attenuation was observed using a psaA deletion mutant in three 
murine models of infection, i.e. colonization, otitis media, and systemic infection (17). 
In addition, mucosal immunization of mice with PsaA was shown to be highly protective 
against pneumococcal carriage (14). PiuA and PiaA have been shown to be required for 
full virulence in both systemic and pulmonary models of infection (4), and both active and 
passive immunization protects mice against systemic pneumococcal infection (5).
The pneumococcal ABC transporter for branched chain amino acids (BCAAs), among 
the most abundant amino acids in proteins, is encoded by the livJHMGF locus. Recently, 
recombinant LivJ, the substrate binding protein of the Liv ABC transporter, was shown to 
specifically bind to leucine, isoleucine, and valine, confirming that BCAAs are the substrates 
of LivJHMGF (1). The ABC transporter locus consists of five genes: livJ, livH and livM, 
each encoding a membrane protein permease; and livG and livF, each encoding an ATPase. 
Adjacent to these genes is acuB, encoding a putative acetoin utilization protein (Table 1 and 
Figure 1). Basavanna et al. demonstrated previously that a ΔlivHMGF mutant was reduced 
in virulence during competitive infection, but was fully virulent when tested individually in 
models of pneumonia and septicemia (1). Since nasopharyngeal colonization is a 
prerequisite for the development of pneumococcal disease, we evaluated the contribution 
of the Liv ABC transporter to pneumococcal colonization using our established mouse 
nasopharyngeal colonization model and two different strains of S. pneumoniae, TIGR4 
and D39. In addition, we examined the contribution of AcuB, the BCAA carrier protein 
BrnQ, the BCAA aminotransferase IlvE, and a putative transcriptional regulator SP0743/
SPD0647, located upstream of livJHMGF, to colonization.
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material and methods
Pneumococcal strains and growth conditions. S. pneumoniae strains TIGR4 (serotype 
4, (22)) and D39 (serotype 2, NCTC 7466) were used in this study. BCAA-related genes 
that were selected for knock-out mutagenesis in both strains are shown in Table 1. All 
wild-type strains and their respective mutants were routinely grown in Todd-Hewitt broth 
supplemented with 5 g l-1 yeast extract (THY), GM17 medium (M17 medium containing 
0.25% [wt/vol] glucose), or on Columbia blood agar (BA) plates (Oxoid) at 37°C and 5% 
CO2. Cultures were grown to an optical density at 620 nm of 0.2 (i.e. mid-log) and stored 
in aliquots at -80°C in 15% glycerol. Prior to infection, aliquots of bacteria were spun down 
and resuspended in sterile PBS to desired concentration. The number of colony forming 
units (CFU) per milliliter (CFU ml-1) in a particular sample was quantified by plating serial 
10-fold dilutions on BA plates.
(Real-time) PCR. All primers used in this study are shown in Table 2. For RNA isolation, 
bacterial strains were grown to mid-log in GM17 medium in triplicate, harvested by 
centrifugation, and treated with 2 volumes of RNAprotect bacterial reagent (Qiagen). 
Total RNA was extracted using the RNeasy Mini kit (Qiagen) after which contaminating 
genomic DNA was removed by treatment with DNase (DNAfree, Ambion). DNA-free total 
RNA (1.0 µg) was reverse transcribed using 300 ng of random hexamers and Superscript 
III reverse transcriptase (Invitrogen). To confirm the absence of genomic DNA, reactions 
without reverse transcriptase were performed. Gene-spanning PCR products were obtained 
using AmpliTaq DNA polymerase (Applied Biosystems) and purified over MinElute 
Table 1. S. pneumoniae genes examined in this study.
TIGR4 ID D39 ID Gene Annotation a
Gene expression ratio
(TIGR4 wild-type/ΔSP0743 or 
D39 wild-type/ΔSPD0647) b
TIGR4 D39
SP0626 SPD0546 brnQ BCAA transport system II carrier protein 0.98±0.11 1.31±0.14
SP0743 SPD0647 Transcriptional regulator, TetR family > 
c > c
SP0749 SPD0652 livJ ABC transporter substrate-binding protein, BCAA transport 0.97±0.11 1.25±0.07
SP0750 SPD0653 livH
ABC transporter membrane-
spanning permease, BCAA 
transport
1.49±0.11 1.3±0.11
SP0749-53 SPD0652-56 livJHMGF Liv ABC transporter n.d. n.d.
SP0754 SPD0657 acuB acetoin utilization protein 1.42±0.16 0.78±0.08
SP0856 SPD0749 ilvE BCAA aminotransferase 1.03±0.15 1.25±0.14
a Annotation is according to the Kyoto Encyclopedia of Genes and Genomes database (www.kegg.com).
b Fold-change as determined by real-time PCR (mean+/-SD).
c Not expressed in knock-out mutant.
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Table 2. Primers used in this study.
Primer Nucleotide sequence (5' to 3') a Target gene b
CJsp0626_L1 GCTGACGTGGTTTGAAGAG brnQ, left flank, -490
CJsp0626_L2 CCACTAGTTCTAGAGCGGCAGCAAAC-CTGTTAGGGTACC brnQ, left flank, +47
CJsp0626_R2 GCGTCAATTCGAGGGGTATCT-GCCAGCCATTGTTGGAATC brnQ, right flank, +1265
CJsp0626_R1 TGTGCTAGCCACATGAATGG brnQ , right flank, +1759
CJsp0626_C GATAGAGCACCTAGAGAAGG brnQ, control, +110
CJsp0743_L1 AGGGTACCTGTGATGGTTAC SP0743, left flank, -393
CJsp0743_L2 CCACTAGTTCTAGAGCGGCGGCTGTT-TCAATGGCTTCTC SP0743, left flank, +96
CJsp0743_R2 GCGTCAATTCGAGGGGTATCAAGGAT-GGCATGAAGGTACC SP0743, right flank, +493
CJsp0743_R1 TAGTCGTCCATTCGGTACTG SP0743, right flank, +950
CJsp0743_C AAACACCTGCACGTTTGACC SP0743, control, +169
CJsp0749_L1 CCAGGAAACACTTGAATATGG livJ, left flank, -488
CJsp0749_L2 CCACTAGTTCTAGAGCGGCGAAGT-GCTACACTTGCAAGC livJ, left flank, +52
CJsp0749_R2 GCGTCAATTCGAGGGGTATCTTCGAT-GCAGACCACAACAC livJ, right flank, +1072
CJsp0749_R1 GACACCAAGAATAGCTGTCG livJ, right flank, +1651
CJsp0749_C CAGTGTTGACTGCTCCAGAC livJ, control, +94
CJsp0750_L1 GAGCCTTCAACATTTGCAGC livH, left flank, -498
CJsp0750_L2 CCACTAGTTCTAGAGCGGCATATC-CTAGGGCTAACAGCG livH, left flank, +66
CJsp0750_R2 GCGTCAATTCGAGGGGTATCAGCTGG-TATCCTTGGTAAG livH, right flank, +831
CJsp0750_R1 GGAATCCCTAAGATACCTGC livH, right flank, +1329
CJsp0750_C ATAGCTGTCGCTAGCATAGC livH, control, +212
CJsp0749/0753_L1 TAGAAGGCAAACTCGACTGG SP0749/0753, left flank, -421
CJsp0749/0753_L2 CCACTAGTTCTAGAGCGGCGAAGT-GCTACACTTGCAAGC SP0749/0753, left flank, +52
CJsp0749/0753_R2 GCGTCAATTCGAGGGGTATCGTC-CTATCAGGAACAGG SP0749/0753, right flank, +643
CJsp0749/0753_R1 CTTGCTTGTGCAATGGTTCC SP0749/0753, right flank, +1168
CJsp0749/0753_C AGACTTCACTTCTCCACAGG SP0749/0753, control, +78
CJsp0754_L1 AGAAGCAAGGAACAACGGTC acuB, left flank, -471
CJsp0754_L2 CCACTAGTTCTAGAGCGGCGCAAAC-CTTGCTCTCTCATC acuB, left flank, +97
CJsp0754_R2 GCGTCAATTCGAGGGGTATCAAGT-GGAAGAAATCGCTCG acuB, right flank, +617
CJsp0754_R1 GGATGGATTTCCAAGATGGC acuB, right flank, +1158
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Table 2. Continued.
Primer Nucleotide sequence (5' to 3') a Target gene b
CJsp0754_C TTGTGCAATGGTTCCCTCAG acuB, control, +162
CJsp0856_L1 TCGTCCTTCTACCTCTTGAC ilvE, left flank, -497
CJsp0856_L2 CCACTAGTTCTAGAGCGGCCCAAT-CAATCGTTACTGTC ilvE, left flank, +21
CJsp0856_R2 GCGTCAATTCGAGGGGTATCTGACG-GGTATTCAGTTTGGC ilvE, right flank, +962
CJsp0856_R1 TCAGTGGTCTCAGAAACAGC ilvE, right flank, +1488
CJsp0856_C TCTCCTTGATCCCATTGTCC ilvE, control, +101
CJsp0742_C GCGTCATCAACAAAGACCTG SP0742, +128
PBpR412_L GCCGCTCTAGAACTAGTGG Sp cassette pR412
PBpR412_R GATACCCCTCGAATTGACGC Sp cassette pR412
HBgyrAF AATGAACGGGAACCCTTGGT gyrA, +448, qRT-PCR
HBgyrAR CCATCCCAACCGCGATAC gyrA, +529, qRT-PCR
HBSP0626F GGTGCTCTATCTGGAGAACATTTTC brnQ, +100, qRT-PCR
HBSP0626R GGGTCAAGACGGCGATACC brnQ, +178, qRT-PCR
HBSP0743F GGAAATCAAAAGGTGTCAGCTCTT SP0743, +416, qRT-PCR
HBSP0743R GCCATCCTTGATCCATTTTAGAA SP0743, +501, qRT-PCR
HBSP0749F CCTTGTAGCAAACGCAGCAA livJ, +972, qRT-PCR
HBSP0749R TGGTCATCATGTAAGCAGTTTTGA livJ, +1117, qRT-PCR
HBSP0750F GGTCTATCTGGTTGGTGCCAATA livH, +321, qRT-PCR
HBSP0750R TAATTGGTCCCAAATCATATCGAA livH, +397, qRT-PCR
HBSP0754F TCATGCAGCAGATTTGATGAGA acuB, +63, qRT-PCR
HBSP0754R TCAGTCACCAAACCAACTAATTGATC acuB, +146, qRT-PCR
HBSP0856F GCTGCAAGTCTCTTACCAGGAAA ilvE, +568, qRT-PCR
HBSP0856R TGTATGAGTTGATGGGTCCAGATAG ilvE, +648. qRT-PCR
749rt1 CGATGCAGACCACAACAC livJ, +1073 (1)
750rt2 CCTAGGGCTAACAGCGC livH, +62 (1)
750rt1.1 GATGGGGGTTACTCCAGG livH, +642 (1)
751rt2.1 CCCAGAGTTGCTACCGC livM, +377, (1)
753rt1.1 GGAGAATCGTCCTATCAG livF, +635 (1)
754rt2.1 CAGGCAGACGGTGCAAACC acuB, +109 (1)
a Underlined sequences are complementary to primers used for amplification of the spectinomycin cassette. 
b Left and right indicate position relative to the target genes used for knock-out mutagenesis, position is 
given with respect to the ATG of the corresponding gene; - and + indicate upstream and downstream 
respectively. Real-time PCR primers are indicated with qRT-PCR.
columns (Qiagen) before sequencing. Relative amounts of livJ, livH, acuB, brnQ, ilvE, and 
SP0743/SPD0647 transcripts were determined by quantitative real-time-PCR (qRT-PCR; 
primers given in Table 2) using the SYBR Green technology on a 7500 Fast Real-Time PCR 
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System (PE Applied Biosystems) according to the manufacturer’s instructions. The relative 
quantification method was used to evaluate the quantitative variation between each wild-
type and its respective mutant for each gene examined (16). The gyrA (SP1219) amplicon 
was used as an internal control for normalization of data.
Construction of directed deletion mutants. A megaprimer PCR method (6) was applied 
to replace target genes in the genome of the S. pneumoniae TIGR4 and D39 strains with a 
spectinomycin resistance cassette amplified from plasmid pR412T7 as described previously 
(2). The resulting PCR products were introduced by competent stimulating peptide 
(CSP)-induced transformation into the corresponding strains using CSP-1 for D39 and 
CSP-2 for TIGR4. Transformants were selected on the basis of spectinomycin resistance 
and were checked by PCR for recombination at the desired location on the chromosome. 
Subsequently, the TIGR4 and D39 wild-types were transformed with 1 μg chromosomal 
DNA isolated from the mutants to prevent the accumulation of inadvertent mutations 
elsewhere on the chromosome. At the same time, wild-types were mock-transformed to 
generate “coupled” wild-type and mutants, where more than one mutant was coupled to a 
particular wild-type.
Colonization model. Eight-week old female outbred CD-1 mice (Charles River Laboratories, 
Germany) were used for the mouse studies. All mice were housed in filter-top cages and 
had access to food and water ad libitum. Mice were allowed to acclimate for a week prior 
to each experiment. At time of infection, mice were lightly anesthetized with 2.5% (vol/
vol) isoflurane / O2, and infected intranasally with either wild-type or mutant bacteria by 
pipetting 10 µl of inoculum (1×106 CFU total) onto their nostrils. At predetermined times 
after infection (t=0.5, 24, 48, 96, 192 h), groups of 6-8 mice were sacrificed by cervical 
dislocation. Bacteria were recovered from the nasopharynx by flushing each nare with 1 
ml sterile PBS (nasopharyngeal lavage, NPL) (11). In addition, both lungs were extracted 
and homogenized in 2 ml sterile PBS. As previously described, intranasal administration 
of pneumococci using such a low volume does not cause lethal infection in mice (8). Mice 
showed no visible signs of disease throughout the course of colonization and the number 
of CFU found in the lungs at the last time point was always below the detection limit. 
Wild-type colonization levels throughout the experiments were ~2×104 CFU/ml for 
D39, while TIGR4 wild-type levels were five times higher at ~1×105 CFU/ml. All animal 
experiments were performed with approval of the Radboud University Nijmegen Medical 
Centre Committee for Animal Ethics. For each mutant, colonization data was expressed 
as a percentage relative to its respective coupled wild-type. The Mann-Whitney test was 
used to detect significant differences, p<0.05 and statistical analyses were performed using 
GraphPad Prism version 4.0.
results and discussion
Strain-specific colonization characteristics of ΔlivJ, ΔlivH, ΔlivJHMGF, and ΔacuB 
mutant strains. In a previous study using a serotype 3 strain, livH, livM, livG, and livF 
were found to form an operon, while both livJ and acuB appeared to be transcribed as 
a single messenger (1). To investigate whether the same genetic organization holds true 
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for the two S. pneumoniae strains used in this study, TIGR4 and D39, we performed 
gene-spanning PCR reactions on cDNA derived from these two strains (Figures 1A, B). 
Interestingly, our results demonstrate that, contrary to the serotype 3 strain, both livJ 
and acuB are transcriptionally linked to livHMGF in TIGR4 and D39 (Figure 1C). PCR 
products obtained with all primer combinations (including those used by Basavanna et 
al. (1)) were of the expected size for both strains using both cDNA and genomic DNA as 
template, and their identity was confirmed by sequencing. Importantly, lack of genomic 
DNA contamination in the cDNA was confirmed by the absence of products for reactions 
with no added RT enzyme (mock RT), and the control PCR spanning SP0742-SP0743 that 
are transcribed in opposite directions (PCR 6) only yielded a product with genomic DNA 
(Figure 1C). Although the co-transcription of livJ with livHMGF appears logical given 
that the products of these five genes together constitute the BCAA ABC transporter, the 
presence of the acuB gene in this polycistronic messenger may be an evolutionary remnant 
Fig. 1. A: Chromosomal organization of the livJHMGF locus and adjacent genes in TIGR4. Each arrows 
represents one gene with the TIGR4 locus number and the gene annotation given above the arrow. Lines 
below indicate the gene-spanning PCR amplicons used for operon analysis. B: Overview of PCRs performed. 
Primers used in Basavanna et al. (1) are indicated. Note that the livJ-acuB intergenic region differs between 
TIGR4 and D39, and that the 754rt2.1 primer has 4 mismatches with D39. C: Results of RT-PCR assessment 
of the transcriptional linkage between the livJHMGF genes in TIGR4 (top) and D39 (bottom). Shown are 
PCR products obtained with either chromosomal DNA, cDNA, or mock reverse transcriptase (RT) reactions 
as template. These results indicate that both livJ and livH, and livF and acuB are transcriptionally linked.
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as this gene has no obvious functional linkage with the Liv transporter. Given the apparent 
difference in genetic organization of this gene cluster in TIGR4 and D39 compared to the 
serotype 3 strain used by Basavanna et al. (1), the regulation of this transporter may have 
differ between strains as well. 
To investigate the contribution of the products encoded by the Liv region to in vitro 
growth and in vivo colonization, we disrupted the individual livJ, livH, and acuB genes 
and the entire BCAA transporter locus encoded by livJHMGF, in TIGR4 and D39. No 
differences in growth in THY in vitro were detected between any of the wild-types and their 
respective mutant strains (data not shown). 
In D39, colonization by the livJ, acuB, and livJHMGF deletion mutants was reduced 
significantly (~15-20%) compared to wild-type at 192 h post-infection only (Figure 2A; 
p<0.0047, 0.0027, and 0.0303, respectively). In addition, a similar colonization trend was 
observed for these mutants (Figure 2A): a 5-10% reduction in colonization 48 h post-
infection (significant only for ΔacuB) with a subsequent increase to wild-type levels at the 
96 h time point. However, deletion of livJ, acuB or the entire livJHMGF locus had a slightly 
different effect in a TIGR4 background (Figure 2B). Colonization of the ΔlivJ mutant was 
significantly reduced (5-7%) in a TIGR4 background 24 and 96 h post-infection (p<0.008 
and 0.0426, respectively), while mice infected with the ΔacuB or ΔlivJHMGF mutants 
maintained colonization levels equivalent to TIGR4 wild-type-infected mice throughout the 
course of infection (Figure 2B). Finally, deletion of livH alone did not affect the colonization 
potential of either D39 or TIGR4 (Figures 2A, B). 
Although no role for AcuB in pneumococcal colonization had been described thus far, 
previous studies have pointed towards a role for the BCAA Liv ABC transporter in various 
aspects of pneumococcal virulence. For instance, both LivJ and LivH were identified by 
negative selection virulence screens: LivH was picked up in an STM screen of a modified 
otitis media chinchilla model (7), and LivJ was one of the attenuated mutants found during 
an experimental meningitis GAF screen (18). In addition, Basavanna et al. showed reduced 
virulence of serotype 3 livH and livHMGF mutants in competitive infection models of both 
pneumonia and septicemia. Since it was impossible to establish a colonization model with 
their serotype 3 strain, the researchers examined the colonization potential of the livHMGF 
mutant in a TIGR4 background, and found no attenuation of the mutant 48 h post-infection 
when in competition with its wild-type (1). Our single infection colonization results are in 
line with the results of Basavanna et al. since TIGR4ΔlivJHMGF colonized the nasopharynx 
equally well as its wild-type throughout 192 h. Since D39ΔlivJHMGF was found to be 
significantly attenuated at 192 h, the contribution of this transporter to colonization may 
be strain-specific. Several studies have shown the genetic background of a pneumococcal 
strain can effect virulence, both in vitro and in vivo (1,3,8,12). Collectively, our results and 
those of Basavanna et al. suggest that these genes are mainly involved in disease aspects 
other than pneumococcal colonization. 
Strain-specific contribution of BrnQ and IlvE to colonization. In addition to the BCAA 
ABC transporter Liv, we also investigated the contribution of BrnQ (a BCAA carrier 
protein) and IlvE (a BCAA aminotransferase) to pneumococcal colonization. In a D39 
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background, the deletion of brnQ resulted in significantly reduced colonization of the 
mouse nasopharynx compared to the wild-type from 48 h post-infection onwards (Figure 
2A). A similar trend was observed in TIGR4, albeit not statistically significant (Figure 2B). 
Interestingly, nasopharyngeal colonization levels of the D39 ilvE mutant were slightly but 
significantly higher (~5-8%) than those of the wild-type at 0.5, 24, and 96 h post-infection, 
while the ilvE mutant was significantly attenuated to 80% of wild-type 192 h post-infection 
(Figure 2A). In TIGR4, colonization levels of the ilvE mutant were comparable to wild-type 
except at 96 h, where a small (6%) but significant decrease in colonization was observed for 
this mutant (Figure 2B).
Fig. 2. Nasopharyngeal colonization kinetics of ΔlivJ, ΔlivH, ΔlivJHMGF, ΔacuB, ΔbrnQ, ΔilvE, and 
ΔSPD0647/SP0743 mutants in S. pneumoniae D39 (A) and TIGR4 (B). Groups of 6 to 8 mice were 
intranasally infected with 1×106 CFU of wild-type or respective mutant. Colonization levels of each mutants 
are expressed as percentage relative to respective wild-type at t= 0.5, 24, 48, 96, 192 h post-infection. The 
dotted line indicates the 100% wild-type level of colonization. Wild-type colonization levels were ~2×104 
CFU/ml for D39 and ~1×105 CFU/ml for TIGR4 throughout the course of the experiment. Bars represent 
mean + SEM. *, P < 0.05.
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Not much is known about the contribution of BrnQ and IlvE to pneumococcal 
infections. BrnQ is a member of the LIVCS family of BCAA transporters which have been 
proposed to function dually as a sodium/BCAA symporter (20). ilvE was found via STM to 
be an essential gene in lung infection (10). Furthermore, the expression of ilvE was found 
to be statistically significantly down-regulated after 0.5 h incubation with A549 human lung 
epithelial cells (21). 
SP0743/SPD0647 is required for full pneumococcal colonization. We also investigated 
the role of the putative transcriptional regulator ΔSP0743/ΔSPD0647, located upstream of 
the Liv operon (Figure 1A), to colonization. In vitro growth of these mutants was slightly but 
not significantly reduced compared to their respective wild-types in THY, but comparable 
to wild-type in GM17 media (data not shown). During the course of colonization with 
either ΔSP0743 or ΔSPD0647, significant attenuation in bacterial load of the nasopharynx 
of mice was observed in both D39 and TIGR4 (Figure 2). In D39, there was initially a 
>25% decrease in bacterial load in the nasopharynx compared to its wild-type at 24 h post-
infection, which then increased over time; whereas in the TIGR4 genetic background, more 
than 10% decrease in bacterial load was observed after 24 h post-infection and this level of 
attenuation was maintained throughout the course of infection. 
Due to the upstream location of this putative transcriptional regulator, we examined 
whether SP0743/SPD0647 controlled the expression of the liv operon in either D39 or 
TIGR4. Real-time PCR analysis showed that SP0743/SPD0647 do not regulate expression of 
the liv operon, nor of any of the other BCAA-related genes examined (Table 1). Therefore, it 
is likely that the reduction in colonization observed here with SP0743/SPD0647 is not due to 
changes in gene expression of liv, but by some other method that remains to be investigated. 
In addition, the genes that SP0743/SPD0647 do regulate remain to be determined.
SP0743 was previously identified in two virulence screen studies, namely as an attenuated 
mutant in an otitis media STM screen (7), and conversely, as an enriched mutant in a rabbit 
meningitis GAF screen (18). Taken together, these results suggest that the contribution of 
this putative transcriptional regulator to virulence may be site-, rather than strain-specific.
conclusions
The data presented here suggest that the putative transcriptional regulator SP0743/
SPD0647 is required for full pneumococcal colonization, while the contribution of the 
Liv ABC operon, AcuB, and BrnQ is limited to prolonged pneumococcal colonization. In 
addition, the observed phenotypes appear to be dependent on strain background. Finally, 
we hypothesize that although there are no obvious paralogs of the Liv BCAA transporter 
in either TIGR4 or D39, a strain-specific redundancy of (amino acid) ABC transporters in 
the pneumococcal genome may still have accounted for these observations. Alternatively, 
the requirement for BCAA uptake could have been compensated by pneumococcal genes 
encoding enzymes required for BCAA synthesis.
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abstract
The respiratory tract pathogen Streptococcus pneumoniae needs to adapt to the different 
levels of carbon dioxide (CO2) it encounters during transmission, colonization, and 
infection. Since CO2 is important for various cellular processes, factors that allow optimal 
CO2 sequestering are likely to be important for pneumococcal growth and survival. In this 
study, we showed that the putative pneumococcal carbonic anhydrase (PCA) is essential for 
in vitro growth of S. pneumoniae under the CO2-poor conditions found in environmental 
ambient air. Enzymatic analysis showed that PCA catalyzes the reversible hydration of CO2 
to bicarbonate (HCO3-), an essential step to prevent the cellular release of CO2. The addition 
of unsaturated fatty acids (UFAs) reversed the CO2-dependent in vitro growth inhibition 
of S. pneumoniae strains lacking the pca gene (Δpca), indicating that PCA-mediated CO2-
fixation is at least associated with HCO3--dependent de novo biosynthesis of UFAs. Besides 
being necessary for growth in environmental ambient conditions, PCA-mediated CO2-
fixation pathways appear to be required during intracellular survival in host cells. This effect 
was especially pronounced during invasion of human brain microvascular endothelial cells 
(HBMEC) and uptake by murine J774 macrophage cells but not during interaction of S. 
pneumoniae with Detroit 562 pharyngeal epithelial cells. Finally, the highly conserved pca 
gene was found to be invariably present in both CO2-independent and naturally circulating 
CO2-dependent strains, suggesting a conserved essential role for PCA and PCA-mediated 
CO2-fixation pathways for pneumococcal growth and survival. 
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introduction
The Gram-positive bacterium Streptococcus pneumoniae, or pneumococcus is a human 
respiratory tract pathogen that contributes significantly to global mortality and morbidity. 
In addition, it is an important asymptomatic colonizer of the human nasopharynx, 
with carriage rates around 10% in adults and over 40% in children (6). Pneumococcal 
colonization and infection are closely linked, but knowledge of the factors that contribute 
to transmission, carriage, disease, and transition from carriage to disease is still limited. 
Research on components that physically contribute to host-pathogen interactions, such 
as capsular polysaccharides, adhesins, and toxins, has provided valuable insights into the 
process of pneumococcal pathogenesis (20). In contrast, the influence of environmental 
factors on pneumococcal growth and survival remains fairly unexplored.
S. pneumoniae needs to adapt to various aerobic and anaerobic conditions, reflecting the 
different niches it occupies during transmission, colonization, and invasive disease. During 
niche transition, oxygen (O2) levels change considerably. Levels of O2 are 21% in ambient 
air, decrease to 10 to 15 % in the alveoli of the lungs, and are about 5 % in resting cells. 
In O2-rich conditions, S. pneumoniae expresses pyruvate oxidase (SpxB), which generates 
acetyl-phosphate as a source of ATP and hydrogen peroxide (H2O2) for inter-species 
competition at the mucosal surfaces of the nasopharynx (41). The presence of O2 is also a 
prerequisite for the pneumococcal X-state (4,14), which is a physiological condition that 
allows for genetic transformation and an adequate response to environmental stress (32). 
Recently, it was shown that the fatty acid (FA) content of the pneumococcal cell membrane 
(31) and the expression of 69 genes (8) change in response to the availability of O2. Finally, 
changes in O2 levels can also affect production of the polysaccharide capsule (48), which is 
the major pneumococcal virulence determinant.
Similar to those of O2, the levels of carbon dioxide (CO2) vary considerably among 
the different pneumococcal niches inside and outside the host. Ambient levels of CO2 in 
the environment are 0.038%, while CO2 levels inside the human body, in particular in the 
lower respiratory tract, can reach 5% or more. The importance of this gaseous compound 
for S. pneumoniae is illustrated by the observation that depletion of CO2 from ambient air 
completely inhibits pneumococcal growth (21). Moreover, about 8% of all clinical isolates 
require a CO2-enriched environment for growth in laboratory conditions (3). This intrinsic 
CO2 dependence of S. pneumoniae, and many other (micro)organisms is most likely related 
to an anabolic need for CO2 or bicarbonate (HCO3-) during biosynthesis of nucleic acids, 
amino acids, and FAs (1). Pathogens can often sequester CO2 directly from host tissues, 
but in the absence of sufficient levels of extracellular CO2, endogenous CO2 needs to be 
enzymatically fixated. Carbonic anhydrases (CAs; EC 4.2.1.1) are enzymes that catalyze 
the reversible reaction CO2 + H2O << HCO3- + H+. Because HCO3- cannot passively diffuse 
across biological membranes, its formation significantly delays the release of intracellular 
CO2. At least five different classes of CAs have been described, and most eukaryotic, 
prokaryotic, and archaeal species express at least one CA class (39,40). 
Genome analysis (39) has revealed that S. pneumoniae has one putative CA; 
a β-class CA that is highly conserved in all available pneumococcal genome sequences. 
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Pneumococcal CA (PCA) is highly homologous to CAs in other streptococcal species, 
such as Streptococcus pyogenes. The closest nonstreptococcal PCA homologs are found in 
Mycobacterium species, while PCA homologs in other respiratory tract pathogens such as 
Neisseria meningitidis and Haemophilus influenzae are more divergent (40). The aim of this 
study was to investigate the functional characteristics of the pca gene and the encoded PCA 
enzyme in S. pneumoniae and to establish the relevance of PCA for pneumococcal growth 
and survival under CO2-poor conditions in vitro. Further, we examined the importance of 
PCA during host-pathogen interaction. 
materials & methods
Bacterial strains and growth conditions. The bacterial strains that were used in this study 
are listed in Table 1. S. pneumoniae strains were routinely grown under static conditions 
in GM17 broth (23) or on blood ager (BA) plates composed of Columbia agar (Oxoid) 
supplemented with 5% sheep blood (Biotrading). Cultures were incubated in a 5%-CO2 
incubator at 37ºC. To compare growth under CO2-poor and -rich conditions, mid-log 
cultures of pneumococcal strains in CO2-enriched GM17 were diluted 50-fold in medium 
that was exposed overnight to ambient air (0.038% CO2) or ambient air enriched with 
5% CO2, respectively. Pneumococcal genetic transformation was performed as described 
previously (10), and importantly, for preparation of competent S. pneumoniae strains 
lacking the pca gene (Dpca), all media were first exposed to ambient air enriched with 5% 
CO2. For transformation of the CO2-dependent carriage strains, a 1:1 mixture of competent 
stimulating peptide 1 (CSP-1) (100 ng/ml) and CSP-2 (100 ng/ml) was used. Viable-bacteria 
counts were derived from CFUs after plating 10-fold serial dilutions in PBS. Escherichia 
coli strains were routinely grown at 37°C on Luria Bertani (LB) agar plates or in LB broth 
in a shaking incubator at 200 rpm. E. coli transformation was performed by the CaCl2 
competence method (35). Lactococcus lactis strains were routinely grown on GM17 agar 
plates or in GM17 broth as static cultures at 30°C. L. lactis transformation was performed 
by electroporation (23). The antibiotics and stock solutions used for complementation 
studies were ampicillin, 100 mg/ml; spectinomycin, 150 mg/ml; kanamycin, 500 mg/ml for 
S. pneumoniae and 50 mg/ml for E. coli; trimethoprim, 0.25 mg/ml; chloroamphenicol, 2.5 
mg/ml for S. pneumoniae and 5 mg/ml for L. lactis; adenine, 5 mg/ml in 0.05 M HCl; uracil, 
2 mg/ml in 1% (Na2CO3); arginine, 20 mg/ml; aspartic acid, 20 mg/ml (pH 7); palmitic acid 
or oleic acid, 200 mM in ethanol; sodium salicylate, 1 M; and bovine liver catalase, 200,000 
U/ml (Sigma). 
DNA extraction and PCR conditions. Chromosomal DNA was isolated from S. pneumoniae 
and E. coli broth cultures by cetyltrimethylammonium bromide (CTAB) extraction as 
described previously (47). Plasmids were isolated from E. coli and L. lactis broth cultures 
with the Qiaprep mini- or midi- kit (Qiagen). For construction of directed-deletion 
mutants and the glutathione-S-transferase (GST) fusion protein cloning, the proofreading 
Pwo DNA polymerase (Roche) was used. For other PCR-based approaches, the AmpliTaq 
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DNA polymerase (Applied Biosystems) was applied. The primers (Biolegio, Nijmegen, 
Netherlands) that were used in this study are listed in Supplementary Table S1.
Construction of pneumococcal mutants. Directed-deletion mutants of S. pneumoniae 
were generated by allelic exchange of the target gene with an antibiotic resistance marker 
as described previously (10). Briefly, overlap-extension PCR was applied to insert the 
kanamycin or spectinomycin resistance cassette of the pR410 or pR412 plasmid (Table 
2), respectively, between the two 500-bp flanking sequences surrounding the target gene. 
The overlap extension PCR products were transformed into S. pneumoniae, and directed 
mutants were obtained by selective plating. Correct integration of the antibiotic resistance 
cassette into the target gene was validated by PCR. Gene deletion mutants were crossed 
Table 1. Bacterial strains used in this study.
Species and strain Relevant characteristics a Reference
S. pneumoniae
  R6 Wild type strain, unencapsulated (19)
  D39 Wild type strain, serotype 2 (25)
  TIGR4 Wild type strain, serotype 4 (45)
  R6Dpca Dspr0026; Spr This study
  D39Dpca DSPD0030; Spr This study
  TIGR4Dpca DSP0024; Spr This study
  R6 bga::nisRK Nisin-responsive R6 strain; spr0565::nisRK; Tmpr (23)
  R6 bga::nisRKDpca Nisin-responsive R6 strain; spr0565::nisRK, Dspr0026; Tmpr Spr This study
  R6DpcaDspxB Dspr0026, Dspr0642; Spr Kmr This Study
  TIGR4DpcaDspxB DSP0024, DSP0730; Spr Kmr This Study
  TIGR4Dcps Unencapsulated TIGR4 strain; ΔSP0343-0365;  Kmr (11)
  TIGR4DcpsDpca Unencapsulated TIGR4 strain; ΔSP0343-0365, DSP0024; Kmr Spr This Study
  D39Dcps Unencapsulated D39 strain; ΔSPD0312-0333; Kmr (11)
  D39DcpsDpca Unencapsulated D39 strain; ΔSPD0312-0333, DSPD0030; Kmr Spr This study
  H23 CO2-dependent carriage isolate
Laboratory 
collection
  H26 CO2-dependent carriage isolate
Laboratory 
collection
E. coli 
  DH5α Cloning strain (17)
  BL21 Expression strain Novagen
L. lactis 
  NZ9000 Cloning strain (24)
a Sp, spectinomycin resistant; Tmpr, Trimethoprim resistant; Kmr, kanamycin resistant.
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back to the wild type strain, using chromosomal DNA of the mutant strains as the donor 
during transformation. Since the flanking sequences of all the target genes used in this 
study were homologous in the R6, D39, and TIGR4 strains, gene deletions were introduced 
into D39 and TIGR4 by transformation with the PCR-amplified gene deletions and 500-bp 
flanking sequences of the R6 mutant derivatives. 
Plasmid construction. All plasmids used in this study are listed in Table 2. To obtain the 
plasmids for complementation of the CO2-dependent growth defect of the Dpca strains, 
the pca gene of S. pneumoniae TIGR4 and the ecca gene (ECDH10B_106) of E. coli DH5α 
were PCR-amplified with the PBNISPCA_L/PBNISPCA_R and the PB_NISECCA_L/PB_
NISECCA_R primer pairs, respectively. The PCR products were cloned into the pCR2.1 
cloning vector of a TA cloning kit (Invitrogen) to obtain pCR2.1-PCA_L and pCR2.1-ECCA, 
respectively. In the next step, the genes were excised by BsaI/EcoRI digestion and ligated 
in the NcoI/EcoRI-digested pNG8048 plasmid to obtain pUO3 and pUO1, respectively. To 
obtain the plasmid for overproduction of GST-PCA, the pca gene of S. pneumoniae TIGR4 
was PCR-amplified with the PBPCA_S/PBPCA_E primer pair, and cloned into pCR2.1 
to obtain pWA1. In the next step, the pca gene was excised by BamHI/EcoRI digestion 
and subcloned behind the GST gene in BamHI/EcoRI-digested pGEX-1N vector to obtain 
pWA4. Cloning of the pCR2.1 and pGEX-1N plasmids was performed in E. coli DH5α, 
and cloning of the pNG8048E plasmids was performed in L. lactis NZ9000. The nucleotide 
sequences of the PCR products in the pCR2.1 plasmid were confirmed by sequencing.
Production and purification of recombinant GST-PCA. For GST-PCA production, an 
overnight culture of E. coli BL21 (pWA4) was diluted 50-fold in prewarmed (37ºC) 2×LB 
supplemented with 0.5% glucose. At an optical density at 600 nm (OD600) of 0.6 to 0.8, 
0.1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) was added, and cultures were 
Table 2. Plasmids used in this study.
Plasmid Relevant characteristicsa Reference
  pR410 Donor for kanamycin resistance cassette (43)
  pR412 Donor for spectinomycin resistance cassette (28)
  pCR2.1 Cloning vector; Apr Kmr Invitrogen
  pGEX-1N Expression vector N-terminal GST-tag; Apr Novagen
  pNG8048E Expression vector, nisin-inducible promotor; Car (23)
  pWA1 pCR2.1 with pca gene, BamHI site; Apr Kmr This study
  pWA4 pGEX-1N with gst-pca construct; Apr This study
  pCR2.1-PCA_L pCR2.1 with pca gene, BsaI site; Apr Kmr This study
  pCR2.1-ECCA pCR2.1 with ecca gene, BsaI site; Apr Kmr This study
  pUO1 pNG8048 with ecca gene behind nisin-inducible promotor; Car This study
  pUO3 pNG8048 with pca gene behind nisin-inducible promotor; Car This study
a Apr, ampicillin resistant; Kmr, kanamycin resistant; Car, chloroamphenicol resistant.
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shifted to room temperature. After 4 h, cells were placed on ice, pelleted by centrifugation, 
resuspended in ice-cold lysis buffer (50 mM Tris-HCl [pH 7.5], 300 mM NaCl, 0.5 mM 
[DTT], 1.5 mM MgCl2, 0.2 mM EDTA, 1% Triton X-100) with 1× protease inhibitor 
mixture (Complete Mini; Roche Applied Science) to a cell density equivalent to OD600 of 
100, and lysed by sonication. Insoluble debris in the lysate was removed by centrifugation at 
16,000 × g for 10 min at 4ºC, and the supernatant was incubated overnight with prewashed 
(1× PBS) glutathione Sepharose 4 Fast Flow beads (GE Healthcare) at 4°C. Nonspecifically 
bound proteins were removed by washing the beads three times with lysis buffer for 15 min 
at 4 °C. GST-PCA was eluted with elution buffer (50 mM Tris-HCl [pH 8.0], 300 mM NaCl, 
10 mM glutathione, and 0.5 mM DTT). The elutate was dialyzed against 50 mM Tris, pH7.5. 
The protein concentration in the GST-PCA solution was determined with a bicinchoninic 
acid (BCA) protein assay kit (Pierce).
Carbonic anhydrase activity assay. The activity of CAs was determined by the changing-
pH/dye indicator method (22) on a RX.2000 rapid-mixing stopped-flow unit (Applied 
Photophysics, United Kingdom). Briefly, enzyme samples were diluted in reaction buffer at 
pH 7.5 (50 mM HEPES [pH 7.5], 200 mM phenol red, and 200 mM Na2SO4) or at pH 8.4 
(50 mM TAPS [pH 8.4], 200 mM m-cresol purple, and 200 mM Na2SO4), and the reaction 
was initiated by addition of an equivalent amount of CO2-saturated water. The subsequent 
restoration of the CO2/HCO3- balance was monitored by the color conversion of the pH-
sensitive dye indicators at 558 nm (pH 7.5) or 578 nm (pH 8.4). All reactions were performed 
at 25°C. The CA activities of GST-PCA and human CA II ([hCAII]; Sigma) was measured at 
a final concentrations of 100 mg/ml and 0.5 mg/ml, respectively. When appropriate, 50mM 
Tris-HCl (pH7.5) and dimethyl sulfoxide (DMSO) were included as nonenzymatic controls. 
The stock solutions for CA inhibitions studies were 100 mM acetazolamide ([AZA] Sigma) 
and 100 mM ethoxyzolamide ([EZA] Sigma) in DMSO. 
Cell lines, culture conditions, and host-pathogen studies. The human pharyngeal epithelial 
cell line Detroit 562 (CCL-138; ATCC) was routinely grown in RPMI 1640 medium without 
phenol red (Invitrogen, The Netherlands) supplemented with 1 mM sodium pyruvate and 
10% fetal calf serum (FCS). The human brain endothelial cell (HBMEC) line was cultivated 
in RPMI 1640 medium supplemented with 10% FCS, 10% Nu-serum, 2 mM L-glutamine, 
1 mM sodium pyruvate, 1% minimum essential medium (MEM)-vitamins, and 1% 
nonessential amino acids (42). Prior to infection, HBMEC monolayers were incubated for 
1 h in culture medium with 10 ng/ml of tumor necrosis factor alpha (TNF-α). The murine 
macrophage-like cell line J774 (TIB 67; ATCC) was cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) GlutaMAX-I (Invitrogen, Netherlands) with 10% FCS. All cells were 
cultured in a 5%-CO2 incubator at 37ºC. 
Pneumococcal adherence, invasion, and intracellular survival studies were performed 
essentially as described previously (7,11,16). Briefly, monolayers of J774, Detroit 562, or 
HBMECs were infected with bacteria in 5%-CO2-enriched culture medium with only 1% 
FCS (infection medium). Subsequently, the pneumococci were allowed to adhere to the cells 
for 0.5 h, 1 h, or 2 h, respectively, and nonadherent bacteria were removed by washing. To 
quantify adherence, host cells were detached from the wells and lysed with 0.025% Triton 
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X-100 or 1% saponin and trypsin-EDTA (0.05%-0.02%). To determine the level of invasion 
into the host cells, extracellular S. pneumoniae cells were killed by a 1-h incubation with 1 
ml 5%-CO2-enriched infection medium supplemented with gentamycin (200 µg/ml) and 
penicillin G (10 µg/ml) before cells were lysed. To examine intracellular survival, cells were 
infected and treated with gentamycin and penicillin G as described above, after which cells 
were washed once and fresh 5%-CO2-enriched medium containing gentamycin (13.34 µg/
ml) and penicillin G (0.67 µg/ml) (1/15 of beginning antibiotic concentration) was added 
to each well for prolonged incubation. For all in vitro cell culture studies, the pneumococcal 
wild-type and mutant strains grew comparably in infection medium alone. Results were 
corrected mathematically to account for small differences in count in the initial inoculum.
In vivo colonization and bacteremia experiments. Bacteremia and nasopharyngeal 
colonization experiments in mice were conducted with 9-week-old female outbred CD-1 
mice (Harlan, Horst, Netherlands) as described recently (18). Briefly, for the colonization 
experiments, 1×106 CFU in 10 ml PBS were administered to the nostrils of groups of five 
mice for each strain, and bacteria were recovered from the nasopharynx by flushing the 
nose with 2 ml of sterile PBS at 96 h. Bacteremia experiments were performed twice with 
groups of at least five mice for each strain. Mice were infected intravenously in the tail vein 
with 1 × 106 CFU in 100 ml PBS, and bacteria were recovered from the blood by retro-orbital 
puncture. For mice in which no bacteria were found, a lower limit of detection (22 CFU/
ml) was used. Results were corrected mathematically to account for small differences in 
bacterial count in the initial inoculum. All experiments were performed with the approval 
of the Animal Experimentation Committee (DEC) of the Radboud University Nijmegen 
Medical Centre.
In silico analysis. The subcellular location of PCA enzyme was predicted by various online 
prediction servers, such as PSORTb (http://www.psort.org) and TMHMM (http://www.cbs.
dtu.dk/services/TMHMM). Conservation of the pca gene and PCA protein was performed 
by the genomic BLAST service on the website of the National Center for Biotechnology 
Information (NCBI) of the U.S. National Library of Medicine (http://www.ncbi.nlm.nih.
gov/).
Statistical analysis. For in vitro host-pathogen studies, data were analyzed using an 
unpaired Student’s t-test, with P values <0.05 considered significant. All statistical analyses 
were performed using GraphPad Prism version 4.0.
results
The pca gene is required for pneumococcal growth under CO2-poor conditions. To 
determine the importance of the pca gene for pneumococcal growth, pca deletion mutants 
(Dpca) were constructed from three S. pneumoniae strains: i.e., R6 (Dspr0026), D39 
(DSPD_0030), and TIGR4 (DSP_0024). All Dpca strains were able to grow normally on BA 
plates and Trypticase soy broth (TSB) agar plates supplemented with catalase (Trypticase 
soy agar [TSA]) under ambient air enriched with 5% CO2 (data not shown). In vitro growth 
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rates in 5%-CO2-enriched GM17 broth medium were similar for the Δpca and wild-type 
strains, with cultures reaching an OD620 of 0.3 or more (Fig. 1A, left panel). In GM17 broth 
medium that was exposed to ambient air, the wild-type strains were also able to reach a 
high OD620. In contrast, growth of all Δpca strains under these CO2-poor (0.038%) growth 
conditions was attenuated, and cultures did not reach an OD620 above 0.1 (Fig. 1A, right 
panel). Growth of the Δpca strains under CO2-poor conditions was also impaired on TSA 
plates and reduced on BA plates (data not shown). 
To exclude polar effects due to disruption of the pca gene, we provided the pca gene 
in trans on the pUO3 plasmid behind a nisin-inducible promoter. Induction of pca gene 
expression by addition of nisin restored growth of the nisin-responsive R6bga::nisRKΔpca 
(pUO3) strain in CO2-poor GM17 broth (Fig. 1B). Introduction of the pUO1 plasmid with 
the gene for E. coli carbonic anhydrase (ECCA) (12) into R6bga::nisRKΔpca also reversed 
the CO2 dependence of this strain (FIG. 1B). Interestingly, complementation by ECCA 
did not appear to require induction with nisin. Because pUO1 could not restore the CO2 
dependence of the R6Dpca strain lacking the NisRK sensor for nisin (data not shown), it is 
likely that autoinduction of the NisRK two-component signal transduction system resulted 
in expression of small but sufficient amounts of ECCA. 
PCA has carbonic anhydrase activity. The PCA enzyme was further characterized with 
enzymatic activity and inhibition assays. To facilitate the measurement of PCA enzymatic 
activity, PCA was overproduced as a GST fusion protein in E. coli. Since no endogenous E. 
coli CA activity was detected in the lysates of control cells expressing only the GST protein, 
the CA activity in E. coli cells expressing GST-PCA can be fully ascribed to the presence 
of the recombinant protein (data not shown). The affinity-purified recombinant GST-PCA 
Fig. 1. Disruption of the pca gene in S. pneumoniae leads to CO2-dependent growth inhibition. (A) Growth 
characteristics of the S. pneumoniae R6, D39, and TIGR4 wild type and Δpca strains in CO2-rich and 
CO2-poor GM17 broth medium. (B) Growth of the S. pneumoniae R6bga::nisRK Δpca harboring either 
pNG8048E (empty vector), pUO1 (ecca), or pUO3 (pca) in CO2-poor GM17 broth medium without (-nis) 
and with (+nis) 20 ng/ml nisin. Growth of the pneumococcal cultures was monitored by recording the OD620. 
All curves in the graph present the averages of the results of three independent growth experiments.
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Fig. 2. Enzymatic activity and 
inhibition studies on recombinant 
GST-PCA. (A) The CA activity of 
GST-PCA (100 µg/ml) was measured 
by the changing-pH/dye indicator 
method at pH 7.5 and pH 8.4. (B) 
Inhibitory effect of the sulfonamides 
AZA (100 µM) and EZA (100 µM) on 
the CA activity of GST-PCA at pH 8.4. 
Under all conditions tested, hCAII (0.5 
µg/ml) and nonenzymatic reactions 
were included as positive and negative 
controls, respectively. The curves for 
the non-enzymatic control reactions 
of the inhibition study overlapped with 
the curves of hCAII with inhibitor and 
for the clarity of the graph were not 
displayed. All curves in the graphs 
present the averages of the results of 
three independent CA activity assays. 
Abs., absorbance. 
Fig. 3. Bicarbonate and oleic acid revert the CO2 dependence of Δpca strains. (A) Growth of S. pneumoniae 
TIGR4Δpca in CO2-poor GM17 broth medium supplemented with NaHCO3 (10 mM), adenine (200 mg/ml), 
uracil (200 mg/ml), arginine (200 mg/ml), aspartic acid (200 mg/ml), palmitic acid (0.01 mM in 0.1% Tween 
40), or oleic acid (0.01 mM in 0.1% Tween 40). (B) Growth of the S. pneumoniae TIGR4Δpca in CO2-poor 
GM17 broth medium with 0.1% Tween 20, Tween 40, or Tween 80. The growth of all pneumococcal broth 
cultures was monitored by recording the OD620. All curves in the graph present the averages of the results of 
three independent growth experiments.
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protein catalyzed the conversion of CO2 to HCO3- at pH 8.4, whereas the enzymatic activity 
was almost completely abrogated at pH 7.5 (Fig. 2A). Sulfonamides such as AZA and 
EZA are broad-range CA inhibitors that are active against most CAs (39), including the 
homologous Rv1284 CA in Mycobacterium tuberculosis (29). Interestingly, the presence of 
100 µM AZA or 100 µM EZA did not reduce the CA activity of recombinant GST-PCA, 
whereas that of hCA II was completely inhibited (Fig. 2B). Since both compounds also did 
not induce CO2 dependence in S. pneumoniae wild-type strains (data not shown), these 
sulfonamides are unlikely to have high affinity for PCA. 
PCA is linked to UFA biosynthesis. The biosynthesis pathways for nucleic acids, fatty 
acids, and several amino acids all contain an essential HCO3--dependent carboxylation step 
that could potentially account for the observed growth defect of microbial CA mutants 
in CO2-poor conditions (1). To investigate if one or more of these carboxylation steps are 
responsible for the growth inhibition of S. pneumoniae Dpca strains in CO2-poor GM17 
Fig. 4. Scavengers for endogenous 
ROS delay the CO2-dependent 
growth defect of Δpca strains. 
(A) Growth of the R6 and TIGR4 
S. pneumoniae Dpca strains in 
CO2-poor GM17 broth medium 
without (-sal) or with 5 mM (+sal) 
sodium salicylate. (B) Growth of 
the S. pneumoniae R6 and TIGR4 
Dpca and ΔpcaΔspxB strains in 
CO2-poor GM17 broth medium 
without (-cat) or with (+cat) 10,000 
U/ml of catalase. The growth of all 
pneumococcal broth cultures was 
monitored by recording the OD620. 
All curves in the graphs present the 
results of a single experiment that 
are characteristic of those for three 
independent growth experiments. 
73
broth medium, we complemented pneumococcal cultures with sodium hydrogencarbonate 
(NaHCO3) or various metabolic intermediates (i.e., adenine, uracil, arginine, aspartic acid, 
palmitic acid (in 0.1% Tween 40), or oleic acid (in 0.1% Tween 40) (Fig. 3A). As predicted, 
NaHCO3 fully reversed growth of the S. pneumoniae TIGR4Δpca strain under CO2-poor 
conditions. The unsaturated fatty acid (UFA) oleic acid was the only metabolic intermediate 
that could partially restore growth as well, although not to the same level as NaHCO3. Other 
sources of UFAs, such as Tween 20 and Tween 80 (30), could also (partially) reverse the CO2 
dependence of the S. pneumoniae TIGR4Δpca strain (FIG. 3B). In contrast, the saturated 
fatty acid (SFA) palmitic acid (Fig. 3A) or Tween 40 (Fig. 3B), which is a Tween derivative 
that is solely composed of SFA, was ineffective.
Because the supplementation with SFAs could not reverse the CO2-dependent growth 
inhibition of the Dpca strains, CO2 fixation by PCA appears to be essential when insufficient 
UFAs are available in the growth medium. The synthesis of UFAs and SFAs in S. pneumoniae 
occurs essentially by the same pathway (27). The dependency of the Δpca strains on UFA 
supplementation for growth under CO2-poor conditions therefore suggests that under this 
condition UFAs are more readily depleted. Recently, it was reported that the reactive oxygen 
species (ROS) scavenger salicylate increased the unsaturation index of bacterial-membrane 
fatty-acyl chains under aerobic (thus CO2-poor) growth conditions by protecting UFAs 
against endogenous oxidative stress (31). In line with this observation, cultures of the S. 
pneumoniae R6Δpca and TIGR4Δpca strains grown under CO2-poor conditions reached 
an almost 2-fold higher optical density when supplemented with salicylate (Fig. 4A). 
Neutralization of endogenous H2O2, which also plays an important role in lipid peroxidation 
(38), through the addition of high concentrations of catalase restored growth of the 
S. pneumoniae R6Δpca and TIGR4Δpca strains to an almost 3-fold-higher optical density 
(Fig. 4B). Despite the involvement of pyruvate oxidase (SpxB) in endogenous H2O2 
production (41), disruption of the spxB gene in the TIGR4Δpca and R6Δpca strains did not 
restore growth to the same level as that in the catalase-complemented cultures (Fig. 4B). 
Moreover, addition of catalase still promoted growth of the S. pneumoniae TIGR4DspxBDpca 
and R6DspxBDpca strains (Fig. 4B).
PCA is required for intracellular survival inside host cells. Membrane fatty acids are 
essential for pneumococcal growth and survival (26) and are important targets for host 
defense mechanisms (38). Because our experiments suggest that PCA activity and UFA 
biosynthesis are linked, we investigated the specific contribution of PCA to pneumococcal 
host-pathogen interactions. To identify PCA-mediated effects on the interaction of 
S. pneumoniae with host cells, we assessed the ability of the Dpca strains to adhere to, invade, 
and survive in different cell lines. First, we studied the interaction of S. pneumoniae with 
human pharyngeal epithelial Detroit 562 cells, which are representative of the host cells 
encountered by S. pneumoniae during colonization of human upper airways. Disruption of 
the pca gene in the unencapsulated (Dcps) derivative of the S. pneumoniae TIGR4 strain did 
not lead to decreased adherence to (Fig. 5A) or invasion of (Fig. 5C) these epithelial cells. 
However, at 1 h after pneumococcal invasion of the host cells, we observed a statistically 
significant 1.3-fold reduction in intracellular survival of the TIGR4DcpsDpca strain 
in Detroit 562 cells (Fig. 5E). Next, we examined the role of PCA during interaction of 
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Fig. 5. PCA is required for invasion and intracellular survival in host cells. (A and B) In vitro adherence 
of the TIGR4ΔcpsDpca strain to Detroit 562 cells and HBMECs (A) and binding of D39ΔcpsDpca by J774 
cells (B). The relative adherence and binding efficiencies were correlated to those of the TIGR4Dcps and 
D39Dcps strains, respectively. (C and D) Invasive properties of TIGR4ΔcpsDpca strain toward Detroit 562 
cells and HBMECs (C) and uptake of the D39ΔcpsDpca strain by J774 cells (D). The relative invasion and 
uptake efficiencies were correlated to the number of viable intracellular cells of the TIGR4Dcps and D39Dcps 
strains, respectively. (E and F) Intracellular survival kinetics of the TIGR4Δcps and TIGR4ΔcpsDpca strains 
in Detroit 562 cells (E) and HBMECs (F). (G) Phagocytic killing of the D39Δcps and D39ΔcpsDpca strains in 
J774 cells. Intracellular survival and phagocytic killing were correlated to viable-bacteria counts at time zero. 
*, statistically significant differences (P < 0.05).
S. pneumoniae with the HBMEC line. Endothelial cells are the main component of the 
blood-brain barrier, and penetration of this barrier by pathogens can lead to meningitis. 
Adherence to HBMEC was not significantly different between the TIGR4Dcps and 
TIGR4DcpsDpca strains (Fig. 5A). In contrast, the number of viable intracellular bacteria 
that could be recovered from HBMECs directly after pneumococcal invasion was reduced 
7-fold for the TIGR4DcpsDpca strain compared to that of the TIGR4Dcps strain (Fig. 5C). 
Interestingly, at 2 and 4 h after invasion, the relative decreases in the numbers of viable 
intracellular bacteria were equal for the two strains (Fig. 5F). Finally, we investigated the 
role of PCA during interaction of S. pneumoniae with mouse J774 macrophage cells, which 
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are primary immune cells important for clearance of bacterial infections. Exposure of J774 
cells to TIGR4Dcps induced morphological and phenotypical changes in J774 cells, such as 
surface detachment and cell lysis, making readout unreliable and leading to nonreproducible 
results. J774 interaction studies were therefore continued with the S. pneumoniae D39Dcps 
and D39DcpsDpca strains. Although disruption of the pca gene had no significant effect on 
binding of S. pneumoniae by host immune cells (Fig. 5B), the number of viable intracellular 
bacteria directly after uptake by the macrophages was 2-fold lower for the D39DcpsDpca 
Table 3. Characteristics of CO2-dependent carriage isolates.
Straina
Transformation  
(CFU/ml) with DNA fromb: Growth on or in indicated plate or brothc
R6 R6Δpca BA plates TSA plates GM17 broth
GM17 broth  
(0.1% Tween 80)
H23 19,800 14,900 - - + +
H26 67 67 - - - -
a Both strains carry the pca gene.
b No. of colonies growing on BA plates under CO2-poor conditions.
c +, growth; -, no growth.
strain than for the D39Dcps strain (Fig. 5D). Moreover, temporal monitoring revealed 
that phagocytic killing of intracellular bacteria continued to be significantly faster for the 
D39DcpsDpca strain than for the D39Dcps strain (Fig. 5G). Despite the in vitro contribution 
of PCA to pneumococcal intracellular survival, no significant difference between the 
S. pneumoniae TIGR4 wild-type and TIGR4Δpca strains was observed in mouse models of 
pneumococcal nasopharyngeal carriage and bacteremia (Supplementary Figure S1). 
The pca gene is present in CO2-dependent circulating strains. The pca gene appears 
to be a highly conserved gene, which is present in all 11 complete and 18 draft S. 
pneumoniae genomes that are currently available in the public databases. Still, about 8% 
of all S. pneumoniae isolates from various sources have been reported as CO2 dependent 
(3). To exclude the possibility that the pca gene is absent in these circulating strains, we 
investigated whether the CO2 dependence of these isolates is related to the absence of a 
functional pca gene. Two out of 126 carriage strains (H23 and H26) isolated from healthy 
Venezuelan children (our unpublished data) did not grow on BA and TSA plates unless 
the environment was enriched with 5% CO2. PCR-analysis indicated that the pca gene 
was present in both CO2-dependent strains (Table 3), and genetic transformation of these 
strains with chromosomal DNA from both the S. pneumoniae R6 wild-type and R6Δpca 
strains resulted in CO2-independent colonies (Table 3). These results suggest that the 
observed CO2-dependence of the H23 and H26 strains is associated with a genetic defect or 
a missing gene other than pca. In addition, further phenotypical characterization of these 
strains showed that their CO2 dependence was different from that of the S. pneumoniae 
Δpca strains used in this study. Although both strains were completely CO2-dependent for 
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growth on BA plates, the H23 strains reached high optical densities in CO2-poor GM17 
broth medium. In contrast, the H26 strain did not grow at all in CO2-poor GM17 broth 
medium, not even when it was supplemented with UFA (Tween 80) (Table 3).
discussion
The respiratory tract pathogen S. pneumoniae needs to adapt to the various conditions it 
encounters during transmission, colonization, and disease. Currently, relatively little is 
known about the genetic and metabolic factors that contribute to an adequate response 
of this bacterium to changes in CO2 availability. In this study, we showed that the putative 
carbonic anhydrase in S. pneumoniae has an important role for growth in CO2-poor 
conditions.
Our experiments clearly showed that the pca gene encodes a functionally active 
carbonic anhydrase. All the Dpca strains were growth-deficient in CO2-poor conditions 
but could be complemented by the addition of HCO3-, the expected end product of PCA 
enzymatic activity. In addition, growth of the Dpca strains could be restored by in trans 
expression of the well-characterized homologous β-CA (ECCA) from E. coli. Finally, 
recombinant GST-PCA was able to catalyze the conversion of CO2 to HCO3-. Interestingly, 
PCA did not appear to be active at the physiological pH of 7.5. This is not unusual for 
β-CAs, and has been observed for ECCA and the H. influenzae CA (HICA). Most likely, this 
pH-dependent behavior is linked to the pH-dependent coordination of Zn2+ in the active 
site  (13). Furthermore, both ECCA and HICA appear to have an alternative bicarbonate 
binding site that renders the enzyme inactive at physiological pH when sufficient substrate is 
present (13). Although PCA appears to miss essential amino acids that form the alternative 
bicarbonate binding site, it is also not unlikely that differences exist between its CA activity 
in enzymatic assays and in physiological conditions. Another striking characteristic of PCA 
is its lack of affinity for broad-range carbonic anhydrase inhibitors. This indicates that this 
enzyme is deviant from other well-characterized CAs, which is not surprising, as there is 
huge variation among the different CAs and CA inhibitors were often developed against 
unrelated human CAs (hCAs). In fact, differences between PCA and hCAs could benefit the 
therapeutic potential of PCA inhibitors.
Our metabolic complementation experiments revealed, in analogy to the role of CAs 
in other microorganisms (1,5), that the cellular function of PCA in CO2-poor conditions 
is at least linked to FA biosynthesis. This implies that PCA provides HCO3- required for 
the carboxylation of acetyl coenzyme A (acetyl-CoA) by acetyl-CoA carboxylase to form 
malonyl-CoA, which is the first committed step of FA biosynthesis (15). We did not observe 
a stimulating effect of any of the other tested metabolic intermediates on the growth of the 
S. pneumoniae Dpca strains in CO2-poor GM17 broth medium. This implies that GM17 
medium contains limiting amounts of UFAs, but sufficient levels of the other metabolites to 
support growth. Based on the UFA supplementation experiments and previous observations 
of other microorganisms (1,5), we can predict that other carboxylation reactions, e.g., those 
involved in  biosynthesis of some amino acids, pyrimidines, and purines, also depend on 
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PCA activity when CO2 levels are low. Still, we feel that support of UFA biosynthesis is one 
of the most relevant aspects of PCA function. Although S. pneumoniae is able to tolerate low 
levels of membrane SFAs, insufficient UFAs lead to decreased cell viability (2). In ambient-
air conditions, both environmental and cellular UFAs are prone to oxidation and can be 
replaced only by the PCA-supported de novo biosynthesis of UFAs. In addition, endogenous 
production of ROS by S. pneumoniae itself leads to increased cellular UFA peroxidation 
(31). Due to the transient phenotype of the pca mutation, it was not possible to perform a 
straightforward experiment to directly link the disruption of the pca gene to an alteration 
in the membrane FA composition or increased ROS sensitivity. In the absence of CO2, the 
Dpca strains do not grow, whereas in the presence of CO2, the Dpca and wild-type strains are 
phenotypically identical. In analogy with studies of S. pneumoniae UFA auxotrophs (27), we 
did attempt to complement cultures of the Dpca strains in CO2-poor conditions with UFAs 
to restore growth and allow characterization of membrane FAs. However, supplementation 
of cultures of the pneumococcal wild-type and Dpca strains with UFAs completely repressed 
expression of the FA biosynthesis gene cluster (our unpublished data), which inevitably 
results in a membrane that is predominantly composed of exogenous FAs (9). 
It is tempting to speculate about the role of PCA in neutralizing the detrimental effect 
of pneumococcal SpxB activity. In ambient air, SpxB produces H2O2, acetyl-phosphate, 
and CO2. Production of H2O2 leads to UFA peroxidation (31), whereas acetyl-phosphate 
can readily be converted to acetyl-CoA by phosphate acetyl-transferase to support de 
novo FA biosynthesis. PCA then acts to convert CO2 to HCO3-, allowing carboxylation of 
acetyl-CoA to form malonyl-CoA. Currently, this hypothesis is not supported by our own 
observations, as catalase improved growth of both the S. pneumoniae Dpca and DpcaDspxB 
strain cultures. However, the interconnection between SpxB activity and FA biosynthesis 
is still poorly understood, and might involve different metabolic and regulatory pathways 
(31,44). Alternatively, this suggests that other sources of endogenous oxidative stress, such 
as the Fenton reaction (31) or lactate oxidase activity (44), have a profound impact on the 
growth arrest of the Δpca strains in CO2-poor conditions as well. 
The role of PCA in the de novo biosynthesis of UFAs and, possibly, other metabolites 
could also explain the decreased viability of the S. pneumoniae Dpca strains after invasion 
of endothelial cells and uptake by macrophages. During phagocytosis, and possibly 
endocytosis (33), a substantial portion of the intracellular bacteria is sorted to the host-cell 
lysosome. The low pH of this compartment reduces HCO3- availability, and the production 
of ROS leads to peroxidation of bacterial membrane UFAs (38) and nucleic acids (37). 
Interestingly, the effect of pca disruption on S. pneumoniae invasion and intracellular 
survival inside Detroit 562 pharyngeal epithelial cells was not as pronounced as in the two 
other cell types. Whether this difference reflects on the different routes for pneumococcal 
invasion of Detroit 562 cells, by interaction with the polymeric immunoglobulin receptor 
(pIgR) (49) and HBMECs by interaction with the platelet-activating factor receptor (PAFr) 
(34) remains to be studied. A role for microbial carbonic anhydrases inside host cells was 
earlier suggested for a Salmonella enteric serovar Typhimurium CA (mig-5), which was 
expressed after uptake in macrophages and a mutant of whichhad a marked decrease in 
spleen colonization of mice (46). In contrast to findings for Salmonella CA mutants, we 
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were not able to link PCA with virulence in animal models of bacteremia. However, this 
observation is in line with the outcome of a previous study showing that mice deficient in 
the NADPH oxidase subunit gp91, which is essential for lysosomal ROS production, were as 
sensitive to pneumococcal infection as wild-type mice (36). Furthermore, it is known that 
pneumococcal capsular polysaccharides prevent recognition and uptake of the bacterium 
by host immune cells, and once S. pneumoniae remains extracellular during infection of the 
blood it might utilize serum HCO3- and FAs (9). Possibly, the role of PCA in pneumococcal 
disease is more pronounced in animal models of disease in which the bacterium needs 
to traverse the boundaries of epithelial and endothelial cells for dissemination from the 
respiratory tract to the blood and cerebrospinal fluid.
Finally, the role of PCA in S. pneumoniae can be projected onto CAs in other (respiratory 
tract) pathogens. Although CAs are ubiquitous enzymes in many microorganisms, most 
studies have investigated the role of CAs that are exposed to the surface or periplasm, 
have species-specific functions, or do not belong to the class of β-CAs (39). Here, we show 
that cytosolic β-CAs related to PCA are involved in FA biosynthesis and may offer novel 
opportunities for the design of broad-range therapies. Furthermore, PCA is probably 
only one of the factors that contribute to the adaptation of S. pneumoniae to CO2-poor 
conditions, which might be relevant for pneumococcal transmission in environmental 
ambient air. Detailed examination of the metabolic pathways that depend on PCA-
mediated CO2 fixation and the identification of the genetic basis for the CO2 dependence 
observed in approximately 8% of all circulating pneumococcal isolates is expected to lead 
to novel insights into the way respiratory pathogens adapt to the CO2- and HCO3--poor 
environments they encounter during transmission, colonization, and disease.
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Supplemental Table S1. Primers used in this study.
Primer name Target Nucleotide sequence (5’-3’)
Overlap extension PCR
  PBMrTn9 Sp/Km cassette; control CAATGGTTCAGATACGACGAC
  PBpR410_L Km cassette pR410 (5’) ACGCGCAAGCTGGGGATC
  PBpR410_R Km cassette pR410 (3’) ACCCGAGCTCGAATTGACG
  PBpR412_L Sp cassette pR412 (5’) GCCGCTCTAGAACTAGTGG
  PBpR412_R Sp cassette pR412 (3’) GATACCCCTCGAATTGACGC
  PBspr0023_L1 Spr0023, left flank (5’) CGCTTGCTGGATTGCACAC
  PBspr0023_L2 Spr0023, left flank (3’) CCACTAGTTCTAGAGCGGCATGCGCTGTCTCACGCTTG
  PBspr0023_R1 Spr0023, right flank (3’) GCAACAACTACCACAGTCTG
  PBspr0023_R2 Spr0023, right flank (5’) GCGTCAATTCGAGGGGTATCGAGCGTATTGTCCAGGCTG
  PBspr0023_C Spr0023, control AGAGGTAGAGAACCTCAGTC
  PBspr0024_L1 Spr0024, left flank (5’) CGTGGTTTTGAATTGGTTTCG
  PBspr0024_L2 Spr0024, left flank (3’) CCACTAGTTCTAGAGCGGCGCTCCTCTAACTCACGG
  PBspr0024_R1 Spr0024, right flank (3’) TTCTGCACGAACACTCTGC
  PBspr0024_R2 Spr0024, right flank (5’) GCGTCAATTCGAGGGGTATCGCCAAGTGATTGAGTGTGAG
  PBspr0024_C Spr0024, control GCGTCAATTCGAGGGGTATCGAGCGTATTGTCCAGGCTG
  PBspr0025_L1 Spr0025, left flank (5’) TCCTTTACTCTCGTCAGCTG
  PBspr0025_L2 Spr0025, left flank (3’) GTCTGAGCACCACAGTCTG
  PBspr0025_R1 Spr0025, right flank (3’) CCACTAGTTCTAGAGCGGCAACCTCAACCTCTTC
  PBspr0025_R2 Spr0025, right flank (5’) GCGTCAATTCGAGGGGTATCAACGCATCAACGAAGCTGC
  PBspr0025_C Spr0025, control TTGAGACTTGTAGGAGAAGAG
  PBspr0026_L1 Spr0026, left flank (5’) GGTAACACCGACCATGTTTG
  PBspr0026_L2 Spr0026, left flank (3’) CCACTAGTTCTAGAGCGGCGACACGATTCCCTCCTTG
  PBspr0026_R1 Spr0026, right flank (3’) TGGAATCCCAAACCGGAGG
  PBspr0026_R2 Spr0026, right flank (5’) GCGTCAATTCGAGGGGTATCAGGAAGTATGACAGTCGTAG
  PBspr0026_C Spr0026, control GGTAACACCGACCATGTTTG
  PBspr0027_L1 Spr0027, left flank (5’) TAGCTATTGTGACCTGTATGG
  PBspr0027_L2 Spr0027, left flank (3’) CCACTAGTTCTAGAGCGGCCTCGAACCGTCCGTATAG
  PBspr0027_R1 Spr0027, right flank (3’) GTAAGGCATGACAACATTGAC
  PBspr0027_R2 Spr0027, right flank (5’) GCGTCAATTCGAGGGGTATCAGAGTTGCCTTTAGCGATTC
  PBspr0027_C Spr0027, control GCGTCAATTCGAGGGGTATCAGGAAGTATGACAGTCGTAG
  PBSP0730_L1 SpxB, left flank (5’) ATCGCCATCGAGTCAGCAG
  PB SP0730_L2 SpxB, left flank (3’) GATCCCCAGCTTGCGCGTTAAGCATTGCTGCAGATG
  PB SP0730_R1 SpxB, right flank (3’) CAAGCACTAGACCAGCAGG
  PB SP0730_R2 SpxB, right flank (5’) CGTCAATTCGAGCTCGGGTCTCTTCTTGGAAGAAGAAG
  PB SP0730_C SpxB, control CTGGACCACCTGAACCAAC
suPPlemental material
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Supplemental Table S1. Continued
Primer name Target Nucleotide sequence (5’-3’)
GST-PCA
  PBpca_start: Sp_0024 (5’), BamHI GGATCCCTCGTATTTTGAACAGTTTATGCAAGCC
  PBpca_end Sp_0024 (3’) TTATAATTCTACGACTGTCATACTTCC
Complementation
  PBnispca_L Sp_0024, BsaI GGCGGTCTCTCATGTCGTATTTTGAACAGTTTATG
  PBnispca_R Sp_0024 TGCTCTAGAGCCTGAAAGGAACATCCCTC
  PBnisecca_L ECDH10B_0106, BsaI GGCGGTCTCTCATGAAAGACATAGATACACTC
  PBnisecca_R ECDH10B_0106 TGCTCTAGAGTGTTGCATCCGGCATGGC
Supplemental Figure S1. PCA is not 
required for pneumococcal carriage and 
bacteremia. (A) Bacterial loads in the 
nasopharyngeal lavage fluid of mice 72 hrs 
after intranasal infection with 106 CFU of 
S. pneumoniae TIGR4 wild type (wt) or 
Δpca. (B) Bacterial loads in the blood of 
mice 24 hrs after intravenous infection 
with 106 CFU of the S. pneumoniae TIGR4 
wild type (wt) or Δpca strain. Each dot in 
the graph represents an individual mouse, 
and the line indicates the mean.
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abstract 
Streptococcus pneumoniae is an important human bacterial pathogen, causing such 
infections as pneumonia, meningitis, septicemia, and otitis media. Current capsular 
polysaccharide-based conjugate vaccines protect against a fraction of the over 90 serotypes 
known, whereas vaccines based on conserved pneumococcal proteins are considered 
promising broad-range alternatives. The pneumococcal genome encodes two conserved 
proteins of an as yet unknown function, SP1298 and SP2205, classified as DHH (Asp-
His-His) subfamily 1 proteins. Here we examined their contribution to pneumococcal 
pathogenesis using single and double knockout mutants in three different strains: D39, 
TIGR4, and BHN100. Mutants lacking both SP1298 and SP2205 were severely impaired in 
adherence to human epithelial Detroit 562 cells. Importantly, the attenuated phenotypes 
were restored upon genetic complementation of the deleted genes. Single and mixed mouse 
models of colonization, otitis media, pneumonia, and bacteremia showed that bacterial 
loads in the nasopharynx, middle ears, lungs, and blood of mice infected with the mutants 
were significantly reduced from those of wild-type-infected mice, with an apparent additive 
effect upon deletion of both genes. Minor strain-specific phenotypes were observed, i.e., 
deletion of SP1298 affected host-cell adherence in BHN100 only, and deletion of SP2205 
significantly attenuated virulence in lungs and blood in D39 and BHN100 but not TIGR4. 
Finally, subcutaneous vaccination with a combination of both DHH subfamily 1 proteins 
conferred protection to nasopharynx, lungs, and blood of mice infected with TIGR4. We 
conclude that SP1298 and SP2205 play a significant role at several stages of pneumococcal 
infection, and importantly, these proteins are potential candidates for a multicomponent 
protein vaccine.
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introduction
Streptococcus pneumoniae is a Gram-positive bacterium causing serious invasive diseases, 
such as pneumonia, septicemia, and meningitis. In addition, this human pathogen is 
the causative agent of less serious but highly prevalent mucosal infections, such as otitis 
media (OM) and sinusitis. Young children under the age of 2 years, the elderly, and 
immunocompromised individuals account for the majority of pneumococcal morbidity and 
mortality observed worldwide (10). One of the main virulence factors of the pneumococcus 
is its polysaccharide capsule, of which over 90 serotypes distinct in biochemical structure 
have been identified to date. The polysaccharide capsule contributes to protection against 
phagocytosis, enabling the pneumococcus to evade the immune system of the host (23,24). 
Current pneumococcal vaccines, such as Pneumovax 23 (23-valent; Merck), Synflorix (10-
valent; GlaxoSmithKline, United Kingdom), and Prevnar (7- and 13-valent; Pfizer) target 
this polysaccharide capsule. While these vaccines do provide good immune protection, it 
is restricted to the serotypes included in the vaccine. As a result, serotype replacement is 
already occurring, and the need for a serotype-independent vaccine is urgent (17,38). 
A promising alternative vaccine approach explores the use of immunogenic, surface-
exposed protective proteins. Pneumococci are estimated to express over 100 surface 
proteins, of which some are known to have a role in pathogenesis and virulence, but mostly 
their function is unknown (70). Among these surface proteins that are under investigation 
as vaccine candidates are the pneumococcal surface proteins A and C (PspA and PspC) and 
the pneumococcal surface adhesin A (PsaA). The choline-binding proteins PspA and PspC 
are key virulence factors due to their ability to interfere with complement deposition. PspA is 
expressed by all pneumococci, is highly immunogenic, and is an inhibitor of C3, preventing 
opsonization and hence phagocytosis (59,60,68). PspC is a paralog of PspA which interacts 
with the complement-inhibitory factor H (21,33,48). PsaA is a metal-binding lipoprotein 
with specificity for Mn2+ and Zn2+ (22), both essential ions for pneumococcal growth 
and survival. One of the most well-studied proteins is pneumolysin (Ply). Although Ply 
is not a surface protein, it is an important virulence factor that is produced by all known 
clinical isolates of S. pneumoniae. Ply is a member of the cholesterol-dependent pore-
forming toxin family that can directly damage epithelial surfaces and reduce the migration 
of phagocytic polymorphonuclear leukocytes (PMNs) (66). Vaccination studies using the 
above-mentioned proteins have shown that they can protect mice from pneumococcal 
disease (1,14,15,45,49-52,69). In addition, these studies have clearly demonstrated that 
combinations of distinct pneumococcal proteins often enhance protection. Although these 
results are promising, there is still a need for additional protein targets to further improve 
existing experimental protein vaccine formulations. 
Throughout the last decade, many genomic tools have been developed and used to 
identify potential protein vaccine targets, such as transcriptome analysis (53), differential 
fluorescence induction (43), and signature-tagged mutagenesis (STM) (27,37,57). We 
recently developed genomic array footprinting (GAF), a mutant library-based negative 
selection screen that uses microarrays to identify conditionally essential genes (8,18). 
We have applied the GAF technology to various in vivo animal models of pneumococcal 
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disease, i.e., colonization, bacteremia, and meningitis, to identify S. pneumoniae genes 
essential during infection (30,31,47). Interestingly, two pneumococcal proteins, SP1298 and 
SP2205, consisting of 311 and 657 amino acids, respectively, were consistently identified in 
all infection models. These two conserved proteins, of an as yet unknown function, are 
annotated as DHH subfamily 1 proteins in the pneumococcal genome. DHH family proteins 
belong to the superfamily of phosphoesterases (PE) and are named after their characteristic 
amino acid signature, Asp-His-His (DHH), found in a conserved N-terminal motif (i.e., 
motif III) (Fig. 1). The DHH family can be further divided into two distinct subfamilies, 
which share the four conserved N-terminal motifs but have different C-terminal motifs. 
Subfamily 1 proteins are found predominantly in bacteria and archaea, while subfamily 2 
proteins are also represented in eukaryotes. H-prune, the human homolog of the Drosophila 
prune protein, is an example of a eukaryotic DHH subfamily 2 protein suggested to be 
involved in cell migration (20). DHH domain proteins have been identified in a variety 
of prokaryotes, such as Bacillus subtilis, Escherichia coli, Helicobacter pylori, Mycoplasma 
species, and Streptococcus gordonii (2). RecJ of E. coli is one of the most well-known bacterial 
DHH subfamily 1 proteins possessing exonuclease activity (42,63). Recently, SMU.1297, a 
DHH-domain containing protein, was found in another streptococcal species, Streptococcus 
mutans (75). Yet little is known about DHH subfamily 1 proteins of S. pneumoniae. 
In the current study, we examined the contributions of SP1298 and SP2205 to 
pneumococcal virulence using single and double knockout mutants of three different 
strains of S. pneumoniae: D39, TIGR4, and BHN100 (serotypes 2, 4, and 19F, respectively). 
We chose to examine the effects of both DHH subfamily 1 proteins in three pneumococcal 
strains, since it has been shown that the genetic background can have a major influence 
Fig. 1. Sequence alignment of DHH motifs from selected bacterial DHH subfamily 1 proteins. The number of 
amino acids not shown in the alignment are depicted in parentheses. Bold black shading indicates conserved 
residues, and gray shading indicates similarity between residues. Dashes indicate gaps created to optimize 
alignment within motifs. Sequences are listed in order of similarity to SP1298. SP1298, S. pneumoniae TIGR4 
SP1298; SMU1297, S. mutans AU159 SMU.1297; YtqI, B. subtilis YtqI; MgORF1, M. genitalium MG_190; 
MpORF4, M. pneumoniae MPN140; SP2205, S. pneumoniae TIGR4 SP2205; SMU2140, S. mutans AU159 
SMU.2140c; YybT, B. subtilis YtqI; Sp_RecJ, S. pneumoniae TIGR4 SP0611 (RecJ); and Ec_RecJ, E. coli RecJ.
Figure 1
MOTIF I MOTIF II MOTIF III
SP1298 (16) IIIHRHMKPDPDALGSQVGLKALLEHHF (25) DRAYQGALVIVCDTANTARIDDKRYSQG (0) DFLIKIDHHPNDDVYG
SMU1297 (16) IIIHRHMKPDPDALGSQVGLKEMITSNF (25) DKDYEGALVIVVDTANRPRIDDQRYLNG (0) NFLIKIDHHPDEDHYG
YtqI (14) IILHRHVRPDPDAYGSQCGLTEILRETY (25) NETYEGALVIVCDTANQERIDDQRYPSG (0) AKLMKIDHHPNEDPYG
MgORF1 (18) IVIFHHVRPDGDCLGAQQGLFHLIKANF (27) ESFLKEALAIVVDANYKNRIELRELLDK (3) KAVLRIDHHPNEDDLN
MpORF4 (23) IVIFHHIRPDGDCLGAQHGLARLIQTNF (29) PELMQQALAVIVDANYKERIECRDLLDQ (3) KAVLRIDHHPNEDDLN
SP2205 (339) VFVVGHKNLDMDALGSAVGMQLFASNVI (40) GMVTNRSLLILVDHSKTALTLSKEFYDL (1) TQTIVIDHHRRDQDFP
SMU2140 (339) VFVVGHKNLDMDALGASVGMQAFANNII (38) EQVSDNSLLVMVDHSKLQLTLSRELYNK (1) TEVIVIDHHRRDDDFP
YybT (340) VIIMGHKFPDMDSIGAAIGILKVAQANN (39) EISNDDTLLVIVDTHKPSLVMEERLVNK (1) EHIVVIDHHRRGEEFI
Sp_RecJ (71) ENILVYGDYDADGMTSASIVKESLEQLG (25) IEQEGISLIVTVDNGVAGHEAIALAQSM (1) VDVIVTDHHSMPETLP
Ec_RecJ (81) TRIIVVGDFDADGATSTALSVLAMRSLG (25) AHARGAQLIVTVDNGISSHAGVEHARSL (1) IPVIVTDHHLPGDTLP
  MOTIF IV   DHHA1 MOTIF
SP1298 (15) ITLFAQTTQLALADRDAELLFAGIVGDTGRFLYPSTTARTLRLAAYLREH (70) LWGIFVEQADGHYRVRLRS-KVHPINEIAKE---------HDGGGHPLASGANSYSL (16)
SMU1297 (15) ITDFALQNQLKLSDQAARLLYAGILGDTGRFLYPATTSKTFIIASELLKY (70) VWAIFVEQADGHYRVRLRS-KSTVINEVAKR---------HAGGGHPLASGANSYSL (15)                                                  
YtqI (18) LYLEGKEHGWKLNTKAAELIYAGIVGDTGRFLFPNTTEKTLKYAGELIQY (70) AWVFFVEEDD-QIRVRFRS-KGPVINGLARK---------YNGGGHPLASGASIYSW (18)                                                 
MgORF1 (16) IVEMATVAKWTIPPVAATLLYIGIYTDSNRFLYSNTSYRTLYLAAILYKA (68) IWLFFIEQANNEIRIDLRS-NGINVRDIAIK---------YGGGGHNNASGAIITNK (17)                                         
MpORF4 (16) VVDLAVQAKWKLSPPAATALYLGIYTDSNRFLYSNTSWRTLYLGSMLYRA (68) IWLFFIEEGKNHYRVEFRS-NGINVREVALK---------YGGGGHIQASGAVLKSK (16)                                    
SP2205 (21) LIQFQNSKKNRLSRMQASVLMAGMMLDTKNFTSRVTSRTFDVASYLRTRG (66) ASFVLAKNTQGFISISARSRSKLNVQRIMEE---------LGGGGHFNLAAAQIKDV (23)                          
SMU2140 (21) LLQFQNGK-YHLNKIQASIVMAGIMLDTKSFSTRVTSRTFDVASYLRTLG (64) ATFVITRNDERTVCISARSRNKINVQRIMEE---------MGGGGHFNLAACQLKGT (24)                                          
YybT (21) LLEYQPKR-LKINMIEATALLAGIIVDTKSFSLRTGSRTFDAASYLRAKG (66) ASFAVARRDEQTVCISARSLGEVNVQIIMEA---------LEGGGHLTNAATQLSGI (23)                                        
Sp_RecJ (40) AFKLACALLEEVQVELLDLVAIGTIADMVSLTDENRILVQYGLEMLGHTQ (115) QTVIVLNIEDGRAKGSARSVEAVDIFEALDPHRDLF----IAFGGHAGAAGMTLEVE (137)
Ec_RecJ (25) GWFDERNIAIPNLAELLDLVALGTVADVVPLDANNRILTWQGMSRIRAGK (124) PVIAFAPAGDGTLKGSGRSIQGLHMRDALERLDTLYPGMMLKFGGHAMAAGLSLEED (318)
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on the contribution of proteins to virulence (9,19). Using four different murine models 
of single and mixed infections representing major phases of pneumococcal carriage and 
disease, we characterized the roles of both DHH subfamily 1 proteins in the pneumococcal 
pathogenesis of colonization, otitis media, pneumonia, and bacteremia. We also assessed the 
contributions of both DHH subfamily 1 proteins to pneumococcal adherence in vitro. Finally, 
we provided evidence that vaccination with a combination of recombinant DHH subfamily 
1 proteins can provide substantial protection against TIGR4-induced pneumonia in mice, 
and we propose that these proteins should be considered potential vaccine candidates.
material & methods
Pneumococcal strains and growth conditions. Pneumococcal strains used in this study are 
shown in Table 1. S. pneumoniae was routinely grown in Todd-Hewitt broth supplemented 
with 5 g liter–1 yeast extract (THY) or on Columbia blood agar (BA) plates (Oxoid) at 37°C 
and 5% CO2. Prior to mouse infection experiments, bacteria were passaged in mice to 
maintain virulence as described previously (Kerr et al., 2004). Cultures of mouse-passaged 
S. pneumoniae strains were grown to an optical density (OD) at 620 nm (OD620) of 0.2, 
and aliquots were stored at –80°C in 15% glycerol. Prior to infection, defrosted aliquots 
were centrifuged, and bacteria were resuspended in sterile phosphate-buffered saline (PBS) 
to the desired concentration. When appropriate, antibiotics were used at the following 
concentrations: spectinomycin, 150 µg ml–1; trimethoprim, 25 µg ml–1; and kanamycin, 500 
µg ml–1. The number of CFU per ml in a particular sample was quantified by plating serial 
10-fold dilutions in PBS on BA plates.
Construction of site-directed deletion mutants. All primers and plasmids used in this 
study are shown in Table 1. A megaprimer PCR method (18) was employed to replace target 
genes in the genomes of the S. pneumoniae TIGR4, D39, and BHN100 strains with the 
spectinomycin resistance cassette amplified from plasmid pR412T7 (8). The resulting PCR 
products were introduced by competence-stimulating peptide (CSP)-induced transformation 
into the corresponding strains, using CSP-1 for D39 and BHN100 and CSP-2 for TIGR4. 
Transformants were selected on the basis of spectinomycin resistance and were checked by 
PCR for recombination at the desired location on the chromosome. In addition, a double 
mutant ΔSP1298ΔSP2205 was generated in each of the three pneumococcal strains. To this 
end, the SP1298 gene was inactivated by allelic replacement with a trimethoprim cassette 
and introduced into the respective ΔSP2205 strains (spectinomycin) by transformation.
Genetic complementation of DHH mutants. Genetic revertants of the SP1298 and SP2205 
BHN100 single mutants were created using CEP, a chromosomal expression platform for 
ectopic, maltose-driven gene expression in S. pneumoniae (25). To this end, the genes 
were amplified with the primer pairs HBSP1298atg/HBSP1298stop and HBSP2205atg/
HBSP2205stop, respectively, using BHN100 chromosomal DNA as a template. After 
digestion by NcoI/BamHI, the SP1298 and SP2205 fragments were ligated with the NcoI/
BamHI-digested plasmid pCEP. The resulting SP1298 and SP2205 ligation mixtures were 
used as the donor in transformation of strains BHN100ΔSP1298 and BHN100ΔSP2205, 
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Table 1. Bacterial strains, primers, and plasmids used in this study.
Strain, plasmid, or 
primer Relevant characteristics or nucleotide sequence (5' to 3') a
Reference/source or 
target gene b
Species and strain
S. pneumoniae
D39 Wild type (serotype 2) NCTC 7466
TIGR4 Wild type (serotype 4) (65)
BHN100 Wild type (serotype 19F) (61)
DSP1298 mutant SP1298 deletion in strains D39, TIGR4, and BHN100 (Spr) This study
DSP2205 mutant SP2205 deletion in strains D39, TIGR4, and BHN100 (Spr) This study
DSP1298DSP2205 
mutant
Double deletion of SP1298 and SP2205 in strains D39, TIGR4, 
and BHN100  (Spr Tmr) This study
BHN100DSP1298 
CEPSP1298
BHN100DSP1298 with SP1298 ectopically expressed from 
CEP (Spr Kmr) This study
BHN100DSP2205 
CEPSP2205
BHN100DSP2205 with SP2205 ectopically expressed from 
CEP (Spr Kmr) This study
BHN100 CEPØ BHN100 wild type with empty CEP (Kmr) This study
E. coli
DH5α Strain for DNA cloning (26)
BL21 Strain for recombinant protein expression Novagen
Plasmids
pR412T7 Donor plasmid for Spr cassette (8)
pKOT Donor plasmid for Tmr cassette (28)
pCR2.1 Cloning vector (Apr Kmr) Invitrogen
pET11c Expression vector (Apr) Novagen
pCEP pSC101 derivative; Sp
r Kmr; carries S. pneumoniae chromo-
somal expression platform, CEP (25)
pLC1a pCR2.1 containing SP1298 gene (BamHI) This study
pLC1b pCR2.1 containing SP1298 gene (XbaI and BamHI) This study
pLC1298 pET11c containing rHisSP1298 gene This study
pLC2 pCR2.1 containing SP2205 gene (AvrII and BamHI) This study
pLC2205 pET11c containing rHisSP2205 gene This study
Primers
CJsp1298_L1 CGTAGAAGGTATCTCCTGAG SP1298; left flank
CJsp1298_L2 CCACTAGTTCTAGAGCGGCGGGTCTGGTTTCATAT-GACG SP1298; left flank
CJsp1298_R1 CCTACAGATGAGTCTGGAAC SP1298; right flank
CJsp1298_R2 GCGTCAATTCGAGGGGTATCTAGCAAGTGGTGCTAAT-TC SP1298; right flank
CJsp1298_C GATGTTCCAGCAAGGCTTTC SP1298; control
HBsp1298_L2 GTCCAAGCTCACAAAAATCCGTGGGTCTGGTTTCAT-ATGACG SP1298; left flank
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Table 1. Continued.
Strain, plasmid, or 
primer Relevant characteristics or nucleotide sequence (5' to 3') a
Reference/source or 
target gene b
HBsp1298_R2 CGTCTATGCGCGTCGTAACTAGCAAGTGGTGCTAATTC SP1298; right flank
CJsp2205_L1 CGCAGAAGATGTATCTCAAG SP2205; left flank
CJsp2205_L2 CCACTAGTTCTAGAGCGGCGTGGATAAGACTC-CAAACGC SP2205; left flank
CJsp2205_R1 CGAATCGGAGCTTGTACTTG SP2205; right flank
CJsp2205_R2 GCGTCAATTCGAGGGGTATCGTAACCTTGTCAGAAG-CAGG SP2205; right flank
CJsp2205_C GCTGTCAAACTTTCTTCCGC SP2205; control
PBpR412_L GCCGCTCTAGAACTAGTGG Sp cassette pR412
PBpR412_R GATACCCCTCGAATTGACGC Sp cassette pR412
PBMrTn9 CAATGGTTCAGATACGACGAC Sp cassette; control
HBTmpFw TCGGATTTTTGTGAGCTTGGAC Tm cassette pKOT
HBTmpRv GTTACGACGCGCATAGACG Tm cassette pKOT
HBSP1298atg GGgTATccATGGAGATTTGCCAACAAATTTTAG SP1298
HBSP1298stop GTTAAAAAACTTGCTTAAAAACTGATAggATcCTTGCCA SP1298
HBSP2205atg TTATGGTAccATGGGTGCCAAGAGGTTTTGAATG SP2205
HBSP2205stop GGAAAAGGAGAAAGAAGAATGAAAGgAtcCTTTcTAG SP2205
HBgyrAF AATGAACGGGAACCCTTGGT gyrA, qRT-PCR
HBgyrAR CCATCCCAACCGCGATAC gyrA, qRT-PCR
HBSP2205F GGGTCTGCTGCTTCAATCAAG SP2205, qRT-PCR
HBSP2205R ACACTCCGAATCTTATCTGAAATAGCT SP2205, qRT-PCR
HBSP1298F GATTACCCTATTTGCCCAAACAA SP1298, qRT-PCR
HBSP1298R ACAATTCCTGCAAAGAGCAACTC SP1298, qRT-PCR
LCSP1298AvrH6F CCCTAGGCATCACCATCACCATCACGAGATTT-GCCAACAAATTTTAG SP1298, AvrII
LCSP1298XbaF CCCTAGGCATCACCATCACCATCACGAGATTT-GCCAACAAATTTTAG SP1298, XbaI
LCSP1298BamR CGGATCCTCAGTTTTTAAGCAAGTTTTTTAAC SP1298, BamHI
LCSP2205AvrH6F CCCTAGGCATCACCATCACCATCACAAGAAACTGA-GAGTGCATTATA SP2205, AvrII
LCSP2205BamR CGGATCCTCATTCTTCTTTCTCCTTTTCC SP2205, BamHI
a Spr, spectinomycin resistant; Tmr, trimethoprim resistant; Amr, ampicillin resistant; Kmr, kanamycin 
resistant. Underlined sequences are complementary to primers used for amplification of antibiotic resistant 
cassettes. Small letters in the sequence indicate nucleotide changes to introduce convenient restriction sites. 
The start and stop codons of SP1298 and SP2205 are shown in bold.
b Left flank and right flank indicate positions relative to the target gene; qRT-PCR denotes primers used for 
real-time PCR; restriction sites introduced for cloning are indicated.
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respectively, followed by selection for kanamycin-resistant transformants, thus generating 
the strains BHN100DSP1298 CEPSP1298 and BHN100DSP2205 CEPSP2205. The complemented 
mutants were checked by PCR for integration at the desired location on the chromosome. 
A control CEPØ strain lacking a gene insert was constructed by transforming BHN100 wild 
type with HindIII-digested pCEP and selecting for kanamycin-resistant transformants. 
To examine SP1298 and SP2205 gene and protein expression levels, bacterial strains were 
grown to mid-log phase in THY medium without or with the addition of 0.4% maltose. 
Aliquots of these cultures were stored at –80°C with 15% glycerol for adherence assays. 
Real-time PCR. Total RNA was extracted using the RNeasy minikit (Qiagen), after which 
contaminating genomic DNA was removed by treatment with DNase (DNAfree; Ambion). 
DNA-free total RNA (2.5 µg) was reverse transcribed using 300 ng of random hexamers 
and Superscript III reverse transcriptase (Invitrogen). To confirm the absence of genomic 
DNA, reactions without reverse transcriptase were carried out. Relative amounts of SP1298 
and SP2205 transcripts were determined by quantitative real-time-PCR (qRT-PCR) using 
the SYBR green technology on a 7500 Fast real-time PCR system (PE Applied Biosystems) 
according to the manufacturer’s instructions. The relative quantification method was used 
to evaluate the quantitative variation between wild-type and complemented strains for 
each gene examined (39). The gyrA (SP1219) amplicon was used as an internal control for 
normalization of data. 
Production of His-tagged SP1298 and SP2205 and generation of polyclonal rabbit 
antisera. The SP1298 and SP2205 genes of S. pneumoniae TIGR4 were PCR amplified with the 
oligonucleotide primer pairs LCSP1298AvrH6F/LCSP1298BamR and LCSP2205AvrH6F/
LCSP2205BamR, respectively. The amplicons were cloned into the pCR2.1 cloning vector 
of the TA cloning kit (Invitrogen) to obtain pLC1a (SP1298) and pLC2 (SP2205). Since 
sequence analysis showed that the AvrII site was not intact for SP1298, we PCR amplified 
SP1298 from pLC1a using the primer pair LCSP1298XbaF/LCSP1298BamR and subcloned 
the amplicon into pCR2.1 to obtain pLC1b. In the next step, the recombinant genes were 
excised with either XbaI/BamHI (SP1298) or AvrII/BamHI (SP2205) digestion and ligated 
to the BamHI/NheI-digested pET11c expression vector to obtain pLC1298 and pLC2205, 
respectively. The nucleotide sequences of the SP1298 and SP2205 genes in pLC1298 and 
pLC2205 were confirmed by sequence analysis. 
For the production of His-tagged SP1298 (rHisSP1298) and His-tagged SP2205 
(rHisSP2205), an overnight culture of E. coli BL21 (pLC1298 or pLC2205) was diluted 50-fold 
in prewarmed (37°C) 2× LB supplemented with 0.5% glucose and 100 µg ml–1 ampicillin. 
At an OD600 between 0.6 and 0.8, 0.1 mM isopropyl-ß-D-thiogalactopyranoside (IPTG) 
was added to the culture. After 2 h, cells were placed on ice, pelleted by centrifugation, 
resuspended in ice-cold lysis buffer consisting of 20 mM sodium phosphate, 0.5 M sodium 
chloride, and 10 mM imidazole (pH 7.4) to an equivalent of an OD600 of 100, and lysed by 
sonication. For pLC2205, 6 M urea, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 0.1% 
Triton X-100 were added to the lysis buffer. For complete cell lysis of the pLC2205 culture, 
6 M urea, 1 mM PMSF, and 0.1% Triton X-100 were first added to the lysis buffer and the 
suspension was frozen at –20°C. Subsequently, a defrosted cell suspension of pLC2205 was 
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sonicated in the presence of 100 mM PMSF, 100 mM benzamidine (BZA), and lysozyme 
(100 mg ml–1). Insoluble debris in both lysates was removed by ultracentrifugation 
(Sorvall WX ultracentrifuge in a Ti70.1 Beckmann rotor) at 40,000 rpm for 1 h at 4°C. The 
resulting supernatants were loaded onto a 1-ml HiTrap Chelating HP column (Amersham 
Biosciences) preloaded with Ni2+, washed with 10 mM imidazole phosphate buffer, and 
eluted with 300 mM imidazole phosphate buffer, and the fractions containing purified 
rHisSP1298 or rHisSP2205 were combined and dialyzed (Slide-A-Lyzer dialysis cassette 
3500 MWO, 0.5 to 3 ml capacity; Pierce). Dialysis buffer for rHisSP1298 contained 10 mM 
HEPES, while rHisSP2205 was dialyzed against 10 mM HEPES, 6 M urea, and 0.1% Triton 
X-100. After dialysis, rHisSP1298 was lyophilized and rHisSP2205 was stored in the dialysis 
buffer; both were stored at –20°C until further use. The identities of the purified proteins 
were confirmed by matrix-assisted laser desorption ionization–time-of-flight (MALDI-
TOF) analysis, and their amounts were determined by the bicinchoninic acid (BCA) assay 
(Bio-Rad). 
For the generation of anti-SP1298 and anti-SP2205 polyclonal rabbit antibodies, a total 
of 400 µg of each protein was used according to the Speedy program of Eurogentec. 
Western blot analysis. Whole-cell bacterial lysates were used in Western blot analysis by 
separating 2.5 × 107 CFU/lane on SDS-PAGE gels (12.5%). After electrophoretic transfer 
onto a nitrocellulose membrane, transfer was visualized by staining membranes with 
Ponceau S (Sigma-Aldrich). Subsequently, membranes were blocked using PBS with 0.1% 
Tween 20, 2% skim milk powder, and 1% bovine serum albumin (BSA) and incubated 
with the primary antibodies (rabbit polyclonal anti-SP1298 or anti-SP2205) followed 
by horseradish peroxidase-coupled secondary anti-rabbit antibody. Immunoblots were 
developed by enhanced chemiluminescence (Amersham). 
Pneumococcal adherence assay. The human pharyngeal epithelial cell line Detroit 
562 (ATCC CCL-138) was routinely grown in RPMI 1640 medium without phenol red 
(Invitrogen, The Netherlands) supplemented with 1 mM sodium pyruvate and 10% (vol/
vol) fetal calf serum (FCS). All cells were cultured at 37°C in a 5% CO2 environment. For 
adherence assays, bacteria were resuspended in RPMI 1640 medium without phenol red 
supplemented with 1% FCS. For adherence experiments with complemented mutants, 
maltose was added to the medium to a concentration of 0.4%. Adherence of pneumococci 
to epithelial cells was carried out as described previously (11,19). Briefly, Detroit 562 cells 
were seeded into 24-well plates and incubated for 48 h. Confluent monolayers were washed 
twice with 1 ml PBS and infected with 1 × 107 CFU ml–1 (multiplicity of infection [MOI] 
of 10 [bacteria/cells]), and pneumococci were allowed to adhere to the cells for 2 h at 37°C 
in a 5% CO2 environment. Nonadherent bacteria were removed by 3 washes of 1 ml PBS, 
after which 200 µl of 0.05% trypsin–1 mM EDTA was added to detach the cells, followed 
by 800 µl of ice-cold 0.025% Triton X-100 in PBS to lyse the cells. Samples were plated 
for CFU count and corrected to account for small differences in the initial inoculum. All 
experiments were performed in triplicate and repeated at least three times. The adherence 
of the mutants is given as the percentage relative to results for the wild type. All bacterial 
strains grew equally well in the tissue culture medium. 
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Mouse studies. Eight-week-old female outbred CD-1 mice (Charles River Laboratories, 
Germany) were used for the colonization, pneumonia, and bacteremia models, while the 
OM experiments were performed with 7-week-old female inbred specific-pathogen-free 
BALB/c mice (Harlan, The Netherlands). All mice were housed in filter-top cages and had 
access to food and water ad libitum. Mice were allowed to acclimate for a week prior to 
each experiment. All animal experiments were performed with approval of the Radboud 
University Nijmegen Medical Centre Committee for Animal Ethics. 
Pneumonia model. Mice were lightly anesthetized with 2.5% (vol/vol) isoflurane over 
oxygen and infected intranasally (i.n.) by pipetting 50 µl of inoculum (5 × 106 CFU total) into 
the nostrils of mice while they were held in an upright position. At predetermined times after 
infection, groups of mice were sacrificed by injection anesthesia, and blood samples were 
taken by retro-orbital bleeding. Bacteria were recovered from the nasopharynx by flushing 
each nare with 1 ml sterile PBS (nasopharyngeal lavage [NPL]) (28). A bronchoalveolar 
lavage (BAL) was performed by flushing the lungs with 2 ml sterile PBS, after which lungs 
were removed from the body and homogenized in 2 ml sterile PBS using a handheld 
homogenizer (Polytron PT 1200; Kinematica AG). 
Colonization model. Mice were infected i.n. under anesthesia as mentioned above with 
a smaller volume of inoculum, 10 µl (5 × 106 CFU total). As described previously, nasal 
instillation of pneumococci with such a low volume does not cause a lethal infection in 
mice (19). Mice showed no visible signs of disease throughout the course of colonization 
and had less than 40 CFU in the lungs at the last time point. At predetermined time points 
after infection, NPL and lungs were collected as described above. 
Otitis media model. Intranasal infection was performed as described above in the 
colonization model with the following exception: methylcellulose (1%) was added to the 
inoculum for all OM experiments in order to minimize leakage of inoculum to the lungs 
(67). Mice were placed in a supine position in the pressure cabin after infection as described 
previously (62). Briefly, an initial pressure rise was set at 10 kPa, and when the mouse 
started to regain consciousness and the first swallowing movements occurred, pressure was 
raised at the rate of 5 kPa per 15 s until a pressure of 40 kPa was reached, enabling the 
inoculum to reach the middle ear cavity. Then, the pressure was lowered gradually until 
atmospheric pressure was reached again. Groups of mice were sacrificed at 24, 48, and 96 
h postinfection, where mice were bled out by retro-orbital puncture, followed by cervical 
dislocation. The bullas enclosing the middle ears (ME) were dissected from the temporal 
bone and homogenized in the presence of 1 ml sterile PBS per ear, as previously described 
(62,67). Bacteria were also recovered from the nasopharynx by performing an NPL using 1 
ml of sterile PBS, and the lungs were extracted and homogenized in 2 ml sterile PBS. 
Bacteremia model. Mice were infected via the tail vein with a 100-µl inoculum (106 to 
107 CFU total). To confirm successful infection, blood was taken from a separate vein 
immediately after injection (t = 0 h). Subsequently, blood was recovered via a tail vein 
puncture from the same mouse at 12 and 24 h postinfection and by retro-orbital puncture 
at the last time point, 36 h. 
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Coinfection experiments. A 1:1 ratio of the wild type and its respective ΔSP1298, 
ΔSP2205, or ΔSP1298ΔSP2205 mutant was used to infect the mice as described for the 
above-mentioned infection models. This setup reduces variation between individual mice, 
inoculation preparation and distribution, and sample collection. Viable bacteria were 
quantified by plating serial dilutions on BA plates, and BA plates supplemented with either 
spectinomycin or spectinomycin and trimethoprim. Subsequently, competitive index (CI) 
scores were calculated for each individual animal as the output ratio of mutant to wild-type 
bacteria divided by the input ratio of mutant to wild-type bacteria. A log CI score of <0 
indicates that the mutant is outcompeted by the wild type. For samples in which no viable 
mutant bacteria were recovered, the lower limit of detection (20 CFU ml–1) was substituted 
as the numerator. If in one particular sample neither wild-type nor mutant bacteria were 
detected, the data were excluded from further analysis. 
Immunizations. Female CD-1 mice (6 weeks old) were subcutaneously immunized three 
times at 14-day intervals with a total of 50 µg protein in alum adjuvant (aluminum hydroxide 
gel; Sigma). Briefly, mice were either primed singly with rHisSP1298 or rHisSP2205 or with 
a combination of the two proteins. The negative-control group consisted of mice given a 
1:1 ratio of alum adjuvant and PBS. One-tenth of the human dose of Prevnar 7 was given 
to the positive-control group. Blood samples from all mice were collected via tail vein 
puncture prior to any immunization, at the time of the third boost, and several days before 
infection. Mice were subsequently challenged i.n. with the TIGR4 wild-type strain (1 × 106 
CFU total) 3 weeks after the last immunization in our pneumonia model and sampled 48 h 
postinfection as described above. 
Detection of antigen-specific IgG by ELISA. IgG titers against SP1298 and SP2205 were 
determined by enzyme-linked immunosorbent assay (ELISA) analysis. High-binding-
capacity microtiter plates (Greiner) were coated with 1 µg µl–1 purified rHisSP1298 or 
rHisSP2205 in 100 µl per well overnight at 4°C. Plates were washed with PBS with 0.05% 
Tween 20 (PBST) and then incubated for 1 h with PBST containing 2% BSA. Three-fold 
serial dilutions of sera were added to the plates and incubated for 1 h at 37°C. After washing, 
the alkaline phosphatase secondary antibody directed to mouse IgG-Fc (Sigma-Aldrich) 
was added for 1 h at 37°C using a 1:25,000 dilution. After washing, 100 µl per well of 
p-nitrophenyl phosphate (1 mg ml–1) in substrate buffer (10 mM diethanolamine and 0.5 
mM magnesium chloride, pH 9.5) was added and the absorbance was read at 405 nm. 
Statistical analyses. For adherence assays, comparisons between wild-type and mutant 
pneumococcal strains were performed using Student’s t test (unpaired). The Mann-Whitney 
test was used for comparison of bacterial load in NPL, ME, BAL fluid, lung homogenate, 
and blood between the wild-type-infected mice and their respective DHH mutant-infected 
mice in all infection models. For the coinfection data, a Wilcoxon test on log-transformed 
CI scores was used to determine if the median CI was statistically significantly different 
from 0 (i.e., no outcompetition). All statistical analyses were performed using the GraphPad 
Prism software program, version 4.0. 
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results
DHH subfamily 1 proteins contribute to pneumococcal adherence in vitro. To assess 
the (strain-specific) contribution of the DHH subfamily 1 proteins SP1298 and SP2205 to 
pneumococcal pathogenesis, directed mutants were generated in three strains: D39, TIGR4, 
and BHN100. Western blot analysis of wild-type, ΔSP1298, ΔSP2205, and double mutant 
cell lysates using anti-SP1298 and anti-SP2205 rabbit serum confirmed that SP1298 and 
SP2205 were expressed in all three wild-type strains but not in their respective single and 
double mutants (data not shown). Importantly, no differences in in vitro growth between 
the wild-type strains and the DHH subfamily 1 mutants were detected. 
Adherence of pneumococci to respiratory epithelial cells is crucial for colonization of 
the nasopharynx. Therefore, we examined adherence of the three wild-type strains and 
their isogenic single and double DHH subfamily 1 mutants to human pharyngeal epithelial 
Detroit 562 cells. Wild-type adherence levels of TIGR4 (~6.5 × 104 adherent CFU) were 
statistically significantly higher than those of the wild types of the D39 and BHN100 strains 
by almost 1 log. Interestingly, no difference in adherence was observed upon deletion of 
the SP1298 gene in TIGR4 and D39, while adherence of BHN100ΔSP1298 was reduced by 
~75%, suggesting that the contribution of SP1298 to adherence is strain specific (Fig. 2A). 
In contrast, all three SP2205 mutants showed a significant decrease in adherence compared 
to their wild types, ranging from 60 to 90% (Fig. 2A). The ability of the double mutants in 
all three strains to adhere was drastically reduced, by >80%, displaying an enhanced effect 
when both genes were deleted (Fig. 2A). 
To confirm that the observed phenotypes were indeed due to the deletion of the SP1298 
and SP2205 genes, we generated genetically complemented mutants by ectopic expression of 
the respective genes from the maltose-inducible CEP site. Given that attenuated adherence 
of both single mutants was observed only in the BHN100 strain, we chose this background 
for genetic complementation. As a control, we generated BHN100 CEPØ, containing the 
empty CEP platform. Real-time PCR and Western blot analysis of the genetic revertants 
showed that SP1298 gene and protein expression was restored to wild-type levels in normal 
medium and was 5-fold higher than that of the wild type upon addition of maltose (Fig. 
2B). For SP2205, both gene expression and protein expression were clearly restored in 
normal medium, but maltose induction was required to reach wild-type levels (Fig.2B). 
Importantly, the ability of the complemented SP1298 mutant to adhere to Detroit cells was 
indistinguishable from that of the wild type when cells were grown without maltose (Fig. 
2C), while the maltose-induced overexpression of SP1298 had a slight adverse effect on 
the adherence ability. Moreover, the adherence of the SP2205 mutant also was no longer 
significantly different from that of the wild type upon complementation, with or without 
maltose induction. In all cases, BHN100 CEPØ behaved as did the wild type. Thus, the 
observed attenuated adherence phenotypes of the DHH mutants were not the result of an 
inadvertent mutation in a nontargeted gene. 
DHH subfamily 1 proteins contribute to various stages of pneumococcal pathogenesis 
in vivo. (i) Colonization. Since colonization of the nasopharynx is a prerequisite for 
pneumococcal infection, we first compared all single and double SP1298 and SP2205 
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Fig. 2. (A) In vitro adherence 
of pneumo-coccal strains 
to the human pharyngeal 
epithelial cell line Detroit 
562. The adherence of the 
mutants is given as the 
percentage relative to that 
for the respective wild type. 
(B) Real-time PCR (upper 
panels) and Western blot 
analysis (lower panels) of 
BHN100 complemented 
SP1298 (left) or SP2205 
(right) mutants. Real-time 
data are expressed as the log2 
ratio of expression relative 
to that for the BHN100 wild 
type grown without maltose. 
Strain names and presence 
of maltose in growth 
medium are indicated at 
the bottom. (C) In vitro 
adherence of BHN100 
complemented mutants to 
Detroit 562 cells, given as 
the percentage relative to 
that for the BHN100 wild 
type grown without maltose. 
The presence of maltose in 
growth medium is indicated 
at the bottom. All values are 
geometric means, and error 
bars represent SEM. *, P < 
0.0001.
mutants to their isogenic parental wild types following intranasal infection in our 
established colonization model. All wild-type strains maintained an overall colonization 
level of approximately 105 CFU during the course of infection (Fig. 3A, C, and E). Even 
though all single and double SP1298 and SP2205 mutants were capable of colonizing the 
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Fig. 3. Bacterial load in the nasal lavage fluid of mice intranasally infected with 5 × 106 CFU of the wild type 
and/or respective DSP1298, DSP2205, or DSP1298DSP2205 mutants. Strain data depicted for TIGR4 (A and 
B), D39 (C and D), and BHN100 (E and F). Data from single-infection experiments are shown in panels A, 
C, and E; data from coinfection experiments are shown in panels B, D, and F. The horizontal line represents 
the lower limit of detection, and error bars represent SEM. Each point in panels B, D, and F represents the log 
competitive index score from an individual mouse. Values < 0 indicate attenuation of the mutant. Horizontal 
lines represent the mean. *, P < 0.05.
murine nasopharynx to various degrees throughout infection, significant decreases in 
bacterial load were observed compared to those of their respective wild types over time. 
Interestingly, SP1298 and SP2205 mutants in a BHN100 background maintained a slightly 
higher level of colonization in the nasopharynx than the SP1298 and SP2205 mutants in 
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the other two pneumococcal backgrounds. The most prominent phenotype was observed 
in the TIGR4 genetic background, where all single and double SP1298 and SP2205 mutants 
were significantly attenuated at all time points from 24 h postinfection onwards (Fig. 3A). 
The double mutants in all three strain backgrounds were significantly impaired in their 
ability to colonize the nasopharynx, but again the most severe attenuation was observed 
in the TIGR4 background, with a 2,500-fold decrease compared to results for the wild type 
after just 24 h (P < 0.005) (Fig. 3A). Since both single mutants in TIGR4 showed a decrease 
of only ~10-fold, this suggests an additive effect when both genes are absent. Mice infected 
with single and double SP1298 and SP2205 mutants of D39 (Fig. 3C) and BHN100 (Fig. 3E) 
also had lower bacterial loads than their respective wild-type-infected mice, especially at 
the later time points.
 To further characterize the potential role of these two DHH subfamily 1 proteins in 
pneumococcal colonization, we examined the phenotype of each mutant when in direct 
competition with its respective wild type, since minor differences between two bacterial 
strains can be unmasked with such a competitive setup. The TIGR4 and BHN100 wild 
types significantly outcompeted their respective single SP1298 and SP2205 mutants 96 h 
postinfection (900- to 7,000-fold; Fig. 3B and F). Interestingly, although outcompetition 
of the D39 single mutants was significant but much less prominent (<10-fold; Fig. 3D) 
than that for the other two strain backgrounds, the double mutants in all strains were 
outcompeted ~500- to 7,000-fold, suggestive of a strain-specific additive effect (Fig. 3B, 
D, and F). Especially for the TIGR4 strain, attenuation levels of mutants differed between 
single infection and coinfection: both single mutants were outcompeted to the same extent 
as the double mutant in coinfection, whereas a 2-log difference in colonization levels was 
observed in single infection. This is most likely due to the enhanced sensitivity of the 
competitive setup, where both single mutants were already outcompeted to levels below our 
detection limit (20 CFU ml–1). 
(ii) Otitis media. The pathogenesis of pneumococcal OM involves translocation of the 
bacteria from the nasopharynx to the middle ear cavity through the Eustachian tube, 
accomplished by the use of a pressure cabin in the murine OM model recently described 
(62). We examined the contribution of the DHH subfamily 1 proteins to experimental OM 
using the mutants in TIGR4 and BHN100 since it has been established that these two strains 
produce higher CFU counts in the middle ear in this model than D39 (62). Colonization 
levels of the middle ear with BHN100 wild type (>105 CFU ml–1) were higher than those 
with the TIGR4 wild-type strain (~104 CFU ml–1) throughout the course of OM infection 
(Fig. 4A and C). 
Attenuation of the BHN100 double mutant was observed at all time points postinfection 
(Fig. 4A). Reduced bacterial loads of <103 CFU ml–1 were observed for BHN100ΔSP1298 
throughout OM infection, albeit only statistically significant at the last two time points, 
while BHN100ΔSP2205 only appeared to be attenuated at 48 h (Fig. 4A). In line with the 
BHN100 data, the TIGR4 double mutant was incapable of colonizing the middle ear at any 
of the time points (Fig. 4C). A consistent reduction in the bacterial load was observed for 
TIGR4ΔSP1298 and to a lesser extent TIGR4ΔSP2205 (Fig. 4C), but this was not statistically 
significant except for TIGR4ΔSP1298 at 96 h due to a large spread of the wild type. 
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In the coinfection experiments, both wild types outcompeted their respective single 
and double SP1298 and SP2205 mutants in the middle ear by 20- to 350-fold (Fig. 4B and 
D). These observations clearly confirmed the single-infection data. Finally, nasopharyngeal 
colonization levels of the wild type and mutants in the OM model were similar to NPL data 
obtained with the colonization model (data not shown). 
(iii) Pneumonia. Pneumococcal pneumonia can occur when bacteria are aspirated from 
the nasopharyngeal niche to the lungs. In the murine pneumonia model, infection was 
monitored at three sites, nasopharynx, lungs, and blood, allowing us to examine aspects 
of both colonization and invasive disease. Nasopharyngeal colonization in the pneumonia 
model was comparable to the results observed in the colonization and OM models (data 
not shown). Interestingly, similar to our observations in the NPL (Fig. 3E), the number 
of BHN100 wild-type bacteria in the BAL fluid (~104 CFU) was higher than those of the 
TIGR4 and D39 wild-type strains after 24 h postinfection (Fig. 5B, E, and H). A very 
pronounced phenotype was seen with the BHN100 single and double SP1298 and SP2205 
Fig. 4. Bacterial load in the middle ear fluid of mice intranasally infected with 1 × 106 CFU of the wild type 
and/or respective DSP1298, DSP2205, or DSP1298DSP2205 mutants. Strain data are depicted in panels A and 
B for BHN100 and in C and D for TIGR4. The single infections shown in panels A and C represent the sum 
of pneumococci in the left and right middle ear fluid. Horizontal line represents the lower limit of detection, 
and error bars represent SEM. Coinfection data are shown in panels B and D, where each point represents the 
log competitive index score from one mouse ear. Values < 0 indicate attenuation of the mutant. Horizontal 
lines represent the mean. *, P < 0.05.
100
dHH SuBfAmILy 1 ProtEInS of StreptococcuS pneumoniae
5
mutants, since they were all significantly attenuated, ~2 logs in the lungs and BAL fluid, 24 
and 48 h postinfection compared to results for the BHN100 wild type (Fig. 5G and H). In 
the lung tissue, we observed that the D39 double mutant was significantly attenuated at all 
time points, while only D39ΔSP1298 was attenuated at 48 h (Fig. 5D). However, bacterial 
loads for all D39 single and double SP1298 and SP2205 mutants recovered in BAL fluid at 
24 and 48 h were significantly lower than wild-type loads (Fig. 5E). For TIGR4, the single 
ΔSP1298 mutant and the double mutant were also unable to cause infection in the lungs and 
BAL fluid at 24 and 48 h (Fig. 5A and B), albeit this was not always statistically significant 
due to a large spread for the wild type. However, infection of mice with TIGR4ΔSP2205 was 
capable of causing disease at wild-type levels 48 h postinfection (Fig. 5A and B). 
In the pneumonia coinfections, we observed that the TIGR4 and BHN100 wild types 
significantly outcompeted their respective SP1298 (20- to 2,200-fold) and SP2205 (70- to 
10,000-fold) mutants at 48 h postinfection in the lung and BAL fluid (Fig. 5C and I), while 
the D39 wild type significantly outcompeted the ΔSP2205 (200-fold) and ΔSP1298ΔSP2205 
(50,000-fold) mutants only in the lung tissue (Fig. 5F). Moreover, we observed that the 
TIGR4 and D39 wild types outcompeted their respective double mutants much more than 
their respective single DHH subfamily 1 mutants, displaying an enhanced effect when both 
genes were deleted (Fig. 5C and F). For example, the TIGR4 double mutant was outcompeted 
by its wild type 40,000-fold, while the single SP1298 and SP2205 mutants were outcompeted 
by only 2,200-fold and 10,000-fold, respectively. 
The TIGR4 and D39 strains and their respective mutants were all able to disseminate 
from the lungs to blood, except for the SP1298 mutants, for which no bacteria were detected 
at any time point (see Figure S1 in the supplemental material). Once in the blood, the TIGR4 
and D39 wild types and their respective ΔSP2205 mutants showed growth characteristics 
similar to those described below for the bacteremia model. 
(iv) Bacteremia. Bacteremia is a severe complication which occurs in approximately 30% 
of pneumonia cases (12). To assess whether the DHH subfamily 1 proteins are required for 
survival of pneumococci once they have entered the bloodstream, we intravenously infected 
mice with wild-type and/or mutant pneumococci. Both wild types (TIGR4 and D39) had 
higher bacterial counts (7- to 25,000-fold more) in the blood than their respective SP1298 
and SP2205 mutants throughout the course of the infection (Fig .6A and C), except for 
the TIGR4ΔSP2205 mutant. The fact that the TIGR4ΔSP2205 mutant behaved as did the 
wild-type in this model is supported by corresponding blood data from the pneumonia 
model. The mice infected with TIGR4ΔSP1298 maintained significantly lower levels (~200-
fold less) of bacteria after 12 h postinfection. In the case of D39, the single ΔSP1298 and 
double mutants were significantly attenuated at all time points, but the ΔSP2205 mutant 
was attenuated only at 32 h postinfection (Fig. 6C). The BHN100 strain was not capable of 
surviving in the blood and was cleared from the bloodstream within 24 h after infection 
(data not shown). Furthermore, we observed that the TIGR4 and D39 wild types statistically 
outcompeted their respective double mutants up to 3 logs more than their respective 
single DHH subfamily 1 mutants, further signifying an additive effect when both genes 
were deleted (Fig. 6B and D). Interestingly, the TIGR4ΔSP2205 mutant was attenuated in 
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Fig. 5. Bacterial load in the lung homogenate and bronchoalveolar lavage fluid of mice following intranasal 
infection with 5 × 106 CFU of the wild type and/or respective DSP1298, DSP2205, or DSP1298DSP2205 
mutants. Strain data depicted for TIGR4 (A, B, and C), D39 (D, E, and F), or BHN100 (G, H, and I) are 
shown. Data from single-infection experiments are shown in panels A, B, D, E, G, and H, and data from 
coinfection experiments are shown in C, F, and I. The horizontal line represents the lower limit of detection, 
and error bars represent SEM. Each point depicted in panels C, F, and I indicates the log competitive index 
score from an individual mouse. Values < 0 indicate attenuation of the mutant. Horizontal lines represent 
the mean. *, P < 0.05.
blood only in a coinfection setup, suggesting this mutant is able to efficiently survive during 
bacteremia only when it is not in direct competition with the wild type. 
DHH subfamily 1 proteins confer protection against pneumococcal disease. To evaluate 
the protection elicited by immunization with the recombinant rHisSP1298 and rHisSP2205 
proteins either singly or in combination, CD-1 mice were immunized with these proteins 
and subsequently challenged with S. pneumoniae TIGR4. The individual IgG titers in sera of 
mice immunized with one or both DHH subfamily 1 proteins or with Prevnar 7 were tested 
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3 weeks after the final immunization. Analysis showed antigen-specific antibody responses 
that were significantly higher than those of their respective negative-pool preimmune 
serum (data not shown). No difference in IgG titers was seen between the singly and 
doubly vaccinated groups. At 48 h postinfection, protection was evaluated by quantifying 
the bacterial load. As expected, mice that received Prevnar 7 were protected (Fig. 7), 
since capsular type 4 is included in this vaccine. While a minor reduction of bacteria in 
the nasopharynx (P < 0.013) of rHisSP1298-vaccinated mice was observed (Fig. 7A), mice 
receiving either rHisSP1298 or rHisSP2205 alone were not protected and succumbed to 
infection just as rapidly as mice receiving the adjuvant only. Interestingly, protection was seen 
only with mice who received a combination of both DHH subfamily 1 antigens. Bacterial 
loads in the nasopharynx, blood, and lungs of these mice were statistically significantly 
lower (P < 0.0001, 0.013, and 0.003, respectively) than those of mice receiving adjuvant only 
(Fig. 7A, B, and D) after subsequent challenge with the TIGR4 wild type. Sixty percent of 
these mice did not develop bacteremia, and clinical signs of disease were minimal.
Fig. 6. Bacterial load in the blood of mice over time following intravenous infection with 1 × 106/7 CFU 
of wild-type and/or respective DSP1298, DSP2205, or DSP1298DSP2205 mutants. Strain data for TIGR4 
(A and B) or D39 (C and D) are depicted. Data from single-infection experiments are shown in panels A 
and C, and data from coinfection experiments are shown in B and D. The horizontal line represents lower 
limit of detection, and error bars represent SEM. Each point depicted in panels B and D indicates the log 
competitive index score from an individual mouse. Values < 0 indicate attenuation of the mutant. Horizontal 
lines represent the mean. *, P < 0.05.
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discussion
Current polysaccharide conjugate vaccines targeting the respiratory tract pathogen S. 
pneumoniae provide excellent protection against invasive disease caused by vaccine 
serotypes yet remain ineffective against circulating nonvaccine serotypes. Vaccines that 
include conserved (surface) proteins involved in pneumococcal virulence are considered 
promising alternatives. To identify such targets, we previously screened for genes essential 
during pneumococcal infection using the GAF technology (8,18,47). These in vivo GAF 
screens have led to the identification of the DHH subfamily 1 proteins SP1298 and SP2205. 
These two proteins have not been identified by previous STM or expression studies and have 
consequently never been considered as virulence factors or vaccine leads in S. pneumoniae. 
This prompted us to examine their role in pneumococcal pathogenesis and protection in 
more detail. 
Our in vitro and in vivo results clearly demonstrate that the two pneumococcal DHH 
subfamily 1 proteins are required for full pneumococcal virulence at several target sites 
Fig. 7. Protection against intranasal challenge with S. pneumoniae TIGR4. Mice subcutaneously immunized 
with alum (open squares), rHisSP1298 (filled triangles), rHisSP2205 (filled circles), a combination of 
rHisSP1298 and rHisSP2205 (filled diamonds), or Prevnar 7 (filled squares) were subsequently challenged 
with TIGR4 wild type. Pneumococci were recovered 48 h postinfection from NPL (A), blood (B), BAL fluid 
(C), or lung homogenate (D). Each symbol represents one mouse. The dotted horizontal line represents 
lower limit of detection. *, P < 0.05.
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of the host, e.g., nasopharynx, middle ear, lungs, and blood. Genetic complementation of 
the SP1298 and SP2205 genes in the BHN100 single mutants resulted in restoration of in 
vitro adherence to wild-type levels, indicating that our observed phenotypes are indeed 
the results of the gene deletions and not an inadvertent mutation in a nontargeted gene. 
Interestingly, an additive effect was observed in vitro and in vivo when both genes were 
deleted. These data suggest that SP1298 and SP2205 may functionally complement each 
other, rendering S. pneumoniae incapable of causing disease when both genes are absent. 
Additive or even synergistic reduction in virulence of pneumococcal mutants lacking 
multiple genes of complementary function has been described previously. For example, 
during their investigation of two iron ABC transporter systems, PiuA and PiaA, Brown et al. 
demonstrated that a single deletion of piuA or piaA resulted in only a moderate reduction in 
virulence, whereas a mutant strain lacking both genes displayed severe attenuation in both 
pulmonary and systemic models of infection (16). In another study, individual ΔaliA, ΔaliB, 
and ΔamiA mutants of the Ami-AliA/AliB oligopeptide permease were only moderately 
impaired in nasopharyngeal colonization, while the triple knockout obl mutant was severely 
attenuated (34). 
Since the pneumococcal genetic background can have a significant impact on the 
contributions of individual genes to virulence, we performed our study using three 
genetically distinct strains. Adherence data showed that the ΔSP2205 and double mutants 
were severely reduced in adherence to Detroit 562 cells in all three genetic backgrounds 
compared to their respective wild types, whereas the ΔSP1298 mutant showed diminished 
adherence only in a BHN100 background. Conversely, in vivo data for all infection models 
demonstrated that the ΔSP1298 and double mutants in all three strain backgrounds were 
significantly attenuated, while the TIGR4ΔSP2205 mutant displayed wild-type levels 
of virulence in lungs and blood in single infection. Attenuation of TIGR4ΔSP2205 was 
observed only in coinfection experiments, specifically in the pneumonia and bacteremia 
models. These data suggest that not only strain-specific but also host site-specific features 
of strains and their respective mutants can occur. An obvious explanation for strain-
specific phenotypes of mutants is the presence or absence of other virulence genes (in)
directly contributing to observed phenotypes. For instance, the type I pilus that has been 
described to be involved in pneumococcal adherence and colonization (3) is encoded by 
the genomes of the TIGR4 and BHN100 strains but not by that of D39. It does not appear 
to be responsible for the strain-specific adherence observed in our study, though, since 
the D39 and TIGR4 mutants showed similar phenotypes. Strain specificity has also been 
described for virulence factors present in all strains; for example, the contribution of PspC 
to pneumococcal virulence has been shown to vary between strains, both at the level of 
virulence during pneumonia and bacteremia and at the level of factor H binding (35,74), 
and we have demonstrated that the putative proteinase maturation protein A (PpmA) 
contributes to adherence in a strain-specific manner (19). Finally, transcriptional response 
regulators (RR), such as RR04 and RR09, have also been shown to affect both virulence and 
gene expression in a strain-specific manner (9,29,44). 
A reasonable explanation for the observed phenotypes of the DHH subfamily 1 mutants 
may be associated with the cellular localization of the DHH subfamily 1 proteins. SP2205 
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is predicted to be surface exposed by virtue of N-terminal transmembrane helices, which 
suggests that its observed contribution to adherence may well be a direct effect, since the 
protein may act as an adhesin. A significant reduction in invasive disease was attributed 
to the deletion of SP1298, which may be the result of an indirect effect, since this protein 
is predicted to be cytoplasmic. SP1298 does not contain known signal sequences or 
typical motifs required for membrane anchoring. However, the presence of known export 
signals is not necessarily a prerequisite for surface exposure, as exemplified by two other 
pneumococcal virulence factors: the plasmin(ogen) binding proteins enolase (Eno) 
and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (5,54). Binding of human 
plasmin(ogen) by pneumococcal Eno and GAPDH enhances bacterial virulence by 
capturing surface-associated proteolytic activity, thus promoting penetration of bacteria 
through reconstituted basement membranes (5-7). Even though these proteins are predicted 
to be cytoplasmic based on their amino acid sequence, immunoelectron microscopy and 
immunoblot analysis have clearly showed that both of these glycolytic enzymes are present 
in the cytoplasm as well as on the bacterial cell surface (5,6). Ply is also a signal peptide-
lacking protein localized in the cytoplasm that, in addition to formation of pores, can 
activate complement and stimulate host cell apoptosis once released from the bacterium 
(13,55,56). Interestingly, unlike the SP1298 and SP2205 mutants, a ply-negative mutant 
could be complemented by the presence of the wild-type strain upon coinfection (4). This 
suggests that while Ply acts at a distance from the pneumococcus, the DHH subfamily 1 
proteins exert their effects in connection with or very close to the cell. Whether the cellular 
localization of SP1298 and SP2205 is the cell surface, cytoplasm, or both remains to be 
investigated, since preliminary fluorescence-activated cell sorter (FACS) analysis using the 
polyclonal antisera was inconclusive (data not shown). 
Even though the exact function of SP1298 and SP2205 in S. pneumoniae is unknown 
at present, their DHH domain(s) (Fig. 1) may shed some light on their putative role in 
pneumococcal pathogenesis. The N-terminal motifs I to IV of DHH family proteins contain 
the residues required for core catalytic activity, and the C-terminal, subfamily-specific 
motifs contribute to substrate specificity (2). In addition to the N-terminal DHH motifs, 
both SP1298 and SP2205 possess a DHHA1 domain, characteristic of members of DHH 
subfamily 1. These domains are ~60 residues long and contain a conserved GGG motif located 
near the C terminus (2). DHH domain proteins are known to function as phosphatases 
or phospho(di)esterases (PDE) capable of hydrolyzing a wide variety of substrates from 
inorganic pyrophosphate to single-stranded DNA (2). A well-studied bacterial example is 
RecJ of E. coli, an exonuclease involved in DNA repair and recombination systems (73), 
of which homologues are found in S. pneumoniae (Fig. 1) and in Bordetella pertussis, 
Haemophilus influenzae, and Neisseria meningitidis (2,63). Some less-well-characterized but 
interesting examples include two DHH proteins of Mycoplasma genitalium and Mycoplasma 
pneumoniae, located in operons encoding proteins required for adherence to the respiratory 
epithelium (32,36,64). Furthermore, SMU.1297, a DHH subfamily 1 protein of S. mutans, 
was recently found to be involved in superoxide stress tolerance by exposing wild-type and 
SMU.1297 mutant strains to menadione, a quinine compound that generates superoxide 
anions in bacteria (75). Analysis of the SMU.1297 sequence showed a high degree of 
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homology to the B. subtilis YtqI protein, which possesses dual activities: oligoribonuclease 
(cleaves small RNAs smaller than 5-mers) and 3’-phosphoadenosine–5’-phosphate (pAp) 
phosphatase in vitro (46). Biochemical analysis of SMU.1297 demonstrated that it has 
pAp phosphatase but no oligoribonuclease activity (75). B. subtilis has another DHH/
DHHA1 domain protein, YybT, which exhibits PDE activity toward cyclic dinucleotides 
(58). Based on their amino acid sequences, SP1298 is ~68% identical to SMU.1297, while 
SP2205 shares 32% homology with YybT. SMU.1297 and YtqI consist of 310 and 313 amino 
acids, respectively, which is comparable to the size of SP1298, while the size of YybT (659 
amino acids) is comparable to that of SP2205. Given these similarities, it is not unlikely that 
SP1298 and SP2205 may possess hydrolase and/or nuclease activity. Characterization of 
their biochemical function(s) will be a subject of future studies. 
The combination of both DHH subfamily 1 antigens SP1298 and SP2205 provided 
the best protection (60%) against pneumococcal infection, while immunization with the 
individual DHH subfamily 1 antigens did not confer significant protection. For more than 
a decade, the protective potential of various pneumococcal virulence factors, such as Ply, 
PspA, PspC, and PsaA, either as single proteins or in combination, has been examined 
(1,15,40,41,49,52,71,72). Two studies performed by Ogunniyi et al. have shown that in 
general, median survival times of mice immunized with different combinations of PspA, 
PsaA, PdB (a genetically detoxified derivative of Ply), and the pneumococcal histidine triad 
(Pht) protein PhtB or PhtE were significantly longer upon pneumococcal challenge than 
survival times of mice immunized with single antigens (49,50). Briles et al. have shown that 
protection against pneumonia improved when mice were immunized with the combination 
of PspA and PdB, compared to results with single-protein immunization (15). These studies 
have convincingly demonstrated that a combination protein vaccine improves the level of 
protection against pneumococcal disease in experimental mouse models. Our study also 
supports the paradigm that a multicomponent protein vaccine will confer protection against 
invasive disease and perhaps against carriage as well. In our opinion, future experimental 
protein vaccine studies should focus on vaccine formulations that comprise protein antigens 
sharing complementary functions or even combinations of functional protein families in 
order to determine whether the protection will be magnified. 
In conclusion, we have demonstrated that the two conserved pneumococcal DHH 
subfamily 1 proteins, SP1298 and SP2205, play a significant role in four important stages of 
pneumococcal pathogenesis, i.e., colonization, otitis media, pneumonia, and bacteremia, 
and that vaccination with a combination of the two proteins is able to confer protection 
against pneumococcal disease. While further research on these two proteins is needed to 
determine their cellular localization during pathogenesis and biochemical function and to 
evaluate the protective potential against other pneumococcal serotypes and genotypes, our 
data suggest that SP1298 and SP2205 are interesting candidates for future protein-based 
pneumococcal vaccines. 
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Supplemental Figure S1. Bacterial load 
in the blood of mice following intranasal 
infection with 5 × 106 CFU of wild-type 
or respective DSP1298, DSP2205, or 
DSP1298DSP2205 mutants. Strain data 
depicted in (A) for TIGR4; (B) for D39; and 
(C) for BHN100. Dotted horizontal line 
represents lower limit of detection and error 
bars represent SEM. *, P < 0.05. 
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Figure S1. Bacterial load in the blood of mice following intranasal infection with 5 × 106
CFU of wild-type or respective ∆SP1298, ∆SP2205, or ∆SP1298∆SP2205 mutants. Strain 
data depicted in (A) for TIGR4; (B) for D39; and (C) for BHN100. Dotted horizontal line 
represents lower limit of detection and error bars represent SEM. *, P<0.05 
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abstract
Streptococcus pneumoniae infections are often difficult to diagnose accurately as it is 
not uncommon that clinical samples are culture-negative, particularly after antibiotic 
administration. The rapid Binax NOW S. pneumoniae urinary antigen test lacks specificity 
in children, owing to pneumococcal antigen reactions in children who are nasopharyngeal 
carriers of S. pneumoniae. A western blot assay with a specific polyclonal antibody was 
developed for direct detection of the putative proteinase maturation protein A (PpmA) 
in urine samples from children with pneumococcal infections. The sensitivity and 
specificity of the assay were 66.7% and 100%, respectively. Previous antibiotic treatment 
or S. pneumoniae nasopharyngeal colonization did not affect PpmA antigenuria. Results 
also demonstrated the presence of PpmA cross-reactive epitopes in commensal bacteria 
that co-colonize the nasopharyngeal niche, although the non-pneumococcal cross-reactive 
protein(s) did not interfere with the detection assay. S. pneumoniae PpmA in the urine of 
children with pneumococcal infections may be a marker that has the potential to be used in 
the clinical diagnosis of pneumococcal infection. 
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introduction
Streptococcus pneumoniae is an important human pathogen that causes meningitis, otitis 
media, sepsis, and pneumonia. Accurate and rapid diagnosis of pneumococcal infections 
is critical because they entail substantial morbidity and mortality worldwide [1, 2]. The 
current reference standard for the diagnosis of S. pneumoniae infections is the isolation 
of the organism in culture from normally sterile body fluids. However, the sensitivity of 
diagnostic cultures has been shown to be low and it takes at least 2 days to obtain a result 
[3]. C-polysaccharide is a cell wall component of S. pneumoniae that can be detected in 
urine of patients suffering from pneumococcal infections. A rapid urinary pneumococcal 
antigen test (Binax NOW S. pneumoniae urinary antigen test; Binax Inc., Portland, ME, 
USA) is available for the detection of this antigen in patients; however, C-polysaccharide 
is also present in small amounts in the urine of healthy children [4, 5]. S. pneumoniae 
present in the nasopharynx is the most likely antigen source in pneumococcal carriers 
testing positive when this assay is used [6]. Positive results in non-carriers might be due 
to undetected, low-level pneumococcal colonization, or colonization by Streptococcus 
mitis, which has been shown to harbour pneumococcal C-polysaccharide-like antigens [7]. 
Furthermore, urine samples can remain positive for weeks after a pneumococcal infection, 
and the test will also be affected if the patient has been vaccinated with a pneumococcal 
conjugate vaccine shortly before the test [6]. Hence, it is doubtful whether this assay is 
useful for discriminating between children with and without pneumococcal infections, 
particularly in developing countries, where nasopharyngeal colonization rates are high [8]. 
Molecular biology-based techniques, including PCR assays and DNA hybridization assays, 
have been reported for the rapid, specific, and sensitive detection of microorganisms in 
blood samples [9, 10]. More recently, a sensitive and specific ELISA has been developed 
to detect pneumolysin in urine samples, thereby allowing differentiation between healthy 
carriers and patients [11].
The putative proteinase maturation protein A (PpmA) of S. pneumoniae is homologous 
to the members of the family of peptidyl-prolyl cis-trans isomerases (PPIases), which 
accelerate the rate-limiting cis-trans or trans-cis conformational changes at X-Pro bonds 
during protein folding [12]. There are three distinct families within the enzyme class 
of PPIases: the cyclophilins, the FK506-binding proteins, and the parvulins. PpmA is 
homologous to the members of the parvulin family. Although PPIase activity has never been 
demonstrated, the protein is considered to be involved in enzyme secretion and activation, 
and it is a surface-located immunogenic lipoprotein that contributes to bacterial virulence 
[13, 14]. PpmA is conserved across serotypes, elicits protective immune responses, and is 
therefore a candidate for the development of new pneumococcal vaccines [15]. 
The present study is the first to provide evidence of the presence of S. pneumoniae PpmA 
in urine samples of children with pneumococcal infections, independently of previous 
antibiotic treatment, and of its absence in such samples from healthy children, even if their 
nasopharynx is colonized with S. pneumoniae. Furthermore, the development of a simple 
western blot assay for the detection of S. pneumoniae PpmA in urine samples is reported, 
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which establishes the necessary basis for future randomized clinical trials of the assay with 
a larger number of individuals.
materials & methods
Bacterial strains. Reference strains were obtained from the American Type Culture 
Collection (ATCC, Manassas, USA), the National Collection of Type Cultures (NCTC, 
London, UK), and the Culture Collection University of Göteborg (CCUG, Göteborg, 
Sweden). The S. pneumoniae D39 ppmA- strain was kindly supplied by P. W. M. Hermans, 
Radboud University Nijmegen Medical Centre. Clinical isolates of Streptococcus mutans, 
Streptococcus agalactiae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria 
meningitidis, Legionella pneumophila, Listeria monocytogenes, Enterococcus faecalis, Proteus 
mirabilis, Providencia stuartii, Serratia marcescens and Candida albicans were obtained 
from the Microbiology Laboratory of the Hospital Universitario Central de Asturias.
Expression and purification of PpmA. S. pneumoniae D39 (NCTC 7466) was 
grown in Todd-Hewitt broth (Oxoid, Basingstoke, England) supplemented with 
0.5% yeast extract, to logarithmic phase at 37oC in a 5% CO2 atmosphere. Genomic 
DNA was extracted using the E.Z.N.A. DNA purification kit (Omega Bio-tek, 
Doraville, GA, USA), following the manufacturer’s recommendations. The ppmA 
gene was amplified from S. pneumoniae genomic DNA, using PCR with the primers 
ppma-fd: (5’-GGAGTACATATGAAGAAAAAATTATTGGCAG-3’) and ppma-r1: 
(5’-CTCATGGATCCGGACTATTCGTTTGATG-3’). The forward and reverse primers 
contain NdeI and BamHI recognition sequences, respectively. The amplified NdeI-
BamHI-digested ppmA fragment was cloned into pET-15b (Invitrogen, Carlsbad, CA, 
USA), encoding a His(6)-tag followed by four amino acids and a thrombin cleavage site. 
DNA sequencing of the recombinant plasmid confirmed the insertion of the ppmA gene, 
previously described by Overweg et al. [13], and its sequence showed 99% identity with 
that of the serotype 4 strain TIGR4 (ORF SP0981; accession number ABJ55379) [16]. The 
ppmA recombinant sequence was different only at the 5’ end, due to the vector-borne 
extension. For the expression of recombinant PpmA protein, the recombinant pET-15b 
was transferred into electro-competent Escherichia coli BL21 (DE3) pLysS (Novagen Inc., 
Madison, WI, USA) by electroporation. Expression of recombinant PpmA was induced 
with 0.1 mM isopropyl-b-D-thiogalactopyranoside at 37oC for 2 h. The His-tagged 36.6 kDa 
PpmA was purified to near-homogeneity from the soluble fraction of recombinant E. coli 
lysates, using immobilized metal affinity chromatography with a His-Bind purification kit 
(Novagen Inc.) under native conditions, following the manufacturer’s recommendations. 
Fractions containing the purified protein were pooled, dialyzed against phosphate-buffered 
saline (PBS), and stored at -20°C.
Production of hyperimmune rabbit sera. Male New Zealand White rabbits were 
intramuscularly immunized with purified 36.6 kDa PpmA (100 μg/immunization) and with 
108 CFU of heat-killed whole S. pneumoniae type 14 (CCUG 1086) and S. pneumoniae R36A 
(a non-encapsulated strain; ATCC 12214), ten times at 2-week intervals. Immunizations 
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were performed using Freund’s incomplete adjuvant (Sigma Chemical Co., St. Louis, MO, 
USA). Pre-immune sera were obtained, and samples of immune serum were drawn weekly 
from the marginal ear veins of the rabbits. Pre-immune sera did not react with PpmA or 
pneumococcal lysates in western blot analysis, and were used as negative controls. The 
animals were bled 7 days after the last immunization. To remove antibodies that recognized 
soluble E. coli proteins, lyophilized lysates were incubated with polyclonal sera at 37oC for 
3 h and overnight at 4oC; the sera were centrifuged at 10 000  g to remove bacterial debris, 
and stored at -20oC until used. Animal experiments were performed in accordance with the 
guidelines of the Institutional Animal Care and Use Committee of the University of Oviedo 
(Spain). 
SDS-PAGE and Western blot. Prior to analysis, urine samples were thawed at room 
temperature, and an aliquot was centrifuged at 15 000 g for 1 min. The supernatants were 
diluted in Laemmli buffer [17], boiled for 5 min, and subjected to electrophoresis. SDS-
PAGE was carried out in the Bio-Rad minigel system (Bio-Rad Laboratories, Richmond, 
CA, USA) with polyacrylamide (12%) gels. The proteins were transferred to poly(vinyllidene 
difluoride) membranes (Inmobilon-P, Millipore, Bedford, MA, USA), using a mini-trans-
blot system (Bio-Rad Laboratories) and the membranes were blocked in Tris buffered 
saline (0.1 M Tris, 0.15 M NaCl, pH 7.5) (TBS) containing 1% blocking reagent (Roche 
Diagnostics GmbH, Mannheim, Germany) for 1 h at room temperature or overnight at 
4oC. Hyperimmune rabbit antisera or human sera were diluted 1:1000 in blocking solution 
(TBS containing 0.1% blocking reagent) and added to the membrane strips. After 1 h 
incubation, membrane strips were washed three times with TBS-Tween 20 (0.05%) for 10 
min. Goat anti-rabbit IgG (whole molecule) peroxidase conjugate (Sigma Chemical Co.) 
or anti-human γ-chain peroxidase conjugate (Sigma Chemical Co.) (each diluted 1:5000) 
was added and the strips were incubated for 30 min. After washing of the strips, protein 
was detected using BM Chemiluminescent blotting substrate (POD) (Roche Diagnostics 
GmbH) and visualized on Kodak film. 
Binax NOW S. pneumoniae test. The Binax NOW S. pneumoniae test (Binax Inc.) was 
performed with non-concentrated urine samples obtained from all enrolled patients 
according to the manufacturer’s instructions. The results were read visually after 15 min. 
The test was interpreted according to the presence or absence of pink-purple-coloured lines. 
PLY-ELISA. All urine samples were tested with pneumolysin (PLY)-ELISA, performed as 
previously described [11]. Briefly, Combiplate white Breakable plates (Labsystems, Helsinki, 
Finland) were coated with anti-PLY mouse monoclonal PLY-7 (1 μg/well) [11] in PBS at 37oC 
for 3 h. Plates were blocked with blocking buffer (ELISA-Light chemiluminescence detection 
system; Tropix, Applied Biosystems, Bedford, MA, USA). Samples were then added to the 
wells and incubated at 37oC for 1 h with shaking. After this, plates were incubated with 
rabbit polyclonal anti-PLY IgG diluted 1:1000 in blocking buffer and incubated at 37oC for 
30 min. Secondary anti-rabbit IgG-alkaline phosphatase antibody (Sigma Chemicals Co.) 
(1:5000) was added and incubated as above. Plates were loaded and read on a Luminoskan 
RS (Labsystems) luminometer after automatic filling of the wells with substrate/enhancer 
solution (0.4 mM CSPD® with 1× Sapphire-II) and incubation at 37oC for 10 min.  
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Bacterial and yeast lysates. Gram-positive bacterial strains were grown overnight in Todd-
Hewitt broth (Oxoid) supplemented with yeast extract, and Gram-negative bacteria were 
grown in 2×TY broth [18]. L. pneumophila and H. influenzae were grown on BCYE and 
chocolate agar-fetal bovine serum plates (Oxoid), respectively. C. albicans was grown on 
Sabouraud agar (Oxoid). Plates were incubated at 37°C under 5% CO2 for 48-72 h. Cells 
were prepared in PBS, lysed by shaking with acid-washed glass beads (106 μm) (Sigma 
Chemical Co.), and centrifuged for 15 min at 3000 g. Soluble proteins were quantified at 
A280nm and adjusted to 1 g/L. For SDS-PAGE, 20 mg of protein per lane were used. Mycoplasma 
pneumoniae FH and Chlamydia pneumoniae CWL-029 cell lysates were purchased from 
Microbix Biosystems Inc., (Toronto, ON, Canada). Mycobacterium tuberculosis and 
Mycobacterium bovis cell lysates were obtained from Unidad de Referencia Regional de 
Micobacterias, Hospital Universitario Central de Asturias (Oviedo, Spain).
Patients and samples. Urine samples were collected from children potentially infected 
with S. pneumoniae at Hospital Universitario Central de Asturias (Oviedo, Spain) and from 
healthy children at Centro de Salud de Lugones receiving routine clinical care, between 
January 2003 and December 2006. The study was performed as a retrospective, multicentre 
study; the samples were obtained with the approval of the Hospital Universitario Central 
de Asturias Research Ethics Committee and informed consent was obtained from the 
childrens’ parents or guardians. Ten-millilitre urine specimens were collected in sterile 
containers, using aseptic techniques, and frozen at –70oC until used. 
The presence of PpmA was tested for in urine samples collected from 84 children, (47 
males and 37 females). The mean and median ages were 5.03 years (± 4) and 4 years (newborn 
to 14 years), respectively. The group with culture-proven pneumococcal infections included 
14 urine samples from patients with pneumonia (n = 9), septicaemia (n = 1), meningitis (n 
= 2), sinusitis (n = 1), and a finger infection (n = 1). The group with probable pneumococcal 
infections included 23 urine samples from patients with pneumonia (n = 15), and otitis (n 
= 8).  The group with non-pneumococcal infections (n = 12) included: four samples from 
patients with pneumonia caused by M. pneumoniae (n = 1), Chlamydia pneumoniae (n = 
1), H. influenzae (n = 1), and respiratory syncytial virus (n = 1); one from a patient with 
gastroenteritis due to Salmonella spp.; one from a patient with tonsillitis due to Streptococcus 
pyogenes; three from patients with a common cold; two from patients with urinary tract 
infection caused by E. coli; and one from a patient with vaginitis caused by Candida spp. 
The non-infectious disease group included samples from children with allergic rhinitis (n = 
5). The group with unknown aetiology of disease was composed of 18 urine samples from 
patients with pneumonia (n = 14), otitis media (n = 2), sinusitis (n = 1) and conjunctivitis 
(n = 1), and all were discarded from test performance calculations. The group of healthy 
individuals included 12 without clinical or radiological signs of pneumonia or infection; 
they had not received any antibiotic treatment during the preceding week. 
Microbiological analysis and diagnostic criteria. Nasopharyngeal swab samples were 
taken using a calcium alginate-tipped swab on a flexible aluminium wire (TRANSWAB; 
Medical Wire and Equipment Co., Ltd., Corsham, UK) and streaked onto horse blood (5%) 
agar supplemented with gentamicin (5 mg/L); the plates were incubated in 5% CO2 for 24 
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h. All S. pneumoniae isolates were identified according to colony morphology, Gram stain, 
optochin susceptibility, and bile solubility.
All urine samples were cultured to control for any cross-reactivity. Cultures of blood 
(ESP system, Difco Laboratories, Detroit, MI, USA), cerebrospinal fluid, ascites, pleural 
fluid, tracheal aspirates, sputum, urine and pus, and of otic and vaginal samples, were 
performed according to standard microbiological methods [19]. Standard methodology 
was used for the microimmunofluorescence, virus culture and shell-vial assays [20]. Specific 
monoclonal fluorescein isothiocyanate-conjugated antibodies were obtained from Vircell 
S.L. (Granada, Spain). A microimmunofluorescence test was performed for detection of 
specific antibodies against Chlamydia pneumoniae in patient sera. Commercial ELISA 
tests were used for detection of IgM against M. pneumoniae and Chlamydia pneumoniae 
(Vircell S.L.). Commercial complement fixation tests were used for detection of IgM/IgG 
against adenovirus and respiratory syncytial virus (Virion, Institute Virion Ltd, Rüschlikon, 
Switzerland). All commercial tests were performed according to the manufacturers’ 
instructions. The diagnosis of acute infection was considered when the IgM test was positive 
or when a 4-fold or greater rise in IgM and IgG titres was observed in sera taken at 3-week 
intervals.
The diagnosis of pneumococcal infection was established on the basis of standard 
radiological, clinical, and laboratory criteria. Patients were classified as having pneumonia 
if they presented with an acute illness with the presence of a new or progressive infiltrate 
seen on a chest radiograph in addition to at least two of the following symptoms: fever, 
cough, shortness of breath, and pleuritic chest pain. Patients were classified as having 
culture-proven pneumococcal infection when S. pneumoniae was isolated from blood 
(n = 9), cerebrospinal fluid (n = 2), pleural fluid (n = 1), ascitic fluid (n = 1) and pus (n = 1). 
Patients were classified as having probable pneumococcal pneumonia when S. pneumoniae 
was isolated from tracheal aspirates (≥106 CFU/ml) (n = 4) or sputum (polymorphonuclear 
neutrophil/squamous epithelial cell ratio ≥ 2 or Q (quality) score ≥ +1 on Gram stain) 
(n = 1), or when both Binax NOW S. pneumoniae urinary antigen and PLY-ELISA urine 
tests were positive (n = 12). Patients were classified as having probable pneumococcal 
otitis media when S. pneumoniae was isolated from otic exudates, and both Binax NOW S. 
pneumoniae urinary antigen and PLY-ELISA urine tests were positive (n = 8). The diagnosis 
of urinary tract infection was considered if >105 CFU/ml of a single bacterium was found 
in urine cultures. Non-infectious diseases were diagnosed according to standard criteria. 
Multiple alignments of protein sequences. The identification of putative PPIases was 
performed using the BLASTP program [21] at The National Center for Biotechnology 
Information (NCBI; http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) and the protein 
sequences of Streptococcus sanguinis SK36, (YP1034736), S. mutans UA159 (NP721076), 
S. agalactiae A909 (YP329554), S. pyogenes MGAS10270 (YP598812), Enterococcus faecalis 
V583 (NP814435), and Listeria monocytogenes strain 4b F2365 (YP014061) were retrieved 
from the NCBI protein data base. The PpmA sequence of S. mitis was retrieved from the 
Institute for Genomic Research database (http://www.tigr.org). Protein sequences were 
aligned using the ClustalW programme (http://www.ebi.ac.uk/clustalw). Calculation of 
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the percentage of amino acid identity was carried out using LALIGN program (http://
www.ch.embnet.org/software/LALIGN_form.html) [22]. The theoretical lipoprotein 
signal peptide-cleaving site was predicted using the LipoP 1.0 Server (http://www.cbs.
dtu.dk/services/LipoP/) [23]. Calculation of percentage of similarity of the sequences was 
carried out using EMBOSS Pairwise Alignment Algorithms (http://www.ebi.ac.uk/Tools/
emboss/align/index.html). The theoretical molecular masses of the predicted proteins were 
calculated using the Compute pI/Mw tool on the ExPASy server (http://www.expasy.ch/
tools/pi_tool.html). 
Statistical analysis. The data were analyzed with GraphPad PRISM software (v.4.00 for 
Windows; GraphPad Software, San Diego, CA, USA). CIs were calculated using Wilson’s 
method. We used the chi-square test or, when appropriate, Fisher’s exact test to compare 
proportions of qualitative variables. The limit of statistical significance was set at a p-value 
of 0.05.
results
Detection of PpmA using Western blot. In order to produce a hyperimmune anti- PpmA 
rabbit antiserum, expression and purification of recombinant PpmA was carried out. 
After induction of recombinant E. coli cultures, two main protein bands were observed 
at 32 and 36 kDa (Fig. 1a, lane 3). The theoretical molecular mass of PpmA (34.4 kDa) 
increased to 36.6 kDa in the recombinant protein, owing to fusion at the N-terminus with 
a His-tag followed by a thrombin cleavage site. The predicted theoretical molecular masses 
(Fig. 1d) of the protein with (36.6 kDa) and without (32.4 kDa) lipoprotein signal peptide 
were very similar to the molecular masses of proteins observed after induction. In order 
to confirm that both proteins were recombinant PpmA, lysates of E. coli were assayed 
using different sera. Proteins reacted with rabbit anti-heat-killed S. pneumoniae type 14 
and anti-unencapsulated S. pneumoniae R36A antisera, and with two adult pneumococcal 
pneumonia patient sera (Fig. 1b). His-tagged PpmA was purified to near-homogeneity 
using immobilized metal affinity chromatography (Fig. 1a). Serum from rabbits immunized 
with 36.6-kDa purified protein showed reactivity against 32-kDa and 36-kDa PpmA in 
recombinant E. coli lysates (Fig. 1c, lane 1). Hyperimmune rabbit antiserum also reacted 
with a 34.4-kDa protein from S. pneumoniae D39 lysates, and no reactivity was observed 
against S. pneumoniae D39 ppmA- mutant lysates (Fig. 1c, lanes 2 and 3). 
Anti-PpmA hyperimmune rabbit antiserum. The specificity of the anti-PpmA 
hyperimmune rabbit antiserum was tested against lysates from nasopharyngeal commensal 
bacteria and microorganisms known to cause pneumonia, sinusitis, otitis, and urinary tract 
infections in children (Table 1). In western blot analysis, anti-PpmA antiserum recognized 
proteins with relative molecular masses ranging between 30 and 40 kDa, in Streptococcus 
spp. and Enterococcus faecalis lysates. BlastP homology searches revealed that pneumococcal 
PpmA shares sequence identity/similarity with PPIases from other streptococci (Fig. 2). 
The protein sequences of S. mitis, S. sanguinis, S. mutans, S. agalactiae, S. pyogenes, and 
Enterococcus faecalis showed percentages of identity with S. pneumoniae PpmA of 93.6%, 
57.6%, 46.4%, 47.5%, 40.1%, and 37.8%, respectively. Percentages of similarity were 97.1%, 
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74.8%, 65.7%, 66.4%, 57.6% and 56%, respectively. PpmA identity and similarity with 
that of other Gram-positive bacteria, e.g. Listeria monocytogenes, was 29.2% and 52.8%, 
respectively. The predicted molecular masses of these proteins were consistent with those 
in antibody-stained bands observed in western blot analysis (Table 1).
Fig. 1. Characterization of recombinant proteinase maturation protein A (PpmA) and hyperimmune rabbit 
antisera. (a) Expression and purification of recombinant PpmA. Lane 1: molecular mass markers. Lane 2: 
PpmA recombinant Escherichia coli BL21 (DE3) pLysS cultures before isopropyl thio-β-d-galactoside (IPTG) 
induction. Lane 3: PpmA recombinant E.  coli BL21 (DE3) pLysS cultures after IPTG induction, showing 
main protein bands (arrows). Lane 4: soluble cell lysate. Lane 5: immobilized metal affinity chromatography 
(IMAC) unbound proteins. Lanes 6–9: IMAC eluted protein fractions. (b) PpmA recombinant E. coli lysates 
were incubated with rabbit anti-Streptococcus pneumoniae type 14 antiserum (lane 1), anti-S. pneumoniae 
R36A antiserum (lane  2), and pneumococcal pneumonia patient sera (lanes  3 and 4). (c) Anti-PpmA 
hyperimmune rabbit antiserum was incubated with PpmA recombinant E. coli lysate (lane 1), S. pneumoniae 
D39 wild-type lysate (lane 2), S. pneumoniae D39 ppmA− lysate (lane 3), and a urine sample from a paediatric 
patient with pneumococcal pneumonia (lane 4). (d) Schematic illustration of the recombinant PpmA full 
expression cassette, showing the theoretical molecular masses of the different expressed proteins.
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Table 1. Reactivity of hyperimmune anti-proteinase maturation protein A (PpmA) rabbit antiserum against 
pathogenic and non-pathogenic commensal bacterial lysates. 
Microorganism a
Reactivity of anti-PpmA antiserum 
(molecular mass, kDa) b
Streptococcus pneumoniae D39 (NCTC 7466) + (34)
Streptococcus mitis ATCC 33399 + (34)
Streptococcus sanguinis ATCC 10556 + (36)
Streptococcus mutans + (36)
Streptococcus agalactiae + (36)
Streptococcus pyogenes ATCC 19615 + (38)
Streptococcus salivarius ATCC 7073 + (38)
Streptococcus oralis ATCC 35037 + (35)
Streptococcus anginosus ATCC 12395 + (35)
Haemophilus influenzae -
Moraxella catarrhalis -
Neisseria meningitidis -
Legionella pneumophila -
Mycoplasma pneumoniae FH c -
Chlamydia pneumoniae CWL-029c -
Klebsiella pneumoniae ATCC 13883 -
Mycobacterium tuberculosis -
Mycobacterium bovis -
Pseudomonas aeruginosa ATCC 27853 -
Listeria monocytogenes -
Enterococcus faecalis + (37)
Proteus mirabilis -
Proteus vulgaris ATCC 13315 -
Providencia stuartii -
Candida albicans -
Enterobacter cloacae ATCC 23355 -
Staphylococcus aureus ATCC 25923 -
Escherichia coli ATCC 25922 -
Serratia marcescens -
a Collection strains and clinical isolates were used. Clinical isolates were obtained from patients at the 
Microbiology Laboratory of the Hospital Universitario Central de Asturias. 
b Relative molecular mass of the proteins recognized. 
c Mycoplasma pneumoniae FH and Chlamydia pneumoniae CWL-029 cell lysates were purchased from 
Microbix Biosystems Inc., Toronto, Canada. Cells were lysed and 20 mg of total protein per lane was used 
for antigen detection using Western blots.
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Fig. 2. Multiple alignment of parvulin-like PPIases and PpmA. Protein sequences were aligned using the 
ClustalW programme and manually coloured. The predicted signal sequence and lipid binding site of PpmA 
is underlined. Regions of 100% identity with PpmA of Streptococcus pneumoniae are shown in dark grey. 
Light grey shadowed residues indicate similarity. Numbers to the left indicate the location within the amino 
acid sequence.
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Detection of PpmA in urine samples. Hyperimmune rabbit antiserum reacted with 
a 34-kDa protein in urine samples from children with pneumococcal infection. A 
representative result of a western blot analysis is shown in Fig. 1c, lane 4. The results of 
PpmA-based western blot analyses of paediatric urine samples are shown in Table 2. The 
sensitivity, specificity, and positive and negative predictive values of the diagnostic test based 
on the detection of PpmA by western blot analysis were 57.1%, 100%, 100%, and 59.2%, 
respectively. Secreted PpmA was observed in eight of 12 children with life-threatening 
pneumococcal infections, with sensitivity and negative predictive values of 66.7% and 87.9 
%, respectively. In contrast, 100% of the urine samples from the healthy, non-pneumococcal 
and non-infectious disease groups yielded negative PpmA results. PpmA was also detected 
in urine samples from adults with culture-proven pneumococcal pneumonia, and no 
reactivity was observed in urine samples from non-pneumococcal pneumonia patients 
(data not shown). The main characteristics of the paediatric patients with pneumococcal 
infections and the results obtained with other urinary antigen tests, as correlated with the 
PpmA test results, are shown in Table 3. No significant differences were found in terms of 
gender or nasopharyngeal pneumococcal carriage. Half of the patients in the present study 
had been treated with antibiotics before the time of collection of the clinical specimens. The 
western blot was positive for PpmA for six of 17 (35.3%) patients who had received prior 
Table 2. Detection of PpmA in urine samples of paediatric patients in relation to patient condition group.
Group (n = 84) Patient no.
No. of positive 
samples (%) 95% CI
    Culture-proven pneumococcal infections a 14 8 (57.1) 32.6 - 78.7
        Pneumonia, meningitis, septicaemia 12 8 (66.7) 38.8 - 86.5
        Others b 2 0 (0) 0.0 - 70.0
    Probable pneumococcal infections 23 9 (39.1) 22.1 - 59.3
        Pneumonia c 15 6 (40) 19.7 - 64.3
         Otitis d 8 3 (37.5) 13.5 - 69.6
    Non pneumococcal infections 12 0 (0) 0.0 - 28.2
         Pneumonia 4 0 (0) 0.0 - 54.6
         Others e 8 0 (0) 0.0 - 37.2
    Non infectious diseases 5 0 (0) 0.0 - 48.9
    Healthy subjects 12 0 (0) 0.0 - 28.2
    Unknown aetiology 18 2 (11.1) 1.9 - 34.1
a S. pneumoniae was isolated from blood (n = 9), cerebrospinal fluid (n = 2), pleural fluid (n = 1), ascitic 
fluid (n = 1) and pus (n = 1). 
b Sinusitis (n = 1) and finger infection (n = 1). 
c S. pneumoniae was isolated from tracheal aspirates (n = 5), sputum (n = 1), or both; Binax NOW S. 
pneumoniae urinary antigen (Binax Inc.) and PLY-ELISA urine test results were positive (n = 12). 
d S. pneumoniae was isolated from otic exudates and both Binax NOW S. pneumoniae urinary antigen 
(Binax Inc.) and PLY-ELISA urine test results were positive (n = 8). 
e Gastroenteritis due to Salmonella spp. (n = 1), tonsillitis caused by Streptococcus pyogenes (n = 1), 
common cold (n = 3), urinary infection caused by Escherichia coli (n = 2), and vaginitis due to Candida 
spp. (n = 1). 
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Table 3. Main characteristics of patients with pneumococcal infections as correlated with positive urinary 
PpmA antigen test results. 
Characteristics (n = 37)
Patient 
No.
No. of positive 
samples (%) 95% CI P
Gender
    Male 21 10 (47.6) 28.3 - 67.6 0.8150
    Female 16 7 (43.8) 23.1 - 66.9
Nasopharyngeal carriage
    Positive 10 4 (40.0) 16.7 - 68.8 0.7256
    Negative 27 13 (48.2) 30.7 - 66.0
Age 
     ≤ 2 years 10 8 (80.0) 47.9 - 95.4 0.0625
     > 2 years 27 11 (40.7) 24.5 - 59.3
S. pneumoniae blood culture
    Positive 9 5 (55.6) 26.6 - 81.2 0.7034
    Negative 28 12 (42.9) 26.5 - 61.0
Binax NOW test
    Positive 35 17 (48.6) 33.0 - 64.4 0.4895
    Negative 2 0 (0.0) 0.0 - 71.0
PLY-ELISA test
    Positive 31 16 (51.6) 34.8 - 68.0 0.1886
    Negative 6 1 (16.7) 1.1 - 58.2
Diagnosis
   Pneumonia 24 13 (54.2) 35.1 - 72.1 0.1728
   Others a 13 4 (30.8) 12.3 - 57.9 
Previous antibiotic treatment  
    Yes 17 6 (35.3) 17.2 - 58.8 0.3001
    No 17 9 (52.9) 31.0 - 73.8
    Undetermined 3 2 (66.7) 20.2 - 94.4
a Including septicaemia (n = 1), meningitis (n = 2), otitis media (n = 8), sinusitis (n = 1), and a finger 
infection (n = 1) due to Streptococcus pneumoniae.
treatment with antibiotics, and for nine of 17 (52.9%) who had not received prior antibiotic 
treatment; this difference was not statistically significant. 
In the culture-proven pneumococcal infection group, 13 of 14 (92.9%) children were 
positive according to the low-specificity Binax NOW S. pneumoniae urinary antigen test 
(Binax Inc.), whereas 11 of 14 (78.6%) and eight of 14 (57.1%) were positive with the specific 
PLY-ELISA and PpmA western blot assay, respectively (Table 4). Therefore, 11 of 14 (78.6%) 
children were diagnosed as positive when one or both protein-specific antigen tests were used. 
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Table 4. Comparison of three urinary antigen test results in the same urine samples from children with 
proven pneumococcal infections.
Patient Diagnosis
S. pneumoniae culture 
positive Binax NOW PLY-ELISA PpmA western blot
1 Pneumonia Blood + + +
2 Pneumonia Blood + + +
3 Pneumonia Blood + + +
4 Pneumonia Blood + + +
5 Pneumonia Blood + + +
6 Pneumonia Blood + + -
7 Pneumonia Blood + - -
8 Pneumonia Pleural fluid + + +
9 Pneumonia Ascitic fluid + + +
19 Meningitis Cerebrospinal fluid + + +
11 Meningitis Cerebrospinal fluid + - -
12 Septicaemia Blood + + -
13 Sinusitis Blood - - -
14 Finger infection Pus + + -
PpmA, proteinase maturation protein A.
discussion
This study found the presence of S. pneumoniae PpmA in urine, and examined its usefulness 
in the diagnosis of pneumococcal infections in children. Recombinant, full-length PpmA 
without lipoprotein signal peptide has been previously expressed in E. coli, in order to study 
its immunogenicity [15, 24, 25, 26], as the protein has a surface-exposed C-terminal domain, 
whereas the N-terminus is most probably covalently bound to the cell membrane [13]. We 
selected expression of full-length protein in E. coli and subsequent polyclonal antiserum 
production in rabbits. Two protein bands corresponding to PpmA migrated in SDS-PAGE 
gels, suggesting that they corresponded to PpmA with and without the lipoprotein signal 
peptide, as the molecular masses matched the molecular masses predicted for the processed 
and unprocessed protein. Furthermore, after purification, only the higher molecular mass 
protein was obtained, suggesting that the 32.4-kDa protein had lost the N-terminal His-tag. 
This protein was the most prominent after induction, probably because the lipoprotein signal 
peptide of Gram-positive bacteria is recognized by E. coli signal peptidase II, even though 
lipoprotein signal peptides of Gram-positive bacteria differ from those of Gram-negative 
bacteria [23]. It was supposed that both proteins have diacylglycerol attached to the thiol of 
the conserved cysteine, which should reduce its solubility. However, most likely because of 
the high levels of expression after induction in E. coli, a low percentage of the proteins still 
remained in the soluble fraction. His-tagged protein was immunogenic in rabbits. 
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PpmA is homologous to the members of the ubiquitous family of parvulin-like 
peptidyl-prolyl isomerases and is widely represented among bacteria [12, 27]. One urine 
sample from a patient with S. pyogenes infection was tested, and no reactivity was observed, 
probably because of the low amounts of S. pyogenes PpmA homologue released into the 
urine. However, urine samples from patients with Enterococcus faecalis infection will need 
to be tested in order to assess potential cross reactivity. These results are consistent with 
the low level of identity observed among parvulin-like PPIases retrieved from the protein 
databases. PpmA shares a high degree of amino acid sequence identity/similarity only 
with the proteinase maturation protein of S. mitis and a lower degree of identity/similarity 
with parvulin-like PPIases of Streptococcus spp. Interestingly, the present results confirm 
the presence of PpmA cross-reactive epitopes in commensal bacteria co-colonizing the 
nasopharyngeal niche, as previously suggested [24]. These findings explain why a correlation 
between anti-PpmA antibody titres and pneumococcal carriage or infection cannot be 
established, even though PpmA is an immunogenic protein [25, 26]. Presumably, early in 
life, the very first acquisition of microflora on the nasopharyngeal mucosa, in particular of 
streptococci, leads to a systemic antibody response against PpmA.
Owing to the commensal nature of S. pneumoniae, especially in children, the key factor 
in the laboratory diagnosis of invasive pneumococcal infections is the differentiation 
between infection and colonization. The limitation to the application of the Binax NOW test 
for diagnosing pneumococcal infections in children is that false-positive results are obtained 
with samples from healthy children who are nasopharyngeal carriers of S. pneumoniae. 
Therefore, this test can give positive results in patients with non-pneumococcal infections 
who are S. pneumoniae carriers. In contrast, the test for PpmA was specific for pneumococcal 
infections and gave negative results for S. pneumoniae nasopharyngeal carriers. Previously, 
the detection of pneumolysin in urine samples for the differentiation between colonization 
and invasive pneumococcal infections in children has been reported by this group [11]. All 
urine samples from healthy carriers tested negative for the antigen, despite the abundance of 
PpmA in the transparent colony-type variants selected during nasopharyngeal colonization 
[27]. The presumed different antigenic composition of colonizing and invasive pneumococci 
has been investigated repeatedly in the context of pneumococcal virulence gene expression, 
and this has demonstrated that the mechanism of pneumococcal pathogenesis is highly 
complex and multifactorial and that it remains unclear [28, 29, 30, 31]. The key for 
discriminating between healthy carriers and patients might be related to the nature of the 
antigens and their capacity to cross the renal barrier. 
The diagnostic potential of PpmA detection in urine was studied using western 
blot analysis. The test used cannot be considered to be a rapid clinical diagnostic test; 
nevertheless, it is a helpful tool to evaluate the presence of new antigens in urine samples, 
and could be transformed into an ELISA or immunochromatographic assay subsequent 
to the preparation of anti-PpmA monoclonal antibodies. Although detection of PpmA in 
patients with pneumococcal infection was associated with very poor sensitivity and negative 
predictive values, detection of PpmA in patients in whom S. pneumoniae was isolated from 
blood or other sterile fluids notably increased the diagnostic validity. Interestingly, these 
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results were very close to those obtained by pneumolysin detection in urine using an ELISA 
assay [11]. Several factors could be involved in the low sensitivity observed in the western 
blot assay. To our knowledge, there are no data regarding ppmA expression levels in vivo 
during the progress of pneumococcal infection, or regarding the stability of PpmA released 
into the urine. However, we speculate that protein levels in urine are correlated with the 
spread of pneumococci. On the other hand (and on the basis of results obtained with Binax 
NOW), it seems reasonable to think that the number of PpmA molecules per cell could be 
lower than that of C-polysaccharide. 
The strategy of using the Binax NOW S. pneumoniae assay as a primary screen, and 
in addition the PLY-ELISA and PpmA assays with Binax NOW-positive samples, could 
improve the diagnostic accuracy for pneumococcal infections. Although protein antigen 
tests are of relatively low sensitivity, the specificity of the PLY and PpmA assays is higher than 
that of Binax NOW, and therefore positive results obtained with the two assays indicate true 
pneumococcal infections, increasing the accuracy of diagnosis of pneumococcal infections 
in children. The kinetics of PpmA release into the urine of patients with pneumococcal 
infection were not studied here.  A larger, prospective study of paediatric populations with 
controlled immunization status to evaluate the relevance of the detection of this antigen in 
urine will be conducted in the future in this laboratory.
There was a near significant (p = 0.06) difference between patients under 2 years of age 
(80% positive) and patients over 2 years of age (40% positive). Although we have no reliable 
explanation for this finding, it could be due to differences in immunological status, as has 
been suggested for the C-polysaccharide [5]. Previous studies have shown that antibiotics 
could influence the production and release of bacterial virulence factors [32, 33, 34, 35]. 
The diagnosis of S. pneumoniae infection in adults based on the Binax NOW urinary 
antigen test (Binax Inc.) has been established more often in patients who had not received 
antibiotics before the test [36]. In the present study (probably owing to the limited number 
of patients) no correlation between PpmA antigenuria and previous antibiotic treatment 
could be established. 
This study shows for the first time that the kidney barrier in patients with pneumococcal 
infection is permeable to the S. pneumoniae protein PpmA, resulting in its excretion in 
urine, which can be detected using Western blots. Despite the limited sensitivity of the 
PpmA detection assay, the availability of this simple immunoassay using samples obtained 
with non-invasive procedures, e.g. urine, is expected to trigger further research into the 
usefulness of pneumococcal protein antigens as differential biomarkers of pneumococcal 
carriage. Until now, conventional assays of antigenuria have not provided such markers.
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7SummArIzInG dIScuSSIon
Streptococcus pneumoniae is a frequent inhabitant of the nasopharyngeal cavity of the human 
host, where it typically resides asymptomatically. In susceptible individuals, this important 
human pathogen can progress to disease when pneumococci infiltrate the middle ear, 
lungs, blood, and brain. Current vaccination strategy is targeted against the pneumococcal 
polysaccharide capsule. However, these conjugate vaccines are only effective against the 
serotypes included in the vaccine, allowing for serotype replacement to occur with the 
existing non-vaccine serotypes. A thorough understanding of pneumococcal pathogenesis 
is indispensable for combating disease, for development of improved vaccines, and for 
efficient and accurate diagnosis of pneumococcal disease. For more than a decade, research 
groups have used various genome-based strategies to identify pneumococcal (virulence) 
factors that might function as novel targets for therapy, prevention, and/or diagnostics. In 
this thesis, several proteins were investigated as to 1) their contribution to pneumococcal 
pathogenesis, 2) their protective potential and, 3) their diagnostic value.
Pneumococcal PathoGenesis
The interplay between host and pathogen during infection is complex and dynamic, 
requiring multiple factors from either side during the different stages of infection. Adherence 
of pneumococci to respiratory epithelial cells is crucial for colonization of the nasopharynx. 
While colonization is mainly asymptomatic, it is a prerequisite for subsequent disease, such 
as otitis media (OM), pneumonia, and bacteremia. In this thesis, in vitro and in vivo assays 
were used to investigate the contribution(s) of selected pneumococcal proteins to various 
aspects of pneumococcal pathogenesis. Many of these proteins were found to have a role in 
adherence and/or colonization, and in the case of the DHH subfamily 1 proteins, in otitis 
media, pneumonia, and bacteremia as well.
The contents of the pneumococcal surface play an important role in the different stages of 
infection. Peptidyl-prolyl isomerases (PPIases) are ubiquitous foldases, which accelerate 
the cis–trans conformational changes at the Xaa-Pro bonds during protein folding. The 
pneumococcal genome contains four putative PPIases two of which are produced as surface-
associated lipoproteins: the streptococcal lipoprotein rotamase A (SlrA) and the putative 
proteinase maturation protein A (PpmA). Evidence that PPIases contribute to bacterial 
virulence is growing. For example, the macrophage infectivity potentiator (Mip) protein 
of Legionella pneumophila was shown to be involved in entry of host cells and intracellular 
replication (11,12), and for Burkholderia pseudomallei a reduction in its ability to survive 
within cells and significant attenuation in vivo was found upon the loss of the Mip-like 
protein BPSS1823 (42). Previous studies with SlrA have demonstrated PPIase activity and 
a role in colonization, but not invasive disease (27). While no PPIase activity or other 
enzymatic function could be demonstrated for PpmA (27), an increase in survival time of 
ppmA-infected mice in a pneumonia model was observed (45). Using knockout mutants in 
three different pneumococcal strains, we demonstrated a role in adherence and colonization 
for PpmA, albeit in a strain-specific manner ((14) and Chapter 2). In addition, similar to 
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SlrA, we observed that PpmA was involved in immune evasion, as PpmA-deficient strains 
were more easily taken up by human polymorphonuclear leukocytes (PMNs) or ingested 
by murine macrophages than to wild-type (14,27). Recently, the contribution of both SlrA 
and PpmA to otitis media was investigated. Interestingly, pneumococci lacking slrA, but 
not ppmA, were found to be significantly reduced in virulence, while deletion of both had 
an additive effect on attenuation (50). PpmA’s contribution to colonization and immune 
evasion, while strain-specific, is likely to be indirect, probably somehow altering the surface 
composition or folding of adherence factors or other proteins that may prevent recognition 
and uptake by macrophages. Further functional studies are needed to unravel the exact role 
of PpmA.
PpmA has homology to the parvulin family, which are the smallest known proteins with 
PPIase activity that have a lower relative activity against biological substrates compared to 
the cyclophilins (i.e. SlrA) and the FK506-binding proteins (FKBP; i.e. Mip). Perhaps this is 
why no PPIase activity has yet been detected for PpmA, or perhaps there is none to detect. 
Recently, the parvulin-like protein PsrA of Bacillus subtilis was found to catalyze the post-
translocational folding of exported proteins (31). There is also evidence for the first time 
that a novel FKBP, BPSL0918 of B. pseudomallei, possesses no PPIase activity, yet has been 
shown to be essential for intracellular replication and in vivo virulence of the pathogen (41). 
Acquiring the essential minerals and nutritional substrates needed for bacterial growth and 
persistence in vivo, and consequently, for full virulence, is imperative for S. pneumoniae. 
The pneumococcal ABC transporter for branched-chain amino acids (BCAAs) is encoded 
by the livJHMGF locus. Recently, Basavanna et al. showed reduced virulence of livH and 
livHMGF mutants in competitive infection models of both pneumonia and septicemia, but 
found no attenuation of a TIGR4ΔlivHMGF mutant in a competitive colonization model, 
48 h post-infection (5). We investigated the BCAA ABC transporter Liv and several other 
genes predicted to be involved in BCAA transport or metabolism to colonization using 
two pneumococcal serotypes in Chapter 3. In line with results of Basavanna et al. (5), we 
found no attenuation in colonization for a TIGR4ΔlivJHMGF in single infection at 192 h 
post-infection, giving further evidence that the liv locus is not heavily involved in carriage 
(Chapter 3). Similar to results obtained with PpmA, strain-specific phenotypes were 
observed in colonization with deletion mutants of livJHMGF, livJ (encoding the BCAA 
binding protein), brnQ (BCAA carrier protein), and ilvE (BCAA aminotransferase) at time 
points later in infection. The putative regulator SP0743/SPD0647, located upstream of 
the liv locus, was found to be required for full pneumococcal colonization in both strains 
tested, but did not appear to regulate the expression of the liv locus, nor any of the other 
BCAA-related genes investigated. Therefore, it is likely that the reduction in colonization 
observed with the SP0743/SPD0647 mutant was not due to changes in gene expression of 
liv, but by some other targets of SP0743/SPD0647 that are as yet unknown.
During transmission, colonization, and infection, S. pneumoniae will encounter different 
levels of carbon dioxide (CO2) in its environment. CO2 is important for various cellular 
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processes and therefore of importance for pneumococcal growth and survival. Carbonic 
anhydrases (CA) are enzymes that catalyze the reversible reaction CO2 + H2O ↔ HCO3- + 
H+ and since HCO3- is unable to diffuse across biological membranes, its formation will 
significantly delay release of intracellular CO2. The pneumococcal carbonic anhydrase 
(PCA) was shown to be essential for in vitro growth in environmental ambient air (CO2-poor 
conditions), but not in in vivo mouse models of nasopharyngeal carriage and bacteremia 
((9) and Chapter 4). In vitro experiments using human brain microvascular endothelial 
cells (HBMEC) showed that the number of pca mutant bacteria recovered after invasion 
had decreased. This could potentially mean that PCA is involved in the dissemination of 
bacteria in the host, a process that was not investigated here. Whether PCA has a role in 
meningitis remains unclear, as we did not study this molecule in experimental meningitis 
models. Or perhaps PCA’s role in in vitro growth under CO2-poor conditions and the ability 
of the bacteria to adapt to new environments plays a part in the transmission between hosts, 
as very low levels of CO2 are found outside the host. 
Previous studies in our laboratory using genome-wide GAF screens, where mutant libraries 
were applied to various in vivo models to identify genes essential during pneumococcal 
infection, led to the discovery of two DHH subfamily 1 proteins, SP1298 and SP2205 
(28,29,40). These two conserved proteins of an, as yet, unknown function are classified as 
DHH subfamily 1 proteins in the pneumococcal genome. DHH family proteins belong to 
the superfamily of phosphoesterases and are so named after their characteristic amino acid 
signature, Asp-His-His (DHH), located in the conserved N-terminal motif (2). 
An in-depth investigation was performed, where single and double knock out mutants 
in three different pneumococcal strains were tested in four different infection mouse 
models that represent major phases of pneumococcal pathogenesis ((15) and Chapter 5). 
Like for most of the other proteins investigated in this thesis, we were able to demonstrate 
a role for SP1298 and SP2205 in the first stage of pneumococcal infection, adherence and 
colonization. Furthermore, a significant reduction in the bacterial load of the middle ears 
was observed in the otitis media model. In addition, roles in invasive disease were found for 
the two DHH subfamily 1 proteins as pneumococci lacking the genes encoding SP1298 or 
SP2205 were attenuated in the lungs and blood of mice. Not only strain-specific phenotypes 
were observed in all infection models, but also site-specific phenotypes. In particular, the 
SP2205 mutant was just as virulent as wild-type in the lungs and blood of mice, while it was 
attenuated in the nasopharynx and middle ears of mice. In all cases, deletion of both genes 
had an additive effect as attenuation levels observed were greater than either single gene 
deletion alone. Other virulence studies using families of proteins, such as the Pht family, the 
choline-binding proteins PspA and PspC, and the lipoproteins SlrA and PpmA, have shown 
that when all family members are deleted from a strain, virulence is attenuated even more 
as opposed to one deleted member (3,44,50).
While roles for both DHH proteins in pneumococcal virulence are evident, their 
exact mode of action and function remain to be elucidated. SP1298 is predicted to be a 
cytoplasmic protein, making it unlikely that it directly acts as an adhesin, while SP2205 
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could directly act as an adhesin as it is predicted to be on the surface. Proteins possessing 
DHH domains usually function as phosphatases or phosphodiesterases (PDE) (2), as 
demonstrated for some of the most well-characterized DHH proteins which include RecJ 
of Escherichia coli (exonuclease activity) (35,52), YtqI of B. subtilis (oligoribonuclease 
and 3'-phosphoadenosine–5'-phosphate (pAp) phosphatase activity) (38), and another B. 
subtilis protein, YybT (PDE activity) (47). We speculate that SP1298 and SP2205 may also 
possess similar PDE activity which could therefore be their mechanism of action; however 
this has yet to be confirmed. Further experiments are needed to establish their cellular 
localization using FACS, involvement in complement and immune evasion, and their 
functional characterization using a proteomic and transcriptomic approach to determine 
differentially expressed genes in vitro and in vivo. A role in meningitis may also be found for 
the DHH subfamily 1 proteins, as SP2205 was previously found to be attenuated in a GAF 
meningitis screen (40). 
In this thesis, we observed strain-specificity during several studies, most prominently, PpmA, 
SP1298 and SP2205, suggesting that the role(s) of these proteins may be “turned on/turned 
off” depending on strain. In line with our results, an increasing number of other studies 
have also demonstrated differences between various pneumococcal strains (7,18,25,26,32). 
Hendriksen et al. demonstrated a strain-specific role in the global gene expression and 
development of bacteremia in mice with PsaR, a transcriptional regulator responsive to 
Mn2+ (25). Another study investigating how Ply affects the capacity of pneumococci to 
infect the upper and lower respiratory tract of mice found that differences in pneumococcal 
capsule type had significant effects on pneumococcal infection of the nasopharynx, trachea, 
and lungs. In addition, the researchers noted that the combination of capsule type and 
genetic background was important, and that the influence of this combination varied with 
the site of infection (32). Each pneumococcal strain has different characteristics based on 
its genetic background, such as expression of capsule and/or the presence and expression 
(or lack of expression) of other virulence genes that (in)directly contribute to virulence 
phenotypes. The pneumococcal pilus, a structural aspect not found on all pneumococcal 
strains, is one factor that contributes to adherence and virulence as well as stimulating 
the host inflammatory response (4). Strain-specificity may complicate direct conclusions to 
be made about potential pneumococcal antigens as examination of the cellular processes 
involved in virulence becomes complex. Perhaps S. pneumoniae strains exploit different 
host antigens, a characteristic that may (partly) explain whether or not a strain is capable of 
colonizing a host or establishing a more serious infection?
Pneumococcal Vaccination
During the last decade, researchers have focused their attention on the possibility of 
pneumococcal proteins as vaccine targets to elicit an improved, broader protective 
immune response in comparison to the polysaccharide vaccines. The most important 
criteria that potential novel vaccine targets need to meet are: expressed at the surface of 
the pneumococcus, present on a significant proportion of virulent pneumococci (if not all 
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pneumococci), expressed in vivo, no cross-reactivity to other species or human antibodies, 
immunogenic, and non-toxic. In addition, an inexpensive production process and stability 
of storage would be beneficial, especially for developing countries.
In Chapter 5, we showed that (the recombinant forms of) the two DHH subfamily 1 
proteins, SP1298 and SP2205, were able to elicit protection against pneumococcal disease 
in mice when administered together during vaccination, whereas little to no protection 
was observed when either recombinant protein was administered singly (Chapter 5). We 
speculate that a greater level of protection was observed with both proteins since they 
belong to the same superfamily of PDE. While their cellular localization and molecular 
function(s) remain unknown at present, perhaps the function(s) of these two proteins 
complement each other as one may be more important for adherence, and the other for 
invasive disease. In theory, a combination of such proteins could provide protection against 
both carriage and disease. 
Previous studies have indicated that protection against pneumococcal disease using a 
combination of proteins from the same functional family is enhanced when compared to 
just one of the proteins alone. This has been observed with combinations such as PspA and 
PspC which belong to the choline-binding protein family (10,43) and the lipoprotein iron 
transporters PiuA and PiaA (8). In addition, upon immunization with PhtB and PhtE, two 
of the four proteins belonging to the pneumococcal histidine triad protein (Pht) family, 
mice survived significantly longer than after single immunization (24,43). Ogunniyi et al. 
showed that complement deposition on the surface of a mutant lacking all 4 Pht proteins 
(PhtA, PhtB, PhtD, and PhtE) was significantly increased compared to its respective wild-
type (44), which would suggest a drastic reduction in pneumococcal disease if all four 
Pht proteins were used together in an immunization scheme. To our knowledge, this 
experiment has yet to be performed. Our results here have shown that the protective value 
of the two DHH subfamily 1 proteins make them potential candidates as components in a 
future multicomponent protein vaccine.
Pneumococcal diaGnosis
In addition to the necessity for an alternative vaccine, detection of pneumococcal infection 
by use of current diagnostic techniques is in drastic need of an update. Standard protocol 
involves time-consuming laboratory checks requiring skillful knowledge, yet results are still 
not accurate or definitive for a proper diagnosis. Limitations of existing techniques, such 
as low sensitivity and specificity, and cross reactions with other streptococcal species, allow 
for improper treatment, thus, use of antibiotics increases as broad-spectrum antibiotics are 
recommended in case the causative pathogen is unknown. Improvement of diagnostic tools 
would help to reduce worldwide morbidity and mortality of pneumococcal infections, and 
possibly reduce the rise of antibiotic-resistance among bacteria.
In addition to the traditional routine microbiological tests used to detect S. pneumoniae, 
detection of pneumococcal antigen in urine samples has become a non-invasive tool used 
for diagnosis. BinaxNOW detects C-polysaccharide antigen in urine and has shown to be 
more sensitive than blood culture. With the use of this assay, more cases of pneumococcal 
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pneumonia have been identified than by use of traditional means (1,22,34,51). However, 
the assay lacks specificity as it can give positive results in healthy children colonized by 
pneumococci or possibly cross-react with some α–hemolytic oral streptococci (34,53). This 
type of test has led to a shift in the approach used for diagnosis of pneumococcal infection, 
from C-polysaccharide antigen to pneumococcal proteins, which can also be found in the 
urine of healthy children carriers and in patients recovering from pneumococcal infections 
(21). The first such example is an ELISA test that can detect the well-known antigen 
pneumolysin (Ply) in urine, and which has been shown to be highly specific for children 
with pneumococcal diseases (13,19). 
The diagnostic potential of PpmA was assessed in a western blot assay we developed 
for the direct detection of this protein in urine samples from children with pneumococcal 
infection ((20) and Chapter 6). The sensitivity and specificity of the PpmA-based western 
blot assay were 66.7% and 100%, respectively. Importantly, no PpmA was detected in the 
urine of 12 healthy children using this technique. As western blot assays can take more 
than a day to perform, this technique cannot be considered an improvement of speed for 
clinical diagnosis. Also, the sensitivity of the assay could have been higher to allow for more 
accurate results. Hopefully though, our research will serve as a tool for the evaluation of the 
presence of other pneumococcal antigens in urine samples, which can later be extrapolated 
to other rapid diagnostic tests, such as ELISA or immunochromatographic assays. 
State-of-the art methods such as matrix-assisted laser desorption ionization time-of-flight 
mass spectrometry (MALTI-TOF MS) (48,49), RT-PCR (23), Q-PCR (54), and microarray 
analysis (6) are being applied for detection of bacteria in nasopharynx, blood, serum, urine, 
sputum, even in colonies obtained through culture; however, optimization of these techniques 
is still necessary. Use of MALDI-TOF MS is promising as cost and time are reduced, yet the 
differentiation between S. pneumoniae and closely related viridans species such as S. mitis 
remains difficult (48,49). PCR while sensitive has a similar drawback, namely finding the 
right target to use to distinguish between S. pneumoniae and other commensal bacteria. 
Researchers are also investigating the expression patterns of both the host and the 
bacterial pathogens such as S. pneumoniae during infection to obtain more accurate results 
for better diagnosis. Ramilo et al. demonstrated that blood leukocyte gene expression 
patterns can be used to distinguish patients with an acute infection of S. pneumoniae from 
influenza A virus, E. coli, and Staphylococcus aureus (46). In another study, promising 
results were obtained comparing host lung gene expression patterns of mice, as blinded 
researchers were able to distinguish between three different lower respiratory pathogens, 
with distinctive patterns seen already after 2 h infection (17). The drawback of these two 
studies comparing organisms from different pathologic classes is that it may be impossible 
to know whether the effects observed are species-specific or if the effects are due to the 
different classes of bacteria examined. Future experiments comparing other members of 
the same class will make generalizations of gene expression patterns clearer. It is expected 
that in the near future researchers will explore the differences in patterns of gene expression 
of pneumococci during carriage and pneumonia, as it has been shown that different 
quantities of capsular polysaccharide differ between virulent (IPD) and avirulent (carriage) 
pneumococcal phenotypes (33). 
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concludinG remarks 
Taken together, the data described in this thesis provide insight into several new 
pneumococcal (virulence) factors with respect to their role in the molecular pathogenesis 
of S. pneumoniae. The results obtained with the DHH subfamily 1 proteins are of special 
interest and exemplify the phrase “two heads are better than one.” Although many additional 
questions still remain regarding the exact role(s) of the factors studied in this thesis, the data 
described here have contributed to the identification of interesting factors of S. pneumoniae 
which could function as targets for vaccination and/or diagnostics.
As the majority of the data collected in this thesis was gained through use of in vivo 
mouse models, it is important to bear in mind that, with the exception of non-human 
primates, the only natural host of this pneumococcal pathogen is the human (36,39). This 
must be taken into account when translating any experimental animal findings to the human 
physiological setting. For three of our four in vivo models, we infected via the intranasal 
route which is considered the natural route of infection for this pathogen. However, other 
researchers have used intravenous, intraperitoneal, intratracheal, or intratympanical routes 
to study bacteremia, pneumonia, and otitis media. Furthermore, it is evident from the data 
described here that in order to come to a general conclusion about the role(s) (virulence) 
factors may play, experiments using more than one pneumococcal isolate are necessary.
The ideal protection strategy against pneumococcal infection would be to target 
all pneumococcal serotypes while eliciting an immunological response that is not age-
restricted. Theoretically, enhanced protection against colonization and infection with S. 
pneumoniae may be expected when a combination of proteins, perhaps families of proteins 
or combination of families of proteins, with distinct roles in virulence are used. However, 
it is crucial that pneumococcal protein vaccine candidates are compared in various 
combinations using different animal strains and multiple challenge strains to obtain the 
best protein vaccine formulation before being tested in human clinical trials.
future deVeloPments
The molecular details of the interplay between S. pneumoniae and the host mucosa are 
still incompletely understood. A better understanding is needed in order to fully utilize 
the potential of virulence factors as vaccine targets or as use for therapeutic measures. Use 
of other techniques such as X-ray crystallography, functional studies, and sequence and 
bioinformatics analysis, would greatly enhance our knowledge of these (virulence) factors. 
If the molecular pathogenesis is known, inhibitors of enzymes or inhibitors of protein-
protein interactions could be used for the development of new drug targets.
Different vaccine approaches may improve and/or increase protection of the current 
conjugate vaccines (39). As pneumococcal disease begins with colonization of the 
nasopharynx, one circulating concept is vaccinating against pneumococcal carriage rather 
than against invasive disease with a select number of serotypes known to be involved in 
colonization. In this respect, vaccination against carriage would mean that there would 
be a smaller population of carriers in whom colonization could progress to invasive 
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disease, thus reducing pneumococcal carriage and enhancing herd immunity. However 
as with conjugate vaccines, vaccine serotypes are likely to be replaced with non-vaccine 
serotypes. Therefore, the total number of pneumococcal carriers will not change, only the 
composition of the carried pneumococcal population would change; thus, no real difference 
compared to the current situation. Alternatively, the conjugate vaccine could be modified 
or supplemented with a conserved pneumococcal protein as the carrier. A study conducted 
using recombinant PspA1 conjugated to capsular polysaccharide (PS) serotype 23F (rPspA1-
PS23F) demonstrated protection in immunized mice which was significantly higher than 
non-immunized animals, or animals immunized with antigen alone or by co-administration 
(16). Another alternative is the use of a killed, non-encapsulated pneumococci (whole cell 
antigen) vaccine in which a large number of pneumococcal antigens would be presented at 
once generating an increased immune response (30,37). 
The future of improved diagnostic tools may lie within several areas, such as proteomic 
and genomic technologies to identify new markers for diagnosis and new technologies 
for specimen processing, marker detection and typing. Existing assays must be carefully 
optimized to detect pneumococcal disease more accurately. In the future, diagnostic 
techniques should ideally not rely heavily on the culturing of viable organisms, should have 
high rates of specificity and sensitivity, and outcome of results should not be hampered by 
prior antibiotic treatment. Implementation of standard protocol for using a combination of 
assays in parallel for precise detection could be considered. Regardless of the final approach, 
it is clear that future development is focused on ASSURED (affordable, sensitive, specific, 
user-friendly, rapid, equipment-free, delivered to those who need it) tests (53). 
Given the worldwide morbidity and mortality caused by S. pneumoniae surely a solution 
must exist to decrease the incidence of carriage and IPD of this pathogen. While a “cure-all” 
may be possible in the distant future, the question for the present still remains… what are 
the possibilities now?
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Streptococcus pneumoniae, ook wel pneumokok genoemd, wordt veelvuldig gevonden 
in de nasofarynx (een specifiek deel van de neus-keelholte, daar waar de neus overgaat 
in de keel) van zijn menselijke gastheer. In gezonde mensen verloopt dit dragerschap 
zonder enige symptomen, maar bij vatbare personen kan deze bacterie ziekte veroorzaken 
wanneer hij het middenoor, de longen, het bloed en de hersenen infiltreert. Een belangrijke 
virulentiefactor van de pneumokok is het polysaccharidekapsel, dat onderverdeeld wordt 
in zogenaamde serotypes op basis van aanwezige polysaccharides (suikers). De huidige 
vaccinatie strategie is gericht tegen deze kapselpolysaccharides, en wel die van de meest 
voorkomende serotypes. Hoewel deze vaccins effectief zijn, beschermen ze dus slechts 
tegen een fractie van de meer dan 90 verschillende bekende serotypes. Dit leidt ertoe dat 
er een verschuiving plaatsvindt in de populatie bacteriën die ziektes veroorzaakt, en wel 
van de serotypes waartegen het vaccin beschermt naar serotypes die niet in het vaccin 
zitten. Gedetailleerde kennis van de pathogenese van de pneumokok is onmisbaar voor de 
bestrijding van de ziekte, voor de ontwikkeling van betere vaccins, en voor een efficiënte en 
accurate diagnose van een pneumokokkeninfectie. Al meer dan een decennium gebruiken 
onderzoeksgroepen verschillende genoomgebaseerde strategieën om pneumokokken 
(virulentie) factoren te identificeren die zouden kunnen dienen als nieuwe doelwitten voor 
therapie, preventie en/of diagnostiek. In dit proefschrift werden verschillende eiwitten 
onderzocht met betrekking tot 1) hun bijdrage aan de pathogenese van de pneumokok, 2) 
hun beschermende potentieel en, 3) hun diagnostische waarde.
PathoGenese Van Pneumocokken
Het samenspel tussen gastheer en pathogeen tijdens infectie is complex en dynamisch, waarbij 
verschillende factoren van beide kanten nodig zijn gedurende verschillende stadia van de 
infectie. Aanhechting van de pneumokok aan de epitheelcellen van de ademhalingswegen 
is cruciaal voor kolonisatie van de nasofarynx. Ondanks dat deze kolonisatie voornamelijk 
zonder symptomen verloopt, is het een voorwaarde voor latere ziekten, zoals ontsteking 
van het middenoor (OM), longontsteking en bacteriëmie. In dit proefschrift werden in vitro 
en in vivo experimenten uitgevoerd om de rol van een aantal geselecteerde eiwitten van de 
pneumokok in verschillende aspecten van het ziekteverloop te onderzoeken. Veel van deze 
eiwitten bleken een rol te spelen in de hechting en/of kolonisatie, en, in het geval van de 
DHH subfamilie 1 eiwitten, ook in middenoorontsteking, longontsteking en bacteriëmie.
De samenstelling van het oppervlak van de pneumokok speelt een belangrijke rol tijdens de 
verschillende stadia van infectie. Peptidyl-prolyl isomerasen (PPIases) zijn veel voorkomende 
foldases, die cis-trans conformatie veranderingen in de Xaa-Pro verbindingen versnellen 
tijdens het vouwen van eiwitten. Het pneumokokgenoom bevat vier vermoedelijke PPIases, 
waarvan er twee geproduceerd worden als oppervlakte-geassocieerde lipoproteïnen: de 
streptokokken-lipoproteïne rotamase A (SlrA) en de vermeende proteinase maturation 
protein A (PpmA). Het bewijs dat PPIases bijdragen aan bacteriële virulentie groeit. 
151
Bijvoorbeeld, het macrofaag infectiviteit potentiator eiwit (Mip) van Legionella pneumophila 
blijkt betrokken te zijn bij het binnendringen van gastheercellen en intracellulaire 
vermeerdering (11,12), en na uitschakeling van het Mip-achtig eiwit BPSS1823 was het 
vermogen van Burkholderia pseudomallei om in cellen te overleven verminderd en was er 
een significante afname van virulentie in vivo (42). Eerdere studies naar SlrA toonden PPIase 
activiteit en een rol voor het eiwit tijdens kolonisatie, maar niet tijdens invasieve ziekte (27). 
Terwijl er geen PPIase activiteit of een andere enzymatische functie kon worden aangetoond 
voor PpmA (27), werd een toename in de overlevingstijd van muizen geïnfecteerd met 
een ppmA knockout mutant waargenomen in een longontstekingmodel (45). Door gebruik 
te maken van ppmA mutanten in drie verschillende pneumokokken stammen, hebben we 
voor PpmA een rol in de hechting en kolonisatie aangetoond, alhoewel dit verschilde per 
stam ((14) en hoofdstuk 2). Daarnaast zagen we dat PpmA, net als SlrA, een rol speelde in 
het ontsnappen aan het immuunsysteem, omdat PpmA-deficiënte stammen gemakkelijker 
werden opgenomen door humane polymorfonucleaire leukocyten (PMN’s) of door muis 
macrofagen dan wild-type stammen (14,27). Recentelijk werd de bijdrage van zowel SlrA 
en PpmA aan middenoorontsteking onderzocht. Het interessante was dat we wel significant 
verminderde virulentie zagen bij de pneumokok waarbij SlrA ontbrak, maar niet bij de 
PpmA mutant, terwijl het weghalen van beide eiwitten een additief effect had op de afname 
in virulentie (50). De bijdrage van PpmA aan kolonisatie en immuun evasie, hoewel stam-
specifiek, is waarschijnlijk indirect, vermoedelijk omdat PpmA op een of andere manier 
de samenstelling van het oppervlak wijzigt of het vouwen van adhesie factoren of andere 
eiwitten verandert, waardoor herkenning en opname door macrofagen wordt voorkomen. 
Verdere functionele studies zijn nodig om de exacte rol van PpmA te ontrafelen. 
PpmA is homoloog aan de parvulin familie, de kleinste bekende eiwitten met PPIase 
activiteit die een lagere relatieve activiteit hebben tegen biologische substraten vergeleken 
met de cyclophilins (b.v. SlrA) en FK506-bindende eiwitten (FKBP, b.v. Mip). Misschien is 
dit de reden waarom tot er nu toe nog geen PPIase activiteit is gedetecteerd voor PpmA, 
of misschien valt er niets te detecteren. Onlangs bleek dat het parvulin-achtig eiwit PsrA 
van Bacillus subtilis het post-translationale vouwen van geëxporteerde eiwitten kon 
katalyseren (31). Er is ook voor het eerst bewijs dat een pas ontdekt FKBP, BPSL0918 van B. 
pseudomallei, van essentieel belang is voor intracellulaire replicatie en in vivo virulentie van 
de ziekteverwekker, terwijl is aangetoond dat het geen PPIase activiteit bezit (41).
Het verwerven van essentiële mineralen en voedingsstoffen die nodig zijn voor bacteriële 
groei en overleving in vivo, en dus voor volledige virulentie, is noodzakelijk voor S. 
pneumoniae. Het pneumokok ABC transporteiwit voor vertakte-keten aminozuren (BCAAs) 
wordt gecodeerd door het livJHMGF locus. Onlangs toonden Basavanna et al. verminderde 
virulentie aan van livH en livHMGF mutanten in competitieve infectie modellen (i.e., wild-
type en mutant stammen gelijktijdig toegediend) voor zowel longontsteking als bacteriëmie, 
maar vonden geen verzwakking van een TIGR4 livHMGF mutant in een competitief 
kolonisatie model, 48 uur na de infectie (5). In hoofdstuk 3 onderzochten wij de bijdrage 
aan kolonisatie van de BCAA ABC-transporter Liv en een aantal andere genen waarvan 
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voorspeld is dat ze betrokken zijn bij BCAA transport of metabolisme, gebruik makend 
van twee stammen met verschillende serotypes. Net als van Basavanna et al. (5), vonden 
wij geen verminderde kolonisatie voor de TIGR4 livJHMGF mutant in een enkelvoudige 
infectie 192 uur na toediening, wat het bewijs versterkt dat het liv-locus nauwelijks 
betrokken is bij kolonisatie (hoofdstuk 3). Vergelijkbaar met resultaten voor PpmA 
werden stam-specifieke fenotypes waargenomen tijdens kolonisatie met deletiemutanten 
livJHMGF, livJ (coderend voor het BCAA bindend eiwit), brnQ (BCAA drager-eiwit), en 
ilvE (BCAA aminotransferase) op tijdstippen later in infectie. De vermoedelijke regulator 
SP0743/SPD0647, voor het liv locus gelegen, bleek vereist te zijn voor optimale kolonisatie 
van beide geteste pneumokokken stammen, maar bleek niet de expressie van het liv locus 
te reguleren, noch een van de andere onderzochte BCAA-gerelateerde genen. Daarom is 
het waarschijnlijk dat de verminderde kolonisatie waargenomen met de SP0743/SPD0647 
mutant niet komt door veranderingen in de genexpressie van liv, maar door veranderde 
expressie van andere nog onbekende genen gereguleerd door SP0743/SPD0647.
Tijdens overdracht, kolonisatie en infectie, komt S. pneumoniae in zijn omgeving 
verschillende niveaus van kooldioxide (CO2) tegen. CO2 is belangrijk voor verschillende 
cellulaire processen en daarom ook van belang voor groei en overleving van de pneumokok. 
Koolzuur anhydrases (CA) zijn enzymen die de omkeerbare reactie CO2 + H2O ↔ HCO3- 
+ H+ katalyseren en aangezien HCO3- niet in staat is om te diffunderen door biologische 
membranen, zal vorming ervan het beschikbaar komen van intracellulair CO2 aanzienlijk 
vertragen. Wij hebben aangetoond dat het koolzuuranhydrase van de pneumokok (PCA) 
essentieel is voor in vitro groei in de omgevingslucht (CO2-arme omstandigheden), 
maar niet in in vivo muismodellen van kolonisatie en bacteriëmie ((9) en hoofdstuk 4). 
In vitro experimenten met microvasculaire endotheelcellen uit het menselijke brein 
(HBMEC) toonde aan dat het aantal pca mutanten dat teruggevonden werd na invasie 
was afgenomen. Dit zou kunnen betekenen dat PCA betrokken is bij de verspreiding van 
bacteriën in de gastheer, een proces dat hier niet onderzocht is. Of PCA een rol speelt in 
hersenvliesontsteking blijft onduidelijk, omdat wij dit molecuul niet bestudeerd hebben in 
experimentele meningitis modellen. Of misschien is de rol van PCA in in vitro groei onder 
CO2-arme omstandigheden en het vermogen van de bacterie om zich aan te kunnen passen 
aan nieuwe omgevingen van belang bij de overdracht tussen gastheren, aangezien zeer lage 
niveaus van CO2 worden gevonden buiten de gastheer. 
Onlangs is in ons laboratorium een techniek ontwikkeld, genaamd genomic array 
footprinting (GAF), waarmee genen van de pneumokok opgespoord kunnen worden 
die van cruciaal belang zijn tijdens het infectieproces (conditioneel essentiële genen). 
Door GAF toe te passen op verschillende in vivo infectie modellen zijn er vele genen 
geïdentificeerd die tijdens de verschillende fasen van het infectieproces van belang zijn 
voor overleving van de bacterie, waaronder twee zogenaamde DHH subfamilie 1 eiwitten, 
SP1298 en SP2205 (28,29,40). Deze twee geconserveerde eiwitten met een vooralsnog 
onbekende functie zijn geclassificeerd als DHH subfamilie 1 eiwitten in het genoom van de 
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pneumokok. DHH-familie eiwitten behoren tot de superfamilie van phosphoesterases en 
zijn zo genoemd om hun karakteristieke aminozuur patroon, Asp-His-His (DHH), gelegen 
in het geconserveerde N-terminale motief (2).
Een diepgaand onderzoek is uitgevoerd, waar enkele en dubbele deletie mutanten in 
drie verschillende pneumokokken stammen werden getest in vier verschillende infectie-
muismodellen welke belangrijke fasen van het pneumokok ziektebeeld vertegenwoordigen 
((15) en hoofdstuk 5). Zoals voor de meeste van de andere eiwitten die onderzocht zijn in 
dit proefschrift, waren we in staat om een  rol voor SP1298 en SP2205 aan te tonen in de 
eerste fase van een pneumokokkeninfectie, hechting en kolonisatie. Bovendien werd een 
significante vermindering van de hoeveelheid bacteriën in het middenoor waargenomen 
in het otitis media model. Daarnaast bleken de twee DHH subfamilie 1 eiwitten een rol te 
spelen bij invasieve ziekte, aangezien pneumokokken waar de genen coderend voor SP1298 
of SP2205 verwijderd waren verzwakt waren in de longen en het bloed van muizen. Niet 
alleen stam-specifieke fenotypes werden waargenomen bij alle infectie-modellen, maar 
ook locatie-specifieke fenotypes. Met name de SP2205 mutant was net zo virulent als wild-
type in de longen en het bloed van muizen, maar was verzwakt in de nasofarynx en het 
middenoor van muizen. In alle gevallen had deletie van beide genen een additief effect 
omdat het niveau van verzwakking hoger was dan bij deletie van een enkel gen. Ook andere 
virulentie studies die gebruik maakten van eiwitfamilies, zoals de pneumococcal histidine 
triad eiwit (Pht) familie, de choline-bindende eiwitten PspA en PspC, en de lipoproteïnen 
SlrA en PpmA, hebben aangetoond dat wanneer alle gezinsleden werden verwijderd uit 
een stam de virulentie meer afnamdan wanneer slechts een lid verwijderd werd (3,44,50).
Terwijl de rollen voor beide DHH eiwitten in de virulentie van de pneumokok 
evident zijn, moet hun exacte werkingsmechanisme en functie nog worden opgehelderd. 
SP1298 is naar verwachting een cytoplasmatisch eiwit, waardoor het onwaarschijnlijk is 
dat het zelf een directe rol speelt bij hechting, terwijl SP2205 direct kan fungeren als een 
hechtingsmolecuul omdat het voorspeld is dat het voorkomt op het oppervlak. Eiwitten 
met DHH-domeinen fungeren meestal als fosfatasen of fosfodiësterasen (PDE) (2), zoals 
is aangetoond voor enkele van de best gekarakteriseerde DHH eiwitten, onder andere RecJ 
van Escherichia coli (exonucleaseactiviteit) (35,52), YtqI van B. subtilis (oligoribonuclease 
en 3’-phosphoadenosine-5’-fosfaat (PAP) fosfatasenactiviteit) (38), en een ander B. subtilis 
eiwit, YybT (PDE-activiteit) (47). We kunnen ons voorstellen dat SP1298 en de SP2205 ook 
een soortgelijke PDE activiteit hebben wat daardoor mogelijk hun werkingsmechanisme 
is, maar dit moet nog worden bevestigd. Verdere experimenten zijn nodig om hun 
cellulaire lokalisatie te bepalen met behulp van FACS, om een mogelijke rol in complement 
resistentie en immuunevasie vast te stellen, en om hun functionaliteit te karakteriseren 
door differentieel tot expressie komende genen in vitro en in vivo vast te stellen met behulp 
van proteomics en transcriptomics technieken. Een rol in meningitis kan misschien ook 
worden gevonden voor de DHH subfamilie 1 eiwitten, aangezien SP2205 eerder gevonden 
is in een studie waarbij GAF is toegepast op een konijnen meningitis model (40).
In dit proefschrift zagen we stam-specificiteit tijdens verschillende studies, en dit was het 
meest duidelijk voor PpmA, SP1298 en de SP2205, wat suggereert dat de rol(len) van deze 
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eiwitten kunnen worden “ingeschakeld/uitgeschakeld” afhankelijk van de stam. In lijn met 
onze resultaten hebben een toenemend aantal andere studies ook verschillen aangetoond 
tussen verscheidene pneumokokkenstammen (7,18,25,26,32). Hendriksen et al. toonden 
een stam-specifieke rol aan voor de transcriptionele regulator PsaR, zowel wat betreft de 
genen die gereguleerd worden door PsaR, als voor ontwikkeling van bacteriëmie in muizen 
(25). In een andere studie, waarbij onderzocht werd wat de invloed van pneumolysine (Ply) 
is op de capaciteit van de pneumokok om de bovenste en onderste luchtwegen van muizen te 
infecteren, bleek dat een verschil in kapsel serotype een significantgevolg had voor infectie 
met pneumokokken in de nasofarynx, de luchtpijp en de longen. Daarnaast merkten de 
onderzoekers op dat de combinatie van kapsel type en genetische achtergrond van belang 
was, en dat de invloed van deze combinatie varieerde met de locatie van de infectie (32). 
Elke pneumokokken stam heeft verschillende eigenschappen op basis van zijn genetische 
achtergrond, zoals de expressie van het kapsel en/of de aanwezigheid en expressie (of gebrek 
aan expressie) van andere virulentie genen die (in)direct bijdragen aan virulente fenotypes. 
De pilus van de pneumokok, een haarachtige structuur op het oppervlak die niet alle 
pneumokokstammen hebben, is een factor die bijdraagt  aan de aanhechting en virulentie, 
alsmede aan het stimuleren van de gastheer ontstekingsreactie (4). Stam-specificiteit kan 
het trekken van eenduidige conclusies over mogelijke pneumokok antigenen bemoeilijken 
omdat het analyseren van cellulaire processen betrokken bij virulentie complex wordt. 
Misschien gebruiken S. pneumoniae stammen verschillende gastheer antigenen, een 
kenmerk dat (deels) kan zou kunnen verklaren waarom een stam al dan niet in staat is om 
een  gastheer te koloniseren of over te gaan in een meer ernstige infectie?
Vaccinatie teGen Pneumokokken
Gedurende de afgelopen tien jaar hebben onderzoekers hun aandacht gericht op de 
mogelijkheid om eiwitten van de pneumokok te gebruiken voor vaccinatie om daarmee 
een betere en bredere beschermende immuunreactie op te wekken in vergelijking met 
polysaccharide vaccins. De belangrijkste criteria waar een potentieel nieuw vaccindoelwit 
aan moet voldoen zijn: komt tot expressie op het oppervlak van de pneumokok, aanwezig op 
een groot deel van de virulente pneumokokken (zo niet op alle pneumokokken), komt tot 
expressie in vivo, geen gelijkenis met andere soorten of menselijke factoren, immunogeen 
en niet giftig. Bovendien zijn een goedkoop productieproces en de stabiliteit tijdens opslag 
bevorderlijk, vooral voor in ontwikkelingslanden.
In hoofdstuk 5 laten we zien dat (de recombinante vormen van) de twee DHH 
subfamilie 1 eiwitten SP1298 en SP2205 in staat waren om bescherming te bieden tegen 
pneumokokkeninfectie in muizen wanneer ze tegelijk werden toegediend tijdens vaccinatie, 
terwijl weinig tot geen bescherming kon worden waargenomen wanneer een van beide 
recombinante eiwitten afzonderlijk werd toegediend. We speculeren dat een hoger niveau 
van bescherming met beide eiwitten werd waargenomen, omdat ze behoren tot dezelfde 
superfamilie van PDE. Hoewel hun cellulaire lokalisatie en moleculaire functie(s) op dit 
moment nog onbekend zijn, zouden de functie(s) van deze twee eiwitten elkaar aan kunnen 
vullen, waarbij de één belangrijker is voor hechting en de andere voor invasieve ziekte. In 
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theorie zou een combinatie van dergelijke eiwitten bescherming kunnen bieden tegen zowel 
overdracht als ziekte.
Eerdere studies hebben laten zien dat de bescherming tegen pneumokokkenziekte 
verbeterd kan worden door het geven van een combinatie van eiwitten uit dezelfde functionele 
familie in vergelijking met slechts een van de eiwitten alleen. Dit is waargenomen voor 
combinaties zoals PspA en PspC behorende tot de choline-bindende eiwit familie (10,43) 
en de lipoproteïnen PiuA en PiaA betrokken bij ijzer transport (8). Daarnaast overleefden 
muizen beduidend langer na immunisatie met PhtB en PhtE samen, twee van de vier eiwitten 
die behoren tot de Pht familie, dan na immunisatie met een van de twee (24,43). Ogunniyi 
et al. toonden aan dat complement depositie op het oppervlak van een mutant die alle 4 
Pht eiwitten (PhtA, PhtB, PhtD en PhtE) miste significant was toegenomen ten opzichte 
van de wild-type stam (44). Dit zou kunnen leiden tot een drastische vermindering van de 
pneumokokkeninfecties als alle vier Pht eiwitten samen worden gebruikt in een immunisatie 
schema, maar voor zover wij weten moet dit experiment nog worden uitgevoerd. Onze 
resultaten laten duidelijk het beschermende potentieel van de twee DHH subfamilie 1 
eiwitten zien, waardoor ze als mogelijke kandidaten voor toekomstige multicomponenten-
eiwitvaccins gezien kunnen worden.
diaGnose Van Pneumokokken
Naast de noodzaak voor een alternatief vaccin is er drastisch behoefte aan vernieuwing 
van de huidige diagnostische technieken voor de detectie van pneumokokkeninfecties. 
De standaard protocollen vergen tijdrovende laboratorium controles die specifieke kennis 
vereisen, terwijl de resultaten dan nog niet nauwkeurig of definitief genoeg zijn voor een 
juiste diagnose. Beperkingen van de bestaande technieken, zoals een lage gevoeligheid 
en specificiteit, en kruisreacties met andere soorten streptokokken, resulteren in onjuiste 
behandeling, waardoor het gebruik van antibiotica toe neemt omdat breed-spectrum 
antibiotica worden aanbevolen in het geval de causale ziekteverwekker onbekend is. 
Verbetering van diagnostische middelen zou wereldwijd helpen om morbiditeit en 
mortaliteit van pneumokokkeninfecties te verminderen, en mogelijk de toename van 
antibiotica-resistentie bij bacteriën te reduceren.
Naast de traditionele routine microbiologische tests die worden gebruikt om S. 
pneumoniae te detecteren, is het aantonen van pneumokokken antigeen in urine monsters 
uitgegroeid tot een niet-invasief instrument dat wordt gebruikt voor de diagnose. 
BinaxNOW detecteert het C-polysaccharide-antigeen in de urine en is aangetoond 
gevoeliger te zijn dan tests in bloed culturen. Met het gebruik van deze test zijn meer 
gevallen van pneumokokken longontstekingen geïdentificeerd dan met het gebruik van 
traditionele middelen (1,22,34,51). Echter, de test mist specificiteit omdat het positieve 
resultaten geeft bij gezonde kinderen die gekoloniseerd zijn door pneumokokken, of 
eventueel kruis-reageert met orale α-hemolytische streptokokken (34,53). Dit type test 
heeft geleid tot een verschuiving in de aanpak om een pneumokokinfectie te diagnosticeren 
van het C-polysaccharide antigeen naar de pneumokok eiwitten, die ook te vinden zijn 
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in de urine van gezonde kinderen die dragers zijn en bij patiënten die herstellen van een 
pneumokokkeninfectie (21). Het eerste voorbeeld hiervan is een ELISA-test die het bekende 
antigeen pneumolysine (Ply) kan detecteren in urine. Het is aangetoond dat deze test zeer 
specifiek ziekte veroorzaakt door pneumokokken kan aantonen bij kinderen (13,19).
Wij hebben het diagnostisch vermogen van PpmA onderzocht met een western blot 
test ontwikkeld voor de directe detectie van dit eiwit in urine monsters van kinderen 
met pneumokokkeninfecties ((20) en hoofdstuk 6). De sensitiviteit en specificiteit van 
deze western blot assay waren respectievelijk 66,7% en 100%. Belangrijk is dat met deze 
techniek geen PpmA gedetecteerd werd in de urine van 12 gezonde kinderen. Omdat het 
uitvoeren van western blot assays langer dan een dag in beslag neemt, kan deze techniek 
niet worden beschouwd als een verbetering in de snelheid voor klinische diagnose. 
Ook zou de gevoeligheid van de test hoger kunnen om te zorgen voor meer accurate 
resultaten. Toch kan ons onderzoek hopelijk dienen als een middel voor de beoordeling 
van de aanwezigheid van andere pneumokokken antigenen in urine monsters, die later 
kunnen worden geëxtrapoleerd naar andere, snelle diagnostische tests, zoals ELISA of 
immunochromatografische assays.
State-of-the-art methoden, zoals matrix-assisted laser desorption ionisation time-
of-flight mass spectrometry (Malti-TOF-MS) (48,49), RT-PCR (23), Q-PCR (54), en 
microarray analyse (6) worden reeds toegepast voor de detectie van bacteriën in de 
nasofarynx, bloed, serum, urine, sputum, en zelfs in kolonies verkregen door middel van 
cultuur; maar optimalisatie van deze technieken is nog steeds noodzakelijk. Het gebruik van 
MALDI-TOF MS is veelbelovend daar kosten en tijd omlaag gaan, maar de differentiatie 
tussen S. pneumoniae en de nauw verwante viridans soorten zoals S. mitis blijft moeilijk 
(48,49). PCR, hoewel gevoelig, heeft een soortgelijk nadeel, namelijk het vinden van de 
juiste DNA regio waarmee onderscheid gemaakt kan worden tussen S. pneumoniae en 
andere commensale bacteriën.
Wetenschappers onderzoeken ook de expressie patronen van zowel bacteriële 
ziekteverwekkers zoals S. pneumoniae als de gastheer tijdens infectie, om tot nauwkeurigere 
resultaten te komen voor een betere diagnose. Ramilo et al. toonden aan dat genexpressie 
patronen van bloed leukocyten kunnen worden gebruikt om onderscheid te maken tussen 
patiënten met een acute infectie van S. pneumoniae en die met een influenza A-virus, E. coli 
en Staphylococcus aureus infectie (46). In een andere studie werden veelbelovende resultaten 
verkregen met long genexpressie patronen van gastheer muizen, omdat onderzoekers blind 
in staat waren om onderscheid te maken tussen drie verschillende pathogenen van de lagere 
luchtwegen, met al duidelijk verschillende patronen twee uur na infectie (17). Het nadeel van 
deze twee studies, waarbij organismen uit verschillende pathologische klassen vergeleken 
zijn, is dat het misschien niet mogelijk is om te weten of de waargenomen effecten soort-
specifiek zijn of dat de effecten te wijten zijn aan de verschillende klassen van de onderzochte 
bacteriën. Toekomstige experimenten die soorten uit dezelfde klasse vergelijken zullen 
generalisaties van genexpressie patronen duidelijker maken. De verwachting is dat in de 
nabije toekomst onderzoekers de verschillen in genexpressiepatronen van pneumokokken 
gaan verkennen gedurende dragerschap en longontsteking, omdat is aangetoond dat 
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de hoeveelheden van de kapsel polysachariden verschillen tussen virulente (ziekte) en 
avirulente (drager) fenotypen van de pneumokok ( 33).
slotoPmerkinGen
Samenvattend, geven de data beschreven in dit proefschrift inzicht in een aantal nieuwe 
(virulentie) factoren van de pneumokok met betrekking tot hun rol in de moleculaire 
pathogenese van S. pneumoniae. De resultaten verkregen met de DHH subfamilie 1 
eiwitten zijn van opmerkelijk belang en illustreren de woorden “twee weten meer dan een.” 
Hoewel nog steeds veel aanvullende vragen blijven bestaan  over de precieze rol(len) van de 
factoren bestudeerd in dit proefschrift, hebben de beschreven resultaten bijgedragen aan 
het identificeren van interessante factoren van S. pneumoniae die als doelwit voor vaccinatie 
en/of diagnostiek kunnen fungeren. 
Aangezien het merendeel van de verzamelde gegevens in dit proefschrift werd 
verkregen door het gebruik van in vivo muismodellen, is het belangrijk te realiseren dat, 
met uitzondering van de niet-menselijke primaten, de enige natuurlijke gastheer van deze 
pneumokok pathogeen de mens is (36,39). Hiermee moet rekening worden gehouden bij het 
vertalen van alle proefdierbevindingen naar de menselijke fysiologische omgeving. In drie 
van onze vier in vivo modellen, besmetten we de muizen via de intranasale route omdat deze 
beschouwd wordt als de natuurlijke infectieroute voor deze ziekteverwekker. Echter, andere 
onderzoekers gebruikten intraveneuze, intraperitoneale, intratracheale of intratympanicale 
routes om bacteriëmie, longontsteking en middenoorontsteking te bestuderen. Bovendien 
blijkt duidelijk uit de resultaten die hier worden beschreven dat experimenten met meer 
dan één pneumokok-isolaat nodig zijn om te komen tot een algemene conclusie over de 
rol(len) die (virulentie) factoren kunnen spelen.
De ideale beschermingsstrategie tegen pneumokokkeninfectie zou zijn om alle 
serotypes als doel te hebben, terwijl een immunologische reactie ontlokt wordt die niet 
leeftijdsafhankelijk is. Theoretisch is een betere bescherming tegen kolonisatie en infectie 
met S. pneumoniae te verwachten bij gebruik van een combinatie van eiwitten, misschien 
wel een familie van eiwitten of een combinatie van families van eiwitten die verschillende 
rollen in virulentie hebben. Het is echter cruciaal dat kandidaat pneumokokkeneiwitten 
voor gebruik in vaccins worden vergeleken in verschillende combinaties in verschillende 
dierstammen en met verschillende pneumokokken stammen, om zo tot de beste eiwit-
vaccin formulering te komen voordat deze getest wordt in klinische proeven op mensen.
toekomstiGe ontWikkelinGen
De moleculaire details van het samenspel tussen S. pneumoniae en de gastheer zijn nog steeds 
niet volledig begrepen. Een beter inzicht is nodig om het potentieel van virulentie factoren 
voor gebruik in vaccins volledig te benutten of om deze te gebruiken voor therapeutische 
doeleinden. Gebruik van andere technieken, zoals X-ray kristallografie, functionele studies, 
en sequentie- en bioinformatische-analyse, zou onze kennis van deze (virulentie) factoren 
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enorm verbreden. Als de moleculaire pathogenese bekend is kunnen enzymremmers of 
remmers van eiwit-eiwit interacties worden gebruikt voor de ontwikkeling van nieuwe 
doelwitten voor medicijnen.
Verschillende vaccinstrategieën zouden kunnen leiden tot een verbetering en/of een 
toename in bescherming van de huidige conjugaat vaccins (39). Omdat pneumokokkenziekte 
begint met kolonisatie van de nasofarynx, is één van de circulerende ideeën om te vaccineren 
tegen het dragerschap van de pneumokok, in plaats van tegen invasieve ziekte, met een 
beperkt aantal serotypes waarvan bekend is dat ze betrokken zijn bij kolonisatie. In dit 
opzicht zou vaccinatie tegen dragerschap betekenen dat er een kleinere groep dragers is 
waarbij kolonisatie zou kunnen overgaan tot invasieve ziekte, wat leidt tot afname in de 
dragerschap van pneumokokken en het verbeteren van de immuniteit van de bevolking. 
Maar net als bij conjugaat vaccins, zullen vaccinserotypes waarschijnlijk worden vervangen 
door niet-vaccin serotypes. Daarom zal het totaal aantal dragers van pneumokokken 
niet veranderen, alleen de samenstelling van de meegedragen pneumokokkenbevolking; 
daarmee is er dus geen wezenlijk verschil ten opzichte van de huidige situatie. Als alternatief 
zou het conjugaat vaccin kunnen worden aangepast of aangevuld met een geconserveerd 
pneumokokkeneiwit als dragereiwit. Een studie gebruik makend van recombinant-PspA1 
geconjugeerd aan het serotype 23F kapsel polysaccharide (rPspA1-PS23F) liet significant 
hogere bescherming zien in muizen geïmmuniseerd met rPspA1-PS23F dan in niet-
geïmmuniseerde dieren of in dieren die geïmmuniseerd waren met het antigeen alleen of 
tijdens gelijktijdige toediening (16). Een ander alternatief is het gebruik van een dode, niet-
ingekapselde pneumokokken vaccin (bevat alle cel antigenen), waarin een groot aantal van 
de pneumokokken-antigenen in een keer gepresenteerd worden, leidend tot een verhoogde 
immuunreactie (30,37).
De toekomst van verbeterde diagnostische middelen kan in verschillende gebieden 
liggen, zoals proteoom- en genoomtechnologieën om nieuwe diagnostische markers te 
identificeren, en nieuwe technologieën voor de verwerking van monsters, marker detectie 
en typering. Bestaande tests moeten zorgvuldig worden geoptimaliseerd om ziekte 
veroorzaakt door pneumokokken nauwkeuriger op te kunnen sporen. In de toekomst 
zullen diagnostische technieken idealiter niet sterk afhankelijk moeten zijn van het kweken 
van levende organismen, moeten ze hoge specificiteit en gevoeligheid hebben, en mag de 
uitkomst van de resultaten niet worden gehinderd door eerdere behandeling met antibiotica. 
Implementatie van een standaard protocol voor het gelijktijdig gebruik van een combinatie 
van testen voor een nauwkeurige detectie zou kunnen worden overwogen. Ongeacht 
de uiteindelijke aanpak, is het duidelijk dat toekomstige ontwikkelingen gericht zijn op 
ASSURED (affordable, sensitive, specific, user-friendly, rapid, equipment-free, delivered to 
those who need it) testen: betaalbaar, gevoelig, specifiek, gebruiksvriendelijk, snel, zonder 
materiële benodigdheden, en geleverd aan diegenen die het nodig hebben (53).
Gezien de wereldwijde morbiditeit en mortaliteit veroorzaakt door S. pneumoniae 
moet er zeker een oplossing bestaan  om de incidentie van dragerschap en invasieve ziekte 
van deze ziekteverwekker te verminderen. Terwijl “cure-all” mogelijk kan zijn in de verre 
toekomst, luid de vraag voor het heden nog steeds... wat zijn de mogelijkheden nu?
159
references
1. Andreo, F., J. Dominguez, J. Ruiz, S. Blanco, E. Arellano, C. Prat, J. Morera, and V. Ausina. 2006. Impact of 
rapid urine antigen tests to determine the etiology of community-acquired pneumonia in adults. Respir. Med. 
100:884-891.
2. Aravind, L. and E. V. Koonin. 1998. A novel family of predicted phosphoesterases includes Drosophila prune 
protein and bacterial RecJ exonuclease. Trends Biochem. Sci. 23:17-19.
3. Balachandran, P., A. Brooks-Walter, A. Virolainen-Julkunen, S. K. Hollingshead, and D. E. Briles. 2002. Role of 
pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection 
against carriage of Streptococcus pneumoniae. Infect. Immun. 70:2526-2534.
4. Barocchi, M. A., J. Ries, X. Zogaj, C. Hemsley, B. Albiger, A. Kanth, S. Dahlberg, J. Fernebro, M. Moschioni, V. 
Masignani, K. Hultenby, A. R. Taddei, K. Beiter, F. Wartha, E. A. von, A. Covacci, D. W. Holden, S. Normark, R. 
Rappuoli, and B. Henriques-Normark. 2006. A pneumococcal pilus influences virulence and host inflammatory 
responses. Proc. Natl. Acad. Sci. U. S. A. 103:2857-2862.
5. Basavanna, S., S. Khandavilli, J. Yuste, J. M. Cohen, A. H. Hosie, A. J. Webb, G. H. Thomas, and J. S. Brown. 2009. 
Screening of Streptococcus pneumoniae ABC transporter mutants demonstrates that LivJHMGF, a branched-
chain amino acid ABC transporter, is necessary for disease pathogenesis. Infect. Immun. 77:3412-3423.
6. Bentley, S. D., D. M. Aanensen, A. Mavroidi, D. Saunders, E. Rabbinowitsch, M. Collins, K. Donohoe, D. Harris, 
L. Murphy, M. A. Quail, G. Samuel, I. C. Skovsted, M. S. Kaltoft, B. Barrell, P. R. Reeves, J. Parkhill, and B. G. 
Spratt. 2006. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS. 
Genet. 2:e31.
7. Blue, C. E. and T. J. Mitchell. 2003. Contribution of a response regulator to the virulence of Streptococcus 
pneumoniae is strain dependent. Infect. Immun. 71:4405-4413.
8. Brown, J. S., A. D. Ogunniyi, M. C. Woodrow, D. W. Holden, and J. C. Paton. 2001. Immunization with 
components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae 
infection. Infect. Immun. 69:6702-6706.
9. Burghout, P., H. J. Bootsma, T. G. Kloosterman, J. J. Bijlsma, C. E. de Jongh, O. P. Kuipers, and P. W. Hermans. 
2007. Search for genes essential for pneumococcal transformation: the RadA DNA repair protein plays a role in 
genomic recombination of donor DNA. J. Bacteriol. 189:6540-6550.
10. Cao, J., D. Chen, W. Xu, T. Chen, S. Xu, J. Luo, Q. Zhao, B. Liu, D. Wang, X. Zhang, Y. Shan, and Y. Yin. 2007. 
Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, 
PspC, and ClpP. Vaccine 25:4996-5005.
11. Cianciotto, N. P., B. I. Eisenstein, C. H. Mody, G. B. Toews, and N. C. Engleberg. 1989. A Legionella pneumophila 
gene encoding a species-specific surface protein potentiates initiation of intracellular infection. Infect. Immun. 
57:1255-1262.
12. Cianciotto, N. P. and B. S. Fields. 1992. Legionella pneumophila mip gene potentiates intracellular infection of 
protozoa and human macrophages. Proc. Natl. Acad. Sci. U. S. A. 89:5188-5191.
13. Cima-Cabal, M. D., F. J. Méndez, F. Vázquez, C. Aranaz, J. Rodríguez-Alvarez, J. M. García-García, A. Fleites, 
J. Martinez González-Río, L. Molinos, M. de Miquel, and J. R. de los Toyos. 2003. Immunodetection of 
pneumolysin in human urine by ELISA. J. Microbiol. Methods. 54:47-55.
14. Cron, L. E., H. J. Bootsma, N. Noske, P. Burghout, S. Hammerschmidt, and P. W. Hermans. 2009. Surface-
associated lipoprotein PpmA of Streptococcus pneumoniae is involved in colonization in a strain-specific 
manner. Microbiology. 155:2401-2410.
15. Cron, L. E., K. Stol, P. Burghout, S. S. van, E. R. Simonetti, H. J. Bootsma, and P. W. Hermans. 2011. Two DHH 
Subfamily 1 Proteins Contribute to Pneumococcal Virulence and Confer Protection against Pneumococcal 
Disease. Infect. Immun. 79:3697-3710.
16. Csordas, F. C., C. T. Perciani, M. Darrieux, V. M. Goncalves, J. Cabrera-Crespo, M. Takagi, M. E. Sbrogio-
Almeida, L. C. Leite, and M. M. Tanizaki. 2008. Protection induced by pneumococcal surface protein A (PspA) 
is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide. Vaccine 26:2925-2929.
17. Evans, S. E., M. J. Tuvim, J. Zhang, D. T. Larson, C. D. Garcia, S. Martinez-Pro, K. R. Coombes, and B. F. Dickey. 
2010. Host lung gene expression patterns predict infectious etiology in a mouse model of pneumonia. Respir. 
Res. 11:101.
18. Forbes, M. L., E. Horsey, N. L. Hiller, F. J. Buchinsky, J. D. Hayes, J. M. Compliment, T. Hillman, S. Ezzo, K. 
Shen, R. Keefe, K. Barbadora, J. C. Post, F. Z. Hu, and G. D. Ehrlich. 2008. Strain-specific virulence phenotypes 
of Streptococcus pneumoniae assessed using the Chinchilla laniger model of otitis media. PLoS. One. 3:e1969.
19. Garcia-Suárez, M. d. M., M. D. Cima-Cabal, R. Villaverde, E. Espinosa, M. Falguera, J. R. de los Toyos, F. Vázquez, 
and F. J. Méndez. 2007. Performance of a pneumolysin enzyme-linked immunosorbent assay for diagnosis of 
pneumococcal infections. J. Clin. Microbiol. 45:3549-3554.
160
nEdErLAndSE SAmEnvAttInG
8
20. García-Suárez, M. d. M., L. E. Cron, B. Súarez-Álvarez, R. Villaverde, I. González-Rodríguez, F. Vázquez, P. 
W. Hermans, and F. J. Méndez. 2009. Diagnostic detection of Streptococcus pneumoniae PpmA in urine. Clin. 
Microbiol. Infect. 15:443-453.
21. García-Suárez, M. d. M., F. Vázquez, and F. J. Méndez. 2006. Streptococcus pneumoniae virulence factors and 
their clinical impact: An update. Enferm. Infecc. Microbiol. Clin. 24:512-517.
22. Genne, D., H. H. Siegrist, and R. Lienhard. 2006. Enhancing the etiologic diagnosis of community-acquired 
pneumonia in adults using the urinary antigen assay (Binax NOW). Int. J. Infect. Dis. 10:124-128.
23. Greiner, O., P. J. Day, P. P. Bosshard, F. Imeri, M. Altwegg, and D. Nadal. 2001. Quantitative detection of 
Streptococcus pneumoniae in nasopharyngeal secretions by real-time PCR. J. Clin. Microbiol. 39:3129-3134.
24. Hamel, J., N. Charland, I. Pineau, C. Ouellet, S. Rioux, D. Martin, and B. R. Brodeur. 2004. Prevention of 
pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect. Immun. 72:2659-
2670.
25. Hendriksen, W. T., H. J. Bootsma, D. A. van, S. Estevao, O. P. Kuipers, G. R. de, and P. W. Hermans. 2009. Strain-
specific impact of PsaR of Streptococcus pneumoniae on global gene expression and virulence. Microbiology 
155:1569-1579.
26. Hendriksen, W. T., N. Silva, H. J. Bootsma, C. E. Blue, G. K. Paterson, A. R. Kerr, A. de Jong, O. P. Kuipers, P. 
W. Hermans, and T. J. Mitchell. 2007. Regulation of gene expression in Streptococcus pneumoniae by response 
regulator 09 is strain dependent. J. Bacteriol. 189:1382-1389.
27. Hermans, P. W., P. V. Adrian, C. Albert, S. Estevao, T. Hoogenboezem, I. H. Luijendijk, T. Kamphausen, and 
S. Hammerschmidt. 2006. The streptococcal lipoprotein rotamase A (SlrA) is a functional peptidyl-prolyl 
isomerase involved in pneumococcal colonization. J. Biol. Chem. 281:968-976.
28. Hermans, P. W. M., H. J. Bootsma, P. Burghout, J. J. Bijlsma, O. P. Kuipers, and T. G. Kloosterman. October 2008. 
New virulence factors of Streptococcus pneumoniae. The Netherlands patent PCT/NL2008/050191.
29. Hermans, P. W. M., H. J. Bootsma, P. Burghout, J. J. Bijlsma, O. P. Kuipers, and T. G. Kloosterman. October 2009. 
New virulence factors of Streptococcus pneumoniae. The Netherlands patent PCT/NL2009/050600.
30. Hogenesch, H., A. Dunham, B. Hansen, K. Anderson, J. F. Maisonneuve, and S. L. Hem. 2011. Formulation of a 
killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response. J. 
Immune. Based. Ther. Vaccines. 9:5.
31. Hyyrylainen, H. L., B. C. Marciniak, K. Dahncke, M. Pietiainen, P. Courtin, M. Vitikainen, R. Seppala, A. Otto, 
D. Becher, M. P. Chapot-Chartier, O. P. Kuipers, and V. P. Kontinen. 2010. Penicillin-binding protein folding 
is dependent on the PrsA peptidyl-prolyl cis-trans isomerase in Bacillus subtilis. Mol. Microbiol. 77:108-127.
32. Kadioglu, A., S. Taylor, F. Iannelli, G. Pozzi, T. J. Mitchell, and P. W. Andrew. 2002. Upper and lower respiratory 
tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule 
type. Infect. Immun. 70:2886-2890.
33. Kim, J. O. and J. N. Weiser. 1998. Association of intrastrain phase variation in quantity of capsular polysaccharide 
and teichoic acid with the virulence of Streptococcus pneumoniae. J. Infect. Dis. 177:368-377.
34. Klugman, K. P., S. A. Madhi, and W. C. Albrich. 2008. Novel approaches to the identification of Streptococcus 
pneumoniae as the cause of community-acquired pneumonia. Clin. Infect. Dis. 47 Suppl 3:S202-S206.
35. Lovett, S. T. and R. D. Kolodner. 1989. Identification and purification of a single-stranded-DNA-specific 
exonuclease encoded by the recJ gene of Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 86:2627-2631.
36. Lu, L., Z. Ma, T. S. Jokiranta, A. R. Whitney, F. R. DeLeo, and J. R. Zhang. 2008. Species-specific interaction of 
Streptococcus pneumoniae with human complement factor H. J. Immunol. 181:7138-7146.
37. Lu, Y. J., P. Yadav, J. D. Clements, S. Forte, A. Srivastava, C. M. Thompson, R. Seid, J. Look, M. Alderson, A. Tate, 
J. F. Maisonneuve, G. Robertson, P. W. Anderson, and R. Malley. 2010. Options for inactivation, adjuvant, and 
route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin. Vaccine 
Immunol. 17:1005-1012.
38. Mechold, U., G. Fang, S. Ngo, V. Ogryzko, and A. Danchin. 2007. YtqI from Bacillus subtilis has both 
oligoribonuclease and pAp-phosphatase activity. Nucleic Acids Res. 35:4552-4561.
39. Moffitt, K. L. and R. Malley. 2011. Next generation pneumococcal vaccines. Curr. Opin. Immunol. 23:407-413.
40. Molzen, T. E., P. Burghout, H. J. Bootsma, C. T. Brandt, C. E. van der Gaast-de Jongh, M. J. Eleveld, M. M. 
Verbeek, N. Frimodt-Moller, C. Ostergaard, and P. W. Hermans. 2011. Genome-Wide Identification of 
Streptococcus pneumoniae Genes Essential for Bacterial Replication during Experimental Meningitis. Infect. 
Immun. 79:288-297.
41. Norville, I. H., K. Breitbach, K. Eske-Pogodda, N. J. Harmer, M. Sarkar-Tyson, R. W. Titball, and I. Steinmetz. 
2011. A novel FK-506-binding-like protein that lacks peptidyl-prolyl isomerase activity is involved in 
intracellular infection and in vivo virulence of Burkholderia pseudomallei. Microbiology 157:2629-2638.
161
42. Norville, I. H., N. J. Harmer, S. V. Harding, G. Fischer, K. E. Keith, K. A. Brown, M. Sarkar-Tyson, and R. 
W. Titball. 2011. A Burkholderia pseudomallei Mip-like Protein has Rapamycin Inhibitable Peptidyl-Prolyl 
Isomerase Activity and has Pleiotropic Effects on Virulence. Infect. Immun. 
43. Ogunniyi, A. D., M. Grabowicz, D. E. Briles, J. Cook, and J. C. Paton. 2007. Development of a vaccine against 
invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. 
Infect. Immun. 75:350-357.
44. Ogunniyi, A. D., M. Grabowicz, L. K. Mahdi, J. Cook, D. L. Gordon, T. A. Sadlon, and J. C. Paton. 2009. 
Pneumococcal histidine triad proteins are regulated by the Zn2+-dependent repressor AdcR and inhibit 
complement deposition through the recruitment of complement factor H. FASEB J. 23:731-738.
45. Overweg, K., A. Kerr, M. Sluijter, M. H. Jackson, T. J. Mitchell, A. P. de Jong, G. R. de, and P. W. Hermans. 2000. 
The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with 
potential to elicit protective immune responses. Infect. Immun. 68:4180-4188.
46. Ramilo, O., W. Allman, W. Chung, A. Mejias, M. Ardura, C. Glaser, K. M. Wittkowski, B. Piqueras, J. Banchereau, 
A. K. Palucka, and D. Chaussabel. 2007. Gene expression patterns in blood leukocytes discriminate patients 
with acute infections. Blood. 109:2066-2077.
47. Rao, F., R. Y. See, D. Zhang, D. C. Toh, Q. Ji, and Z. X. Liang. 2010. YybT is a signaling protein that contains 
a cyclic dinucleotide phosphodiesterase domain and a GGDEF domain with ATPase activity. J. Biol. Chem. 
285:473-482.
48. Seng, P., J. M. Rolain, P. E. Fournier, S. B. La, M. Drancourt, and D. Raoult. 2010. MALDI-TOF-mass spectrometry 
applications in clinical microbiology. Future. Microbiol. 5:1733-1754.
49. Stevenson, L. G., S. K. Drake, and P. R. Murray. 2010. Rapid identification of bacteria in positive blood culture 
broths by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J. Clin. Microbiol. 
48:444-447.
50. Stol, K., S. van Selm, S. van den Berg, H. J. Bootsma, W. A. Blokx, K. Graamans, E. L. Tonnaer, and P. W. Hermans. 
2009. Development of a non-invasive murine infection model for acute otitis media. Microbiology 155:4135-
4144.
51. Stralin, K. and H. Holmberg. 2005. Usefulness of the Streptococcus pneumoniae urinary antigen test in the 
treatment of community-acquired pneumonia. Clin. Infect. Dis. 41:1209-1210.
52. Sutera, V. A., Jr., E. S. Han, L. A. Rajman, and S. T. Lovett. 1999. Mutational analysis of the RecJ exonuclease of 
Escherichia coli: identification of phosphoesterase motifs. J. Bacteriol. 181:6098-6102.
53. Vernet, G., S. Saha, C. Satzke, D. H. Burgess, M. Alderson, J. F. Maisonneuve, B. W. Beall, M. C. Steinhoff, and K. 
P. Klugman. 2011. Laboratory-based diagnosis of pneumococcal pneumonia: state of the art and unmet needs. 
Clin. Microbiol. Infect. 17 Suppl 3:1-13.
54. Yang, S., S. Lin, A. Khalil, C. Gaydos, E. Nuemberger, G. Juan, J. Hardick, J. G. Bartlett, P. G. Auwaerter, and R. E. 
Rothman. 2005. Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia 
in adult emergency department patients. J. Clin. Microbiol. 43:3221-3226.
162
dAnkwoord
8
dankWoord
Wow! I can’t believe that I am finally writing this… I thought this day would never come. It 
always seemed so far away. And who knew I would get my PhD, get married and have a baby all 
at the same time? I learned a lot about myself when I moved to The Netherlands to pursue a PhD. 
A side I never really knew. Living here and being a PhD student, I had to find so many ways 
to “keep my head above the water.” And just when I thought I might drown… I was always 
able to keep afloat. Whether the help came from one of my colleagues, friends, or family, 
someone was always there to lend a helping hand or a listening ear. That’s for sure! It took 
some time but I’ve found my swimming legs now.
The first person I need to thank is Eric Claassen, for without him and the chance meeting 
on a flight from London to Amsterdam, I never would have ended up in Peter Hermans’ 
lab in Nijmegen. 
A HUGE thank you to Peter Hermans for taking a chance on me and welcoming me into 
his lab. Your enthusiasm for research is “infectious” and inspiring to me. Thank you for all 
your advice and help throughout the years, especially at the very end.
The one person who I could not have done this without is my SUPER post-doc, 
Hester. HB, you are without a doubt meant to have been my mentor. You knew exactly 
how I needed to be taught and how to get things through to me… sometimes more than 
once. ;) Thank you soooo much for ALL your help with your mad scientific writing skills 
(like poetry), pipetting skills (fastest I’ve seen to date), and your advice (always on target 
and thought-provoking).
Elles, since the beginning you were always there for me. You were not just a colleague, 
but a friend as well. We worked some crazy experiments at all hours of the day and night for 
a couple of years. Those were the days... and I think we are both happy those days are behind 
us. You definitely taught me some tricks of the trade that helped me during my time here. I 
am so happy you are my paranimf.
Christa, thank you for always saying “yes, I would love to help you” whenever I needed 
your ultra-fast pipetting skills. I always had fun with you on mouse days. You are by far my 
favorite technician that is from Middelberg. ;) I am also happy that you agreed to be my 
paranimf. And thanks for always answering all my questions with the brutal truth about 
you-know-what.
I am also grateful to two post-docs who helped me, Peter Burghout and Saskia van 
Selm. Peter, you always amaze me about how much information you know on a subject. 
And, I could never have done the protein work without you. However, I’m still not happy 
that I would have to work for hours in the walk-in 4° C room to get my proteins; thanks 
for your black sweater… I don’t even know where it is now?? And Saskia- I thoroughly 
enjoyed working with you. I learned from you patience about taking your time to design 
your experiments. I also loved listening to you sing in the ML-II lab. I think you are the only 
other person than me who would turn up the radio so loud. 
Marilyn and Sofie, I am so grateful for you two girls and all your help with the DHH 
and BCAA mouse experiments that came at the end of my PhD. It was a lot we did!! You 
163
two were truly a blessing at a time when I needed it the most. It was a breath of fresh air and 
a pleasure to work with the both of you.
I did a lot of work and spent a lot of time at the Centraal Dierenlaboratorium (CDL) on 
campus over the years. I would like to acknowledge Claudia, Alex, Iris, Maikel, Bianca, and 
Connie for always helping me. I had a lot of mice that had to be ordered, taken care of and 
I needed a lot of time under the hood as well. Thank you for always being patient and kind 
to me and my team.
I would also like to extend a big thank you to Sven Hammerschmidt and Nadje Noske 
of Germany for their collaboration on my first article on PpmA. And also to Maria del Mar 
García-Suárez and F. J. Méndez in Spain for the PpmA urine paper. Thanks for all your hard 
work!
To the two Kim’s… You ladies are almost done as well. There is a light at the end of the 
tunnel. It’s shiny and bright!! And to Beatriz, my only other “buitenlander” PhD amiga at 
the time… I had a great time with you in Bern!
And to the PhD boys… Stefan, Daan, and Stan- I thank you for your friendship during 
our time together. It was about time we had some boys in the lab. I have a lot of great 
memories of the lab borreltjes or just working in the lab. Stefan, you were always there for 
me when I needed to vent or to be my personal TNT post. Thanks!! 
To the rest of the LKI/LKO lab past and present workers, it was a pleasure working or 
talking with you all during these last years….. Especially Marc E., thank you for your help 
when I needed it whether it was your pipetting skills or your vast computer knowledge. You 
and Christa were always willing to make the mutants for me. And beautiful ones they were!! 
To Bas, I would also like to express my gratitude for your help and positive energy you 
spread while you were with us in Nijmegen. Many thanks go to Ada for always arranging all 
the things that I needed during my time at the lab. And thanks to Angela who helped me 
out in the beginning with my questions dealing with statistics. And to Liesbeth, Marloes L., 
Jeroen M., Laurens, Blanca, and Frank- I am grateful for all the western blot help and tips 
when something didn’t go exactly just right.
And one final note to my fellow ML-II bacteria labmates… Thank you all for letting me 
play my “Mouse Fever” CDs over and over and over again. Lastly, I would like to thank all 
my "little helpers" whose lives were given in order to perform my experiments; for without 
them, this book would not exist nor be the same.
Aside from my colleagues, I could not have been able to get through this crazy period 
without the love and support of my friends and family. And I have a lot of people I would 
like to thank (so bear with me). I would first like to mention my Dutchies I met at Texas 
A&M, for without knowing them, I would never have met my husband and ended up here 
in The Netherlands. Nicolien, Heleen & David, Gio, Sandra & Thomas, Jeroen (Schouw), 
Jeroen (Twin), Martijn, Niki, Christel, and of course, Rick… thank you for your friendship 
these last ten years. I’ll always treasure the great times we had back at Texas A&M. And I 
hope that we can see each other more now. 
A very special thanks to Nicolien, not just for being an amazing friend, but for her help 
with the figures in the Introduction of this thesis, for translating my discussion to Dutch, 
164
dAnkwoord
8
and for designing the cover of my thesis. You did a fabulous job!! You and your parents 
(Wim and Ria) have always been there for me. I am forever grateful for that. 
Schouw, thank you for always letting me crash at your apartment when we didn’t live in 
Nijmegen anymore. Schouwy, you are a great friend to me and I always have a blast hanging 
out with you. Plus, you always have gummies on hand to eat. I wish you and Julia the best in 
Düsseldorf. So after Julia finishes her PhD, y'all are coming back to The Netherlands, right?
To my fellow twin PhDers, Jeroen and Martijn, I’ve enjoyed getting to know you all 
even better since you moved to Nijmegen to work as post-docs. Somehow Jeroen you ended 
up in Peter’s lab with me. And Martijn you work at the NCMLS; I thoroughly enjoyed 
our lunches at the HAN. Good luck to you both with your research and with your ladies, 
Mariëlle (good luck with your PhD) and Sofie.
To Katrijn and Iwan, I am glad that we became friends throughout these last few years. 
And I hope we are able to hang out more in the future. 
To Ana and Jaap, I have really enjoyed getting to know you both. I'm so glad to have 
been in the same Dutch class as you Ana. You have made my stay in Venlo all that much 
more enjoyable. I look forward to a long friendship with you two and seeing our children 
grow up together. 
To the Deijkers and van den Bors families, especially, René & Annelies and Marian & 
Gert... Bedankt det gee mich un paar joar gelede heb toe geloate in ôch hert. You always 
made me feel included wherever we were. And I hope to keep having more memories at 
Heimbach and New Year’s Eve extravaganzas with you all. I always have a good time with 
my cousins Coert, Anke, Simone, and MJ. Also, it has been great hanging out with Roy and 
Maria these last several years. I wish you two all the best with your new baby boy Jason.
I also want to thank Torsten and Vroni for their friendship and interesting talks. And 
Torsten for introducing schnapps; I had no idea there were so many flavors. All I remember 
is Torsten saying, “Come on, just try one more.” Hopefully, we’ll finally make it down to 
Germany and go skiing in the mountains with you and the family... and maybe some more 
schnapps?? 
Also I would like to thank my friends in Boston... Pam, Bruce, Kris, Steve, and the 
Pielocik family who have supported me throughout the years. I miss you all.
For my family and friends in Texas… it has definitely not been easy being away from 
everyone all these years. But I can certainly appreciate those of you who have always 
embraced me whenever I came back home for a visit. The Lara’s from Laredo and the Valley 
are AWESOME!! They are always there for me. The Cron’s are a bit more spread out but 
we have always kept in touch some way or another. Hopefully, we will finally make it to a 
reunion in the future. As for my friends Julie P., Joey & Julie Z., and Stacy J. - we somehow 
always manage to meet up somewhere in Texas. And it's always good times with Sonia and 
Davina down in the Valley... thanks ladies!!
I would also like to thank my friend Teri whom I should get to see a bit more since she 
lives in Germany. But somehow it doesn’t always happen. Yet when we get together, it’s like 
time never passed. Thanks for all the crazy memories in Texas and over here. I look forward 
to some more with you and Wolfie.
165
I can’t imagine visiting Texas without seeing my “besties” Christi and Merlyn. You two 
ladies have known me… I don’t want to say. A long time. We’ve been in each other’s weddings 
and have met each other’s babies. I have truly been blessed to have your friendship throughout 
these years; it has meant so much to me. You have been there for me through everything and 
supported my decision in coming to The Netherlands. I can't thank you two enough. I also 
want to thank Rey, Juan & Mela for always being there. All of you are such a huge support 
system. I wish you and your families a bright future. I love you all so very much.
To my husband’s family, familie Verbeek… Hans & Ien, Rob, Debbie & Quinn, Kelly & 
Marvin, en natuurlijk Oma… wat moet ik zeggen? Jullie waren allemaal mijn familie toen 
mijn eigen familie niet bij mij kon zijn. Ik heb de beste schoonouders van de hele wereld!! 
These last two years you have supported me in every way possible and were there for my 
ups and downs. Bedankt voor alles!! Kel-ly!! Het was leuk om samen te wonen met een zusje 
(die heel goed spekjes kan bakken).
As for my Mom & Dad, my brother Chris & Vianey… I know it’s been hard these last 
years as we do not get to see each other as often, but y'all are always in my thoughts and in 
my heart. I want you to know that without your love and support throughout my life, I never 
would have had the courage to embark on a journey such as this. This thesis is as much yours 
as it is mine. Dad, you’re next to get your PhD now. C&V- I wish you two a beautiful life 
together and hopefully a cousin or two for my daughter to play with when we visit. To the 
moon and back y’all… 
Finally, to my husband and the love of my life, Rick… I wouldn’t know what to do 
without you. Not only are you always there for me… you went above and beyond the call 
of duty these last years (dropping me off to my early morning experiments, picking me 
up from the late-night ones, sometimes helping with counting, and always listening to my 
rants about whatever). Never once did you complain. Thank you for that; it’s just one of the 
many reasons why I love you. But, I’m done babe!! I’m really done!! Now it’s your turn! And 
of course to my beautiful baby girl, Alyssa Lauren… thank you for waiting to come out until 
Mommy was done with her writing. I love you and your daddy so much. Soon it will be just 
the three of us. And then it’s on like DK!!   
166
currIcuLum vItAE
8
curriculum Vitae
Lorelei Elaine Cron was born June 27, 1978, in McAllen, Texas, U.S.A. After graduating with 
Honors from Pharr-San Juan-Alamo North High School in 1996, she attended Texas A&M 
University in College Station, Texas, from 1996-2003. In 2000, she received her Bachelor of 
Science in Biomedical Sciences and in 2003 she received her Master of Science in Laboratory 
Animal Medicine. Her thesis during her Master’s focused on the characterization of the 
serum antibody response of Coxiella burnetii (Q-fever) infected sheep. In addition, she was 
involved in another research project that studied the effect of glucosamine in arthritis using 
a rat model. 
After obtaining her degrees, she worked for 1.5 years in Boston at Massachusetts 
Institute of Technology (MIT) as a supervisor for the Division of Comparative Medicine in 
their animal facilities.  Lorelei was appointed as a PhD student at the Radboud University 
Nijmegen Medical Centre (RUNMC) in 2005, during which time she investigated the 
contribution of several pneumococcal proteins to various aspects of pneumococcal 
pathogenesis, their use as potential vaccine targets, and diagnostic tools as described in 
this thesis.
Lorelei is currently unemployed as she is busy tending to her daughter. At this time, she 
and her husband live in Venlo. Lorelei looks forward to getting back to work in a laboratory 
animal setting in the near future.
167
LISt of PuBLIcAtIonS
list of Publications
García-Suárez, M. d. M., L. E. Cron, B. Suárez-Álvarez, R. Villaverde, I. González-Rodríguez, 
F. Vázquez, P. W. Hermans, and F. J. Méndez. 2009. Diagnostic detection of Streptococcus 
pneumoniae PpmA in urine. Clin. Microbiol. Infect. 15:443-453.
Cron, L. E., H. J. Bootsma, N. Noske, P. Burghout, S. Hammerschmidt, and P. W. Hermans. 
2009. Surface-associated lipoprotein PpmA of Streptococcus pneumoniae is involved in 
colonization in a strain-specific manner. Microbiology. 155:2401-2410.
Burghout, P., L. E. Cron, H. Gradstedt, B. Quintero, E. Simonetti, J. J. E. Bijlsma, H. J. 
Bootsma, and P. W. M. Hermans. 2010. Carbonic anhydrase is essential for Streptococcus 
pneumoniae growth in environmental ambient air conditions. J. Bacteriol. 192:4054-4062.
Cron, L. E., K. Stol, P. Burghout, S. van Selm, E. R. Simonetti, H. J. Bootsma, and P. W. 
Hermans. 2011. Two DHH subfamily 1 proteins contribute to pneumococcal virulence and 
confer protection against pneumococcal disease. Infect. Immun. 79:3697-3710.
Cron, L. E., P. Burghout, M. Eleveld, C. E. van der Gaast-de Jongh, H. J. Bootsma, and 
P. W. M. Hermans. 2012. Contribution of branched-chain amino acid transport genes to 
pneumococcal colonization is strain-specific. Submitted.
168


